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ABSTRACT 
Maternal Diabetes, Related Biomarkers and Genes, and Risk of Orofacial Clefts 
by 
Tiwaporn Maneerattanasuporn, Doctor of Philosophy 
Utah State University, 2017 
 
Major Professor: Dr. Ronald G. Munger 
Department: Nutrition, Dietetics, and Food Sciences 
Orofacial clefts (OFCs) are among the most common congenital birth defects and 
are characterized by incomplete development of the lip or the palate or both. The lip and 
palate develop separately at different times during the first trimester of pregnancy. The 
etiology of OFCs is multifactorial and includes a combination of genetic and 
environmental factors. This project aims to examine the role of maternal diabetes mellitus 
in orofacial clefts through studies of medical histories, biomarkers, and genes. 
Firstly, the association between maternal pre-pregnancy weight and maternal 
diabetes mellitus and the risk of orofacial clefts (OFCs) in a population-based case-
control study of birth certificate data in Utah was examined. The study found that 
maternal obesity increased the risk of OFCs with or without birth defects (non-isolated 
and isolated). Underweight mothers had a reduced risk of cleft lip only (CLO), and an 
increased risk of cleft palate only (CPO). Pre-existing diabetes and gestational diabetes 
mellitus (GDM) increased the risk of non-isolated OFCs. Mediation analysis indicated 
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that obesity had a direct effect of increasing the risk of OFCs without the mediating effect 
of known maternal diabetes.  
Secondly, the association between maternal medical history and maternal 
biomarkers of metabolic syndrome and OFCs was examined using case-control interview 
and clinical examination data from the Utah population. This study was limited to 
isolated OFCs. Mothers having GDM in any pregnancy had an increased risk of OFCs. 
Mothers of children with cleft palate with or without cleft lip (CP/L), compared to 
controls, had higher mean levels of plasma glucose, insulin, triglycerides, waist 
circumference and systolic blood pressure, and lower HDL; these associations were not 
seen for mothers of children with CLO.  Plasma IL-8 and leptin levels were associated 
with CP/L but not with CLO. Metabolic syndrome indices were associated with CP/L; 
these scores were not associated with CLO. 
Finally, the association between genes related to GDM and the risk of OFCs was 
examined using data from a large scale genome-wide association study of European and 
Asian populations. Many genes previously known to be related to GDM were associated 
with OFCs through genetic effects alone and gene-environment interaction effects with 
periconceptional maternal multivitamin use, maternal smoking, and environmental 
tobacco smoke. These results support the hypothesis that GDM may be causally related to 
OFCs via multiple GDM susceptibility genes and interactions with environmental factors. 
Individuals with OFCs face both physical and mental health problems, which 
require multi-specialty team care. OFC prevention and prediction are important to public 
health. This dissertation reported that maternal diabetes mellitus, maternal pre-pregnancy 
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weight and genes related to GDM had an association with the risk of OFCs. Mothers 
having an OFC child had an increased risk of developing metabolic abnormalities later in 
life. Potential risk factors that are reported in this dissertation may be useful for OFC 
prevention. This dissertation also reported potential biomarkers for predicting OFCs. 
Moreover, mothers having an OFC child require regular monitoring for maternal 
metabolic abnormalities later in life. 
(442 Pages) 
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PUBLIC ABSTRACT 
Maternal Diabetes, Related Biomarkers and Genes, and Risk of Orofacial Clefts 
Tiwaporn Maneerattanasuporn 
Orofacial clefts (OFCs) are among the most common congenital birth defects and 
are characterized by incomplete development of the lip or the palate or both. The lip and 
palate develop separately at different times during the first trimester of pregnancy. The 
etiology of OFCs is multifactorial and includes a combination of genetic and 
environmental factors. This project aims to examine role of maternal diabetes mellitus in 
orofacial clefts through studies of medical histories, biomarkers, and genes. 
In a study of Utah birth certificates, mothers with pre-existing diabetes and 
gestational diabetes mellitus (GDM) had an increased risk of OFCs, and obese mothers 
also had an increased risk. Mothers of children with OFCs were more likely than mothers 
of unaffected children to develop obesity, metabolic syndrome and gestational diabetes 
mellitus later in life. These result were more strongly related to cleft palate than cleft lip. 
Many genes related to GDM were associated with OFCs through genetic effects alone 
and gene-environment interaction effects with periconceptional maternal multivitamin 
use, maternal smoking, and environmental tobacco smoke. These results support the 
hypothesis that GDM may be causally related to OFCs via multiple GDM susceptibility 
genes and interactions with environmental factors. 
Individuals with OFCs face both physical and mental health problem, which 
require multi-specialty team care. OFC prevention and prediction are important to public 
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health. This dissertation reported that maternal diabetes mellitus, maternal pre-pregnancy 
weight and genes related to GDM had an association with the risk of OFCs. Mothers 
having an OFC child had an increased risk of developing metabolic abnormalities later in 
life. Potential risk factors were reported in this dissertation that may be useful for OFC 
prevention. This dissertation also reported potential biomarkers for predicting OFCs. 
Moreover, mothers having an OFC child may require regular monitoring of metabolic 
abnormalities later in life. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1 Background 
Orofacial clefts (OFCs) are among the most common congenital birth defects and 
are characterized by incomplete development of the lip or the palate or both. The lip and 
palate develop separately at different times during the first trimester of pregnancy. 
Globally, approximately 1 in 700 newborns suffer from OFCs (1). The prevalence of 
OFCs is different among varying ethnic and racial groups; the highest rate was found in 
Asians and Native Americas (2 per 1000 births) (2). In the United States, Utah has a high 
rate of clefts (2.25 per 1000 births) (3).   
Even though OFCs are not a major cause of death, they have an adverse effect on 
affected children and their families. Children with OFCs have difficulty in feeding, 
speaking, hearing, and socializing. The difficulties faced by children with OFCs include 
the need of multidisciplinary team clinical care (plastic surgery, speech therapy, 
audiology, otolaryngology, dentistry, orthodontics, and psychology) over their lifetime 
(4). Moreover, the parents of affected children have a greater risk of financial and mental 
health problems (5, 6).  
The etiology of OFCs is multifactorial and includes a combination of genetic and 
environmental factors. The environmental factors that may increase the risk of OFCs 
include smoking, alcohol consumption, and certain medications during pregnancy and 
prior to pregnancy. Other environmental factors including maternal nutritional status, 
supplement intake, and eating behavior have also been associated with the incidence of 
OFCs (4). Moreover, some dietary patterns may have a protective effect on the rate of 
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OFCs such as the DASH (Dietary Approach to Stop Hypertension diet) and 
Mediterranean diet patterns (7, 8). 
Insulin resistance and obesity are considered as risk factors of metabolic diseases 
and may be related to the risk of OFCs. Some studies have reported that mothers with 
high body mass index (BMI) have a higher rate of OFCs when compared with mothers 
with normal BMI (9). Moreover, an association between pre-gestational diabetes mellitus 
and OFCs has been reported, but has not been studied in detail (10).  
The genetic factors of OFCs have been studied by many methods such as linkage 
studies and genome-wide association studies (GWAS). The gene-disease associations 
appear different among different ethnic groups (1, 11). The linkage study aims to identify 
genetic markers related to the disease in a family. These studies found have associations 
between non-syndromic orofacial clefts and genes related to growth factors, transcription 
factors, xenobiotic metabolism, immune response and one-carbon metabolism (12). 
GWAS have provided some similar and some different genetic markers associated with 
non-syndromic orofacial clefts but the data are limited. However, no study has reported 
the correlation between genes related to diabetes and metabolic syndrome and the risk of 
OFCs.   
Due to the adverse effect of orofacial clefts on children and their family, studies 
of the complex etiology of OFCs are needed in order to reduce the incidence of OFCs. 
Moreover, studies of the health problems of mothers near the time of conception are 
needed to reduce the incidence of OFCs which occur in the first trimester of pregnancy. 
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1.2 Objectives 
The overall objective is to examine role of maternal diabetes mellitus in orofacial 
clefts through studies of medical histories, biomarkers, and genes. The specific objectives 
and hypothesis are: 
Aim 1: To determine the association between maternal diabetes mellitus and 
gestational diabetes mellitus and the risk of orofacial clefts using data from Utah birth 
certificates, Intermountain Healthcare (IHC) and University of Utah medical records, 
and the Utah Clefts 2  case-control study. 
Hypothesis: Diabetes is more common among mothers of children with orofacial 
clefts compared to controls before, during, and after the index pregnancy. 
Aim 2: To determine the association between the occurrence of maternal diabetes 
and maternal biomarkers of metabolic syndrome and isolated orofacial clefts (OFCs) 
using data from the Utah Cleft 2 case-control study. 
Hypothesis: Mothers of children with orofacial clefts have a higher prevalence of 
maternal diabetes and abnormal biomarkers associated with metabolic syndrome 
compared to controls. 
Aim 3: To determine the association between genes related to diabetes and 
obesity and risk of orofacial clefts  
Hypothesis: Genes associated with diabetes mellitus and obesity are associated 
with the risk of orofacial clefts 
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1.3 Structure of the Dissertation 
This dissertation consists of six chapters. The first chapter introduces the recent 
problems related to OFCs and the way of the dissertation can contribute to solve these 
problems. The second chapter provided and overview of epidemiology, etiology, and 
risk factors of OFCs, diabetes mellitus, and metabolic syndrome. This chapter also 
presented biomarkers and genes related to diabetes and metabolic syndrome. The 
third chapter presented the finding of first aim, which is to determine the association 
between maternal diabetes mellitus and gestational diabetes mellitus and the risk of 
orofacial clefts. The fourth chapter presented the finding of second aim, which is to 
determine the association between maternal biomarkers of metabolic syndrome and 
orofacial. The fifth chapter showed the finding of third aim, which is to determine the 
association between genes related to diabetes and obesity and risk of orofacial clefts. 
The sixth chapter concludes the results from three aims, provides the public health 
significance, and gives suggestion for further research. The references for each 
chapter were listed at the end of each. 
1.4 Study Design 
The study in this dissertation used the data from Utah Birth Defect Network 
(UBDN), the Utah Cleft 2 case-control study, and the International Genetic 
Epidemiology study of Oral Clefts. 
The UBDN, operated by the Utah Department of Health (UDOH) is a statewide 
population-based surveillance system, identifies all prenatal or postnatal major structural 
birth defects in fetuses and neonates. The OFC classifications used in the data analyses 
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were based on the final UBDN diagnoses, which were reviewed by a medical geneticist. 
OFC cases were divided into cleft lip alone, cleft palate alone, cleft lip without cleft 
palate, and cleft lip with cleft palate and classified as isolated, syndromic, or multiple 
birth defect cases. The case mothers of a child with an OFC during 1995-2011 were 
linked to the Utah Population database (UPDB). The UPDB provides information for 
research on genetics, epidemiology, demography, and public health, which receives 
annual updates from birth and death certificates, hospitalization and ambulatory surgery 
records, and driver licenses. Controls were randomly selected from Utah birth certificates 
at a ratio of 4:1 to live-born cases matched by birth month and year. The anonymized 
identification numbers of cases and controls from UPDB were linked to the Utah Birth 
Certificate database. In addition, the UPDB provided information on OFC cases noted in 
fetal and neonatal death records. In total, 1,611 OFC live-born cases and 6,444 controls 
linked to the birth certificate records, in which 1,451 cases and 5,804 controls provided 
complete data, were used for analysis.  
The Utah Cleft 2 study, a collaboration of Utah State University (USU), the 
University of Utah Health Sciences Center and the Utah Department of Health (UDOH), 
is a study of orofacial clefts in Utah. Cases and controls were selected from the 
participants in the Utah Cleft 1 case-control study (13) and the National Birth Defects 
Prevention Study (NBDPS) in Utah (14). In the Utah Cleft 1 study, case‐mothers having 
a child with OFCs between January 1995 and June 2005 were recruited from UDOH, and 
control mothers were randomly selected, frequency matched by birth month and year, and 
gender of case child at ratio 1:1 by using Utah birth certificate files. The NBDPS in Utah, 
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also a state-wide population-based case-control study, recruited case mothers having a 
child with OFCs between 2005-2011 from UDOH database, and randomly selected 
control mothers from birth certificates. The OFC cases were limited to isolated OFCs; 
cases with multiple birth defects were excluded.   
The International Genetic Epidemiology study of Oral Clefts, a part of the Gene-
Environment Association Studies Initiative (GENEVA) of the National Institutes of 
Health (NIH). This study is a multi-center, international study of trios from Europe, the 
U.S., including Utah, China, Taiwan, Singapore, Korea, and the Philippines, which aims 
to investigate genes associated with oral clefts. Families were recruited from treatment 
centers or population-based registries. OFC cases were examined by either a clinical 
geneticist or an experienced clinician to minimize misclassification of the OFCs. All 
cases with cleft palate with or without cleft lip (CP) were analyzed together based on 
evidence that maternal obesity and diabetes have a specific effect on palate development. 
Trios having CL/P and CP (cleft palate with or without cleft lip) were analyzed in this 
study separately. For Asians, 892 CL/P and 910 CP trios, and for Europeans, 665 CL/P 
and 644 CP trios were analyzed in this dissertation. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
 
2.1  Orofacial Clefts 
Orofacial clefts (OFCs) are craniofacial birth defects which can be divided into 
cleft lip only (CLO), cleft lip with cleft palate (CLP), cleft lip with or without cleft palate 
(CL/P), cleft palate only (CPO), and cleft palate with or without cleft lip (CP/L). The 
other terminology is used to describe OFCs: syndromic and non-syndromic (isolated). 
Isolated or non-syndromic OFCs refers to OFCs without other congenital malformations 
or anomalies. Syndromic OFCs means the OFCs with other known patterns of anomalies. 
OFCs with other deformations, which cannot classify to existing syndromes, are multiple 
birth defect OFCs. About 70% CL/P are isolated. Isolated OFCs are not typically a cause 
of mortality, but individuals with OFCs face difficulty with feeding, speaking, hearing, 
and socializing.  
2.1.1 Classification 
Orofacial clefts have many classification systems depending on the purpose. The 
systems are divided into an anatomic system for surgeons and an embryology-based 
system for genetic counselling and research. 
a) Anatomic system 
The common form of CLP involves disruption of tissue planes above the 
lip extending into the nares and/or the hard and/or soft palate. For example, 
the Iowa system (1) classified OFCs into 5 groups  
group 1: cleft of the lip only (either unilateral or bilateral cleft lip) 
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group 2: secondary palate cleft only 
group 3: clefts of the lip, alveolus, and secondary palate (complete cleft 
lip and palate)  
group 4: cleft of lip and alveolus (primary palate cleft and cleft lip)  
group 5: miscellaneous 
Additionally, Millard (2) suggested the ICPR system classifying OFCs 
into 3 groups  
group 1: clefts of the primary palate (lip and/or alveolus) 
group 2: clefts of the primary and secondary palate (lip and/or alveolus 
and palate) 
group 3: clefts of the secondary palate (hard palate and/or soft palate) 
b) Syndromic clefts and multiple birth defects 
This system divides orofacial clefts into syndromic and non-syndromic clefts. 
Syndromic clefts are the orofacial clefts occurring with other birth defects related 
to known genetic syndromes such as Van der Woude syndrome, Treacher Collins 
Syndrome, and Apert Syndrome. Cases with multiple birth defect OFCs have 
OFCs with other congenital deformations, which cannot classify to existing 
syndromes. Non-syndromic clefts have no other structural or functional 
anomalies. 
2.1.2 Embryological development of OFCs 
OFCs results from non-closure of facial structures associated with lip and palate 
formation during the fourth through the twelfth week of pregnancy. The development of 
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face and jaws involves cell migration from the cranial neural crest, proliferation, 
differentiation and apoptosis (3).  
The lip develops between the fourth and eighth week of pregnancy, which 
correlates with the formation of the frontonasal prominence, the paired maxillary 
processes, and the paired mandibular process. By the end of the fourth week of gestation, 
migrating neural crest cells of the first pharyngeal arch form the frontonasal prominence. 
The lower portion of the frontonasal prominence is divided into paired medial and lateral 
nasal processes. By the end of the sixth week of embryogenesis, the medial nasal 
processes merge with each other and with the bilateral maxillary processes to form the 
upper lip and the primary palate, giving rise to the premaxilla (central upper lip, 
maxillary alveolar arch and four teeth, and hard palate anterior to the incisive foramen). 
A cleft lip results from a failure to maintain an epithelial bridge due to lack of 
mesodermal penetration and proliferation from the maxillary and nasal processes.  
The development of the secondary (soft) palate occurs after the primary palate 
(alveolar ridge and a triangular area of the anterior hard palate) during weeks 6-12. 
During the sixth week of development, the maxillary processes of paired palatal shelves 
initially rise vertically down the sides of the developing tongue, and grow to a horizontal 
position above the tongue and come into contact and fuse to form a midline epithelial 
seam during the seventh week. The palatal shelves also fuse in the midline with the 
primary palate anteriorly and with the nasal septum dorsally. These fusion processes are 
complete by the tenth week of pregnancy, separating the oral and nasal cavities, 
permitting simultaneous respiration and mastication.   Clefts of the secondary palate are 
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due to lack of fusion of the palatal shelves.  Normal development occurs sequentially; 
thus a cleft lip may or may not be associated with a cleft palate. 
2.1.3 Epidemiology of OFCs 
Orofacial clefts (OFCs) remains a health issue in both developed and developing 
countries. OFCs occur in every 0.4 to 2 per 1000 births depending on geographic 
location, racial and ethnic groups, maternal age, environmental exposures, and 
socioeconomic status (4, 5). The global average prevalence of OFCs is 1.43 in 1000 live 
births (6, 7). The Centers for Disease Control and Prevention (CDC) reported the 
incidence during 2004-2006 of CL/P was 1.06 in 1000 live births and 0.64 in 1000 live 
births for CP (8). National Birth Defects Prevention Network reported the prevalence of 
OFCs during 2002-2006 of CL/P was 1.33 per 1000 live births, and 0.73 per 1000 live 
births for CP, which is higher than The US prevalence during 1999-2001 (1.05 and 0.64 
per 1000 live births for CL/P and CP respectively) (9). International data from 57 
registries for 1993–98 suggest a variation in prevalence at birth of cleft lip with or 
without cleft palate of 0.34-2.29 per 1000 births, and an even more pronounced variation 
for isolated cleft palate, with prevalence of 0.13-2.53 in 1000 births (10).  Asians and 
Native Americas present the highest rate (2 in 1000 births), Europeans present at a rate 
around 1 in 1000, and Africans have the lowest rate (0.4 in 1000 births) (11). The 
National Center on Birth Defects and Developmental Disabilities updated the prevalence 
of CL/P and CP in the United States during 2006-2010 showing that Alaska (2.01 and 
1.77 per 1000 births respectively), North Dakota (1.58 and 1.51 per 1000 births 
respectively), Oklahoma (0.80 and 1.33 per 1000 births respectively), Utah (1.37 and 0. 
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65 per 1000 births respectively), Washington (1.14 and 0.88 per 1000 births 
respectively), and Colorado (1.17 and 0.82 per 1000 births respectively) are the five 
states with the highest prevalence of CL/P and CP (1.14 and 1.10 per 1000 births 
respectively for overall prevalence in the United States)  (12). Butali and Mossey 
reported that prevalence of OFCs differed among African populations (13), including; 
Uganda (0.75 per 1000 births in 1968), Kenya (1.65 per 1000 births during 1963-1964), 
South Africa (0.33 per 1000 births during 1983-1984), Nigeria (0.3 per 1000 births 
during 1976-1980), Tunisia (1.5 per 1000 births during 1983-1984), Zaire (0.46 per 1000 
births during 1977-1979), Malawi (0.67 per 1000 births during 1998-1999), and Sudan 
(0.9 per 1000 births during 1997-2000). Recent studies also reported the different 
prevalence among regions of Africa, including; 0.313 per 1000 births for South Africa 
during 2002-2006 (14), 0.5 per 1000 births  for Nigeria during 2006-2010 (15), 0.63 per 
1000 births  for Ghana in 2006 (16), 0.77 per 1000 births  for Uganda during 2005-2010 
(17). These studies showed that the prevalence of OFCs in South Africa, Nigeria and 
Uganda increased from the past. 
 The rate of CL/P differs by sex. The ratio of CL/P in males to females is 2:1; a 
ratio of 1:2 of males to females was found in populations of isolated cleft palate. In white 
populations, the male to female ratio for cleft lip with or without cleft palate is about 2:1 
(18). In Japanese populations, CL/P shows a significant excess for males, but this excess 
is not seen for cleft lip alone (19). These findings are similar to studies done in China and 
Nigeria (15, 20). Moreover, among unilateral cleft lip cases, the left: right ratio is 2:1 
(18).  
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2.1.4 Risk factors of OFCs 
The etiology of orofacial clefts is not fully understood. The updated evidence 
suggests that there are the multiple factors for this defect including both genetic and 
environmental factors. 
a) Environmental factors 
i) Maternal smoking 
Maternal smoking has consistently been reported to increase the 
risk of both cleft lip with or without cleft palate and isolated cleft palate. 
An international population-based study, including Norway and the United 
States, reported that mothers with active smoking increased risk of all 
types of isolated clefts (odds ratio (OR): 1.38, 95% confidence interval 
(95% CI): 1.24-1.53 for all OFCs; OR: 1.42, 95% CI: 1.26-1.61 for CL/P, 
OR: 1.27, 95% CI: 1.08-1.51 for CP) (21). A case-cohort study from 
Denmark by Bille et al. (22) collecting first trimester maternal life style 
data found that maternal smoking increased the risk of orofacial clefts 
with statistical significance (OR: 1.50; 95% CI: 1.05-2.14). The meta-
analysis study, analyzing 22 case-control studies, also reported that 
maternal tobacco smoking increased the risk of both CL/P and CP 
(relative risk (RR):1.34, 95% CI: 1.25-1.44 for CL/P and RR: 1.22, 95% 
CI: 1.10-1.35) (23). Another study from Brazil by Leite et al. (24), 
however, did not present a statistically significant association between 
maternal smoking during the first trimester of gestation and orofacial 
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clefts (OR: 1.13, 95% CI: 0.81-1.57). The inconsistent association 
between maternal smoking and OFCs from the Brazil study may result 
from the small sample size and quality of data (recall bias from 
retrospective study).  
The effect of environmental tobacco smoke from passive exposure 
on the risk of OFCs still appears to be inconsistent. The study from Brazil 
(24) reported that maternal passive smoking during pregnancy associated 
with CL/P with statistical significance (OR: 1.39, 95% CI: 1.01-1.98), 
except for CP (OR: 1.67, 95% CI: 0.9-3.11). Case-control studies in 
different cities (Shenyang and Heilongjiang) in China stated that passive 
smoke exposure of mothers increased the risk of OFCs (Shenyang: OR: 
2.05, 95% CI: 1.47-2.87 for OFCs and Heilongjiang: OR: 2.52, 95% CI: 
1.90-3.33 for CL/P, OR: 1.87, 95% CI: 1.28-2.75 for CP) (20, 25). The 
slight association between maternal passive smoke and isolated OFCs and 
CL/P except CP was reported in the international population-based study 
(OR: 1.14, 95% CI: 1.03-1.25 for OFCs; OR: 1.14, 95% CI: 1.02-1.28 for 
CL/P, OR: 1.12, 95% CI: 0.95-1.31 for CP) (21). However, Honein et al. 
reported that environmental tobacco smoke exposure was not associated 
with CL/P and CP (26). 
ii) Alcohol consumption 
Maternal alcohol consumption has been advanced as a risk factor, 
although the evidence is still inconsistent. The study in Brazil by Leite et 
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al. (24) reported maternal alcohol consumption during first trimester was 
associated with CL/P and CP with statistical significance (OR: 2.08, 95% 
CI: 1.27, 3.41 and OR: 2.89, 95% CI: 1.25-8.30, respectively). A recent 
study in Brazil by Bezerra et al. (27) also found that alcohol drinking 
during pregnancy increased risk of non-syndromic OFCs (OR: 3.64, 95% 
CI: 1.6-8.3). The Danish National Birth Cohort (22) presented a slight 
positive association between alcohol consumption during the first 
trimester of gestation without statistical significance (OR: 1.11; 95% CI: 
0.79-1.55). A case-control study in Norway (28) which collected the data 
from 1996 to 2001 showed that mother consuming greater than or equal to 
5 drinks per setting (binge drinking pattern: high dose of alcohol 
consumption in short periods) had increased the risk of CL/P (OR: 2.2, 
95% CI: 1.1-4.2) and the risk of CP (OR: 2.6, 95% CI: 1.2-5.6). The Iowa 
case-control study reported that increased alcohol consumption increased 
risk of isolated CL/P except isolated CP (OR: 1.5, 95% CI: 0.9-2.4 for 1-3 
drinks/month; OR: 3.5, 95% CI: 0.8-15.4 for 4-10 drinks/month; OR: 4.0, 
95% CI: 1.1-15.1 for >10 drinks/month; p-trend 0.007) (29). Additionally, 
a meta-analysis evaluating data from 33 studies (23 case-control and 10 
cohort studies) reported that maternal alcohol consumption during 
pregnancy was not associated with the occurrence of OFCs (30). 
iii) Coffee and caffeine-containing beverages consumption 
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A Norwegian case-control study by Johansen et al. (31) reported a 
statistically significant correlation between coffee consumption and the 
risk of CL/P (OR: 1.39, 95% CI: 1.01-2.39) for 1-2 cups per day and (OR: 
1.59, 95% CI: 1.05-2.39) for 3 cups or more per day. There was no 
statistically significant association between coffee consumption and CP. 
Moreover, the study in Norway (31) presented a negative correlation 
between daily tea consumption of 3 or more cups and both CL/P and CP 
(OR: 0.55, 95% CI 0.32-0.95 and OR: 0.58, 95% CI: 0.31-1.07) when 
compared with no tea intake. However, the evidence for an association 
between coffee intake and orofacial clefts is still inconsistent. Kurppa et 
al. (32) reported that coffee intake of more than 4 cups a day was not 
associated with the risk of orofacial clefts (OR 1.0, 95% CI: 0.6-1.6). On 
the contrary, the cohort study in Denmark showed that daily coffee 
consumption of more than 5 cups reduced the risk of orofacial clefts by 37 
% (95% CI: 0.32-1.44) when compared with no coffee consumption, 
though the confidence intervals in this study are biased and included 1.0 
(22). 
iv) Maternal age 
A meta-analysis (23 published case-control studies) showed that a 
maternal age of 40 years or more increased the risk of CLP by 56% 
compared to a maternal age between 20 and 29 years (33). A population-
based case-control study in China supported the hypothesis of maternal 
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age being associated with OFCs (34). The study reported that mothers 
older than 35 years old experienced an increased risk of CL/P (OR: 2.12, 
95% CI: 1.26-3.57). 
v) Medication 
Therapy with anticonvulsant drugs, notably diazepam, phenytoin, 
and phenobarbital in maternal epilepsy increased the risk of both CL/P 
(OR: 7.77, 95% CI: 2.02-26.0) and CP (OR: 3.61, 95% CI: 0.08-26.5) (35, 
36). Use of valproic acid monotherapy in the first trimester of pregnancy 
increased the risk of cleft palate (OR: 5.2, 95% CI: 2.8-9.9) (37).  
Maternal amoxicillin use in the third month of gestation increased 
the risk of both CL/P and CP with OR: 4.3, 95% CI: 1.4-13.0 and OR: 7.1, 
95% CI: 1.4-36, respectively, and increased the risk of CL/P with OR 2.0, 
95% CI: 1.4-4.1 for the first trimester use of amoxicillin (38).  
The association between maternal corticosteroid use and risk of 
OFCs is still inconsistent. Maternal corticosteroid use had positive 
associations with OFCs (OR: 3.35, 95% CI: 1.97-5.69) (39).  The data 
from MADRE project, an international women’s human right 
organization, showed the association between corticosteroid use in the first 
trimester and the occurrence of CL/P (OR: 2.59, 95% CI: 1.18-5.67)(40). 
The case-control study in Norway presented the positive association of 
dermatologic corticosteroids with both CL/P (OR: 2.3, 95% CI: 0.71-7.7) 
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and CP (OR: 3.4, 95% CI: 0.87-13) (41), which is similar to the result 
from study  in Denmark (42).  
The population-based case-control study in China reported 
analgesics or antipyretics (aspirin, aminopyrine, and phenacetin) increased 
the risk of OFCs (OR: 7.85, 95% CI: 3.15-19.58) (20). 
The association between OFCs and medication used for depression 
and anxiety has been reported in many studies. A case-control study found 
maternal benzodiazepine use increased the risk of CLP (43). Shiono et al. 
reported that maternal diazepam use during the first trimester had no 
significant association with orofacial clefts (RR: 1.22, 95% CI: 0.17-8.95) 
(44). The National Birth Defect Prevention Study found the association 
between OFCs and venlafaxine use one month before conception and 
during early pregnancy (OR:1.5, 95% CI: 0.5-4.3 for CL/P and OR:3.3, 
95% CI: 1.1-8.8 for CP) (45). 
vi) Folate nutritional status 
Folate is a cofactor in the metabolism of one-carbon (the transfer 
and utilization of one-carbon-groups), the synthesis of DNA (donation of 
one-carbon units in the process of DNA -biosynthesis), and the 
remethylation of homocysteine to methionine (46). Maternal folate status 
has been suggested to influence the risk of OFCs (5). The case-control 
study in the Netherlands (47) found that the mothers of children with CL/P 
consumed dietary folate in quantities less than the mothers in the control 
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group. In addition, increasing quartiles of dietary folate intake was 
associated with decreased the risk of CL/P (quartile 1 is reference, quartile 
2 (OR: 0.74; 95% CI: 0.40-1.37), quartile 3 (OR: 0.73; 95% CI: 0.39-
1.35), quartile 4 (OR: 0.63; 95% CI: 0.32-1.23) quartile 5 (OR: 0.54; 95% 
CI: 0.27-1.05); p-trend 0.06). A recent case-control study in Brazil 
reported that low folate levels (< 7 ng/ml) increased risk of non-syndromic 
OFCs (OR: 2.18; 95% CI: 1.12-5.67) (27). 
The data from a Utah case-control study reported that plasma 
folate and erythrocyte folate levels in mothers of children with isolated 
clefts (CL/P and CP) were lower than the controls group with statistical 
significance (48). A report in the Philippines by Munger et al. also 
presented a similar association, and noted that the folate association 
depended on the background of vitamin B6 level (49). However, Bille et 
al. studied the effect of IgG and IgM autoantibodies on folate receptor 
alpha (FRalpha) in pregnant women and found that the levels of folate 
receptor antibody were not associated with increased risk of oral clefts 
(50). 
vii) Vitamin B6 nutritional status 
Vitamin B6, pyridoxine, is a co-factor required for amino acid, 
glucose, and lipid metabolism including the metabolism of folate and 
homocysteine (51).  Mouse studies reported the protective effect of 
vitamin B6 supplementation on incidence of corticosteroid-induced OFCs 
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(52-55) and dexamethasone-induced cleft palate (56). Davis et al. 
presented that mice with vitamin B6 deficiency resulted in birth defects 
including cleft palate (57). Another mouse study found that dietary 
vitamin B6 deprivation leaded to isolated cleft palate in 20% of the 
offspring (58). Moreover, animal studies reported that vitamin B6 
prevented the induction of OFCs by vitamin A excess (59), 
cyclophosphamide (60), and β-aminoproprionitrile (61).  
The association between vitamin B6 nutritional status and OFCs in 
human study is limited.  A case-control study in Netherland by Krapels et 
al. showed no association between dietary vitamin B6 consumption and 
risk of OFCs after adjustment for dietary folate intake (62). This study 
also reported increased dietary consumption of vitamin B6 significantly 
reduced risk of OFCs in periconceptional supplement group (quintile 1: 
1.07-1.51 mg/day is reference, quintile 2: 1.52-1.61 mg /day (OR: 0.69; 
95% CI: 0.24-1.99), quintile 3: 1.62-1.72 mg /day (OR: 0.49; 95% CI: 
0.16-1.54), quintile 4: 1.72-1.84 mg /day (OR: 0.20; 95% CI: 0.07-0.61), 
quintile 5: 1.84-2.42 mg /day (OR: 0.22; 95% CI: 0.08-0.64), p-trend = 
0.0006), but the association was not found in non-supplementary group . A 
human study in Philippines (49) reported the positive association between 
OFCs and maternal vitamin B6 activation coefficient (increased levels 
indicate poorer vitamin B6 status) in both sites (Negros Occidental: tertile 
1 is reference, tertile 2 (OR: 4.01; 95% CI: 1.09-14.75), tertile 3 (OR: 
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6.54; 95% CI: 1.93-22.24), p-trend = 0.002 and Davao: tertile 1 is 
reference, tertile 2 (OR: 2.65; 95% CI: 1.16-6.09), tertile 3 (OR: 6.01; 
95% CI: 2.53-14.30), p-trend < 0.001. A case-control study in Netherland 
(63) showed that mothers having pyridoxal-5’- phosphate (PLP) level ≤ 44 
nmol/L increased risk of OFCs (OR: 2.9; 95% CI: 1.2-7.1), and the risk 
increased in mothers without periconceptional supplement (OR: 16.4; 95% 
CI: 1.8-152.2).  However, the association between vitamin B6 status and 
OFCs was not found in a case-control study in Utah, the United States 
(48). 
viii) Vitamin B12 nutritional status 
Vitamin B12 (cobalamin) functions as a coenzyme in the synthesis 
of methionine by methylation of homocysteine to methionine and 
demethylation of N5-methyl-tetrahydrofolate to tetrahydrofolate. In 
addition, vitamin B12 is a coenzyme of methylmalonyl-CoA mutase. 
Vitamin B12 is involved in the metabolism of fatty acids and amino acids, 
and affecting DNA synthesis and regulation(46).   Lu et al. conducting a 
mouse study reported that vitamin B12 prevented the dexamethasone-
induced cleft palate (64). However, Zho et al. found no association 
between vitamin B12 and cleft palate induced by 2,3,7,8-
tetrachlorodibenzo-p-dioxin and dexamethasone (65).  
A case-control study in Netherland by Krapels et al. (62) found 
that increased dietary intake of vitamin B12 increased risk of OFCs with 
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marginally statistical significance (quintile 1: 2.20-4.13 μg/day is 
reference, quintile 2: 4.14-4.92 μg/day (OR: 0.88; 95% CI: 0.44-1.76), 
quintile 3: 4.92-5.53 μg/day (OR: 1.30; 95% CI: 0.66-2.54), quintile 4: 
5.53-6.24 μg/day (OR: 1.18; 95% CI: 0.60-2.35), quintile 5: 6.27-42.92 
μg/day (OR: 1.79; 95% CI: 0.90-3.56), p-trend = 0.06). Another case-
control study in Netherland by Van Aooil et al. (63) reported that that 
mothers having low serum vitamin B12 levels (≤ 185 pmol/L) increased 
risk of OFCs (OR: 3.1; 95% CI: 1.3-7.4 for total group and OR: 4.4; 95% 
CI: 1.1-18.2 for none periconceptional supplement. 
ix) Zinc nutritional status 
Zinc plays role in the absorption of folate by polyglutamate 
hydrolase, a zinc‐dependent enzyme, and is involved in the conversion of 
5‐methyltetrahydrofolate into tetrahydrofolate by the zinc‐ dependent 
methionine synthase enzyme.  Maternal zinc deficiency can disrupt the 
normal function of trophoblasts, the production and secretion of 
hormones, establishment of the maternal-fetal barrier, and the mediation 
of metabolic exchanges across the maternal-fetal barrier (66). A Dutch 
study (67) used a food frequency questionnaire to assess nutrient intake 
and compare it between mothers of OFCs children and the control group 
mothers. This study reported that zinc intake in mothers in the control 
group was statistically significantly higher than mothers of the OFCs 
group.   
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A case-control study in Philippines (68) showed the correlation 
between poor maternal zinc nutritional status and increased risk of OFCs. 
The mean level of plasma zinc concentration in the control group was 
higher (10.11.6 μmol/l) than in the group of mothers with CL/P children 
(9.61.2 μmol/l) with statistical significance and the group of mothers 
with CP children (9.41.1 μmol/l) without statistical significance. In 
addition, after adjusting for potential  confounding factors, increasing 
quartile of plasma zinc was associated with a decreased the risk of both 
CL/P (quartile 1: ≤8.9 μmol/l is reference, quartile 2: 9.0-9.8 μmol/l (OR: 
0.95; 95% CI: 0.38-2.35), quartile 3: 9.9-10.9 μmol/l (OR: 0.81; 95% CI: 
0.33-1.97), quartile 4: ≥ 11.0 μmol/l (OR: 0.32; 95% CI: 0.11-0.92); p-
trend 0.037) and CP (quartile 1: ≤8.9 μmol/l is reference, quartile 2: 9.0-
9.8 μmol/l (OR: 0.65; 95% CI: 0.16-2.68), quartile 3: 9.9-10.9 μmol/l 
(OR: 0.27; 95% CI: 0.05-1.45), quartile 4: ≥ 11.0 μmol/l (OR: 0.07; 95% 
CI: 0.01-0.73); p-trend 0.007). The case-control study in Poland and the 
Netherlands presented a similar correlation between concentrations of zinc 
and risk of OFCs (69, 70). However, the study in Utah with a much higher 
level of zinc status did not present the association between maternal 
plasma zinc concentration and OFCs (71). 
x) Maternal supplement use 
Maternal use of multivitamin supplements in early pregnancy has 
been linked to decreased risk of OFCs; in a meta-analysis on overall 25% 
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reduction in birth prevalence of OFCs with multivitamin use was reported 
(72). Johnson and Little reported the negative association between 
maternal multivitamin use and both CL/P (OR: 0.75, 95% CI: 0.65-0.88) 
and CP (OR: 0.88, 95% CI: 0.76-1.01) (73).  
Folic acid supplementation has been recommended to reduce the 
risk of OCFs although the evidence is still controversial. A case-control 
study in the Netherlands reported that higher folate supplementation 
lowered risk of CL/P (quartile 1: 152 µg/day is reference, quartile 2: 178 
µg/day (OR: 0.74; 95% CI: 0.40-1.37), quartile 3: 196 µg/day (OR: 1.73; 
95% CI: 0.39-1.35), quartile 4: 213 µg/day (OR: 0.63; 95% CI: 0.32-1.23), 
quartile 5: 242 µg/day (OR: 0.54; 95% CI: 0.27-1.05); p-trend 0.06) with 
marginal statistical significance (47). Data from the Hungarian Congenital 
Anomaly Registry showed that the high dose of folic acid (6 mg) in the 
first month of gestation reduced only the risk of CP (OR: 0.50, 95% CI: 
0.68-0.96 for CP and OR: 0.89, 95% CI: 0.67-1.20 for CL/P) (74). Studies 
in China from different cities (Heilongjiang and Xuzhou) reported the 
protective effect of folic acid (Heilongjiang Province: OR: 0.43, 95% CI: 
0.21-0.88 for CL/P and OR: 0.69, 95% CI: 0.28-1.69 for CP and Xuzhou 
city: OR: 0.23, 95% CI: 0.10-0.55 for OFCs) and multivitamin 
(Heilongjiang Province: OR: 0.0.4, 95% CI: 0.01-0.11 for CL/P and OR: 
0.08, 95% CI: 0.02-0.25 for CP and Xuzhou city: OR: 0.16, 95% CI: 0.04-
0.58 for OFCs) supplement during preconception period on OFCs  (25, 
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75). These studies found a weaker association between high dose of folic 
acid containing multivitamin in the second month and risk of OFCs (OR: 
0.82, 95% CI: 0.64-1.03 for CL/P and OR: 0.70, 95% CI: 0.48-1.02 for 
CP). The protective effect of folic acid containing multivitamin on risk of 
OFCs was supported by a case-control study in Norway (76) and the 
United States (77). However, later data from the National Birth Defects 
Prevention Study (NBDPS) found no association between maternal use of 
supplement containing folic acid and risk of CL/P (OR: 1.01; 95% CI: 
0.82-1.24) and CP (OR: 1.02; 95% CI: 0.77-1.34) (78).  
Moreover, a study in the United States presented that food 
fortification programs with folic acid decreased the prevalence of orofacial 
clefts (prevalence ratio 0.94, 95% CI: 0.92-0.96) (79). A retrospective 
population-based study in Canada reported food fortification program, 
cereal grain products fortified with folic acid, did not decrease the 
prevalence of orofacial clefts (prevalence ratio 1.06, 95% CI: 0.86-1.30) 
(80). 
xi) Maternal obesity 
A cohort study in Sweden presented a positive association between 
maternal obesity and the occurrence of OFCs. Maternal BMI greater than 
29 increased the risk of OFCs 31 % after adjusting the potential variables 
(81). Blomberg and Kallen provided a similar correlation between 
maternal overweight (BMI 25-29.9) and obesity (BMI ≥ 30) and orofacial 
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clefts (adjusted OR: 1.15, 95% CI: 1.04-1.28 and adjusted OR: 1.26, 95% 
CI: 1.09-1.95; respectively) (82). The international consortium of case-
control studies, Utah, Iowa, Norway, and the U.S. National Birth Defects 
Prevention Study, found that maternal obesity (pre-pregnancy BMI >35) 
increased the risk of isolated CLP and CP except CL (OR: 1.30, 95% CI: 
1.05-1.60 for CLP, OR: 1.29, 95% CI: 1.02-1.64 for CP, and OR: 1.03, 
95% CI: 0.78-1.37 for CL) when compared to mothers with normal weight 
(83).  These studies found increased BMI increased risk of all cleft palate 
(p-trend = 0.004) but not isolated cleft lip. A study in Washington State 
also reported the same BMI result as the former studies (adjusted OR: 
1.26, 95% CI: 1.03-1.55) (84). Moreover, the meta-analysis from 18 
articles showed that maternal obesity increased risk of both cleft palate 
(OR: 1.23, 95% CI: 1.03-1.47) and cleft lip and palate (OR: 1.20, 95% CI: 
1.03-1.40) (85). 
xii) Diabetes mellitus (pre-gestational and gestational) 
Many studies have reported the association between maternal 
diabetes and the risk of orofacial cleft in offspring. Spilson et al. 
investigated the 1996 National Center for Health Statistics States Natality 
database and reported that diabetic mothers increased the risk of CL/P, 
(adjusted OR 1.35, 95% CI: 1.00-1.82; P<0.05) (86). Carinci et al. 
reported the positive association between familial diabetes and isolated 
cleft palate (P=0.0014) (87). Data from a large international consortium 
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from the U.S., Denmark, and Norway confirmed that maternal diabetes 
increased the incidence of OFCs (OR 1.33, 95% CI: 1.14-1.55) after 
adjusting for maternal age, education levels, multivitamin use, maternal 
BMI categories, and history of smoking (88). A few studies reported that 
maternal diabetes increased birth defects including orofacial clefts. The 
Atlanta Birth Defects Case-Control Study (89) evaluated the risk of 
malformations from diabetic pregnancy. The study showed that being an 
insulin-dependent diabetic mother increased the risk of cleft palate (RR: 
23.7, 95% CI: 3.1-183.1). Correa et al. analyzed the data from the National 
Birth Defect Prevention Study (NBDPS) and reported an association 
between maternal diabetes mellitus and both isolated defects and multiple 
defects of CL/P and CP (90). Both pre-gestational (type 1 or 2) and 
gestational diabetes mellitus increased the risk of isolated CL/P (OR: 2.93, 
95% CI: 1.45-5.87 and OR: 1.45, 95% CI: 1.03-2.04, respectively) and CP 
(OR: 1.80, 95% CI: 0.67-4.87 and OR: 1.54, 95% CI: 1.01-2.37, 
respectively). 
Data from the a case-control study of Utah births during 1995-
2005 (83) showed that GDM increased the risk of both isolated (OR: 2.63, 
95% CI: 1.30-5.34) and non-isolated clefts (OR: 2.66, 95% CI: 1.02-6.97). 
b) Established Genetic factors  
Jugessur et al. reported that the majority of OFCs are isolated OFCs 
(around 70% of all CLP cases and around 50% of all CPO) (91). Syndromic and 
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multiple birth defects make up the minority of OFCs. Around 75% of syndromic 
orofacial clefts can be described by known genetic conditions including: Van der 
Woude syndrome, Bamforth–Lazarus syndrome, Kabuki syndrome, Pierre Robin 
syndrome, and Treacher Collins syndrome (7).  
Genetic studies have reported genes related to syndromic OFCs and 
provided clear associations between cleft phenotypes and the mutations of genes. 
However, some published genes for isolated OFCs often remain with questions of 
genetic etiology and there is need for more research to confirm and explain these 
associations (91).  
i) IRF6 (Interferon regulatory factor 6) 
Nine interferon regulatory factors have been identified in humans. 
Interferon regulatory factor family relates to innate immunity and 
interferon signaling, while IRF6 is essential for normal epidermal 
differentiation and development. In both vitro and vivo studies found that 
IRF6 suppressed growth and promoted differentiation of keratinocytes, 
cell type in the epidermis, and mammary carcinoma cells (92).   
IRF6 has been reported the association with both syndromic and 
isolated OFCs. IRF6 was found to be the cause of Van der Woude 
syndrome and Popliteal Pterygium syndrome (93). Zucchero et al. (94) 
confirmed the association between IRF6 and non-syndromic CL/P in a 
large study of 10 populations with ancestry in Asia, Europe, and South 
America. Subsequent candidate gene studies confirmed the correlation of 
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IRF6 with non-syndromic CL/P in Belgian (95), Taiwanese (96), and 
Norwegian populations (97). The results from genome-wide linkage 
studies (98) and genome-wide association studies (99-101) also reported 
similar result with candidate gene studies. 
Mouse models have also demonstrated the role of IRF6 showing 
that Irf6 mutant mice presented a hyper-proliferative epidermis causing 
failure to undergo terminal differentiation. The hyper-proliferative 
epidermis causes multiple epithelial adhesions which can occlude the oral 
cavity and lead to a cleft palate (102, 103). 
ii) MAFB (v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog B) 
MAFB gene encodes a basic leucine zipper transcription factor 
which regulates lineage-specific hematopoiesis. MAFB is expressed in the 
palate shelves and the medial edge epithelia during palate formation (101). 
Moreover, MAFB regulates the functions of establishing, differentiating, 
and developing the function of cells, tissues and organs, including 
pancreatic alpha and beta islets (104), which may be related to diabetes.  
 Genome-wide association studies in Chinese Han (105), Hispanic 
(106), European and Asian (101) populations reported an association 
between MAFB and non-syndromic orofacial clefts. However, no 
association was found in a Brazilian population (107). 
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iii) ABCA4 (ATP-binding cassette, sub-family A (ABC1), member 4) 
ABCA4 gene is a member of ATP-binding cassette (ABC) family. 
The ABCA4 gene plays an obvious role in retina photoreceptor cells. 
ABCA4 accelerates the clearance of all-trans-retinal to all-trans-retinol by 
translocating all-trans-retinal from the luminal to the cytoplasmic side of 
the disk membrane. ABCA4 mutation had strong association with vision 
disease such as Stargardt disease, cone-rod dystrophy, and autosomal 
recessive retinitis pigmentosa (108). The function of ABCA4 in other 
organs is unknown.  
The genome-wide association study in the GENEVA Cleft 
Consortium provided the statistical evidence of linkage and association 
between ABCA4 and non-syndromic CL/P (101). This evidence was 
supported with other genome-wide association studies in other populations 
such as Hispanic (106) and Brazilian (107) populations. However, the 
genome-wide association study in a Chinese Han population was not 
associated with the risk of non-syndromic orofacial clefts (105). 
iv) 8q24 
8q24 is a 640-kb region on chromosome 8 with no well-annotated 
genes in this interval. 8q24has been associated with non-syndromic CL/P 
and many types of cancer such as breast (109, 110), prostate (111-113), 
bladder (114), colon (115-117), lung (118), ovarian (119), pancreatics 
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(120), and brain (121) cancer. The 8q24 gene was strongly associated with 
non-syndromic CL/P in GWAS (99, 100). 
v) FOXE1 (Forkhead box E1) 
FOXE1, a member of the forkhead family, is a thyroid-specific 
transcription factor. FOXE1 is essential for the development and 
differentiation of thyroid, and the maintenance of thyroid differentiated 
state in adults (122). FOXE1 expression was observed in the rostral 
epithelium of the oral pharynx, the caudal epithelium of the nasal and 
maxillary processes, and epithelium involved in the fusion between the 
medial nasal and maxillary processes, which represents the role of FOXE1 
in lip development (123). FOXE1 mutation is also associated with thyroid 
agenesis, cleft palate, and choanal atresia (124). Moreno et al. reported 
that FOXE1 had a significant association with non-syndromic orofacial 
clefts (123). This association was confirmed by the subsequent candidate 
gene study in European (125, 126), Thai (127), Arab (128) populations. 
The GWAS in the Hispanic population also reported the association (106). 
vi) VAX1 (Ventral anterior homeobox 1) 
VAX1 is a transcription factor containing a DNA-binding 
homeobox domain in developing anterior ventral forebrain (129).  Mouse 
studies found that VAX1 related to forebrain development and neuronal 
differentiation (129), and VAX1 mutations affected the development of 
basal forebrain and the formation of visual system (130).  
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With GWAS, Mangold et al. and the GENEVA Cleft Consortium 
reported the association between VAX1 and risk of non-syndromic CL/P 
(101, 131). Figueiredo et al. reported VAX1 was associated with the risk 
of orofacial clefts in the Southeast Asian population, but not in the African 
population (132). An animal study found that the mouse knockout for 
Vax1 developed cleft palate and VAX1 was expressed in developing 
craniofacial structures (130) 
vii) Other genes 
The associations between the risk of orofacial clefts and the gene 
related to folate metabolism (MTHFR: Methylenetetrahydrofolate gene, 
MTHFD: Methylenetetrahydrofolate dehydrogenase gene, MTR: 5-
Methytetrahydrofolate-homocysteine methyltransferase, MTRR: 
Methionine synthase reductase, RFC1: Reduced folate carrier 1, FOLR: 
Folate receptor, BHMT: Betaine-homocysteine methyltransferase, and 
CBS: Cystathionine beta-synthase) is still controversial (133). In addition, 
no GWAS has reported the association between OFCs and diabetes-related 
genes. Published genes associated with OFCs have various function, only 
MAFB gene has function on pancreatic alpha and beta cells, which may 
related to diabetes. 
c) Gene-environment interaction  
Many studies have suggested that the development of CL/P and CP 
results from interaction of genetic and maternal environmental exposures. 
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Indeed, interaction between maternal exposures and specific allelic variants 
may have more significant relevance for the occurrence of CL/P and CP than 
studies in maternal exposures or genes alone. 
Maternal smoking has been associated with the increased risk of CL/P due 
to interference of genes in the metabolic pathways related to CLP. GSTT1 
(glutathione S-transferase theta), NOS3 (nitric oxide synthase 3), MSX1 (Msh 
homeobox homolog1), TGFA (transforming growth factor alpha) and TGFB3 
(transforming growth factor beta 3) genes influence the risk of orofacial clefts in 
infants of mothers who smoked during the peri-conceptual period (134-138). 
Beaty et at. (139) reported GRID2 (glutamate receptor, ionotropic, delta 2) and 
ELAVL2 (ELAV like neuron-specific RNA binding protein 2) provided the 
strong evidence for a gene-smoking interaction among European maternal smoker 
but those did not show significant evidence of genotypic effects alone.  Infants 
with allelic variants at the MSX1 (Msh homeobox homolog1) site had 
significantly elevated risk of CL/P with maternal alcohol consumption (> or = 4 
drinks/month) and CP with maternal smoking (> or = 10 cigarettes/day) (140). 
Offspring polymorphism of BMP4T538C (bone morphogenetic protein 4) was 
associated with an increased risk of non-syndromic CL/P for maternal passive 
smoking, and a decreased the risk of CL/P for maternal multivitamin use (141). 
Jia et al. (142) stated that IRF6 (Interferon regulatory factor 6) provided a similar 
result to BMP4T538C. The presence of ADH1C (alcohol dehydrogenase 1C) is 
associated with risk of orofacial clefts that mothers consume alcohol (143). 
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Moreover, CBS and MTHFD2L in Asian population and DHFR, MMAA, MTR, 
and TCN2 in European population show association between orofacial clefts and 
maternal multivitamin use (144). 
2.2 Diabetes Mellitus 
2.2.1 Overview 
Diabetes Mellitus is a disorder of the regulation of blood glucose. Hyperglycemia 
is a characteristic of diabetes mellitus resulting from a defect in insulin secretion or 
insulin action or both.  Diabetes mellitus can be divided into four groups as follows 
(145): 
a) Type 1 diabetes mellitus 
Type 1 diabetes mellitus, accounts for around 5% of all diabetes cases, and 
results from a cellular-mediated autoimmune destruction of β-cells of the pancreas. 
Patients with type 1 diabetes mellitus are typically diagnosed as children or young 
adults. 
b) Type 2 diabetes mellitus 
Type 2 diabetes mellitus is the most common type of diabetes (90-95%). This 
type of diabetes results from insulin resistance or insulin deficiency or both, which is 
caused by genetic and lifestyle factors. The most significant factors leading to type 2 
diabetes mellitus are overweight, abdominal obesity, and physical inactivity. Many 
patients with type 2 diabetes mellitus are undiagnosed for many years because of no 
significant signs and symptoms during the early stages of the disease.   
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c) Gestational diabetes mellitus (GDM) 
GDM is defined as glucose intolerance that begins or is first recognized during 
pregnancy. The cause of GDM is not clear, but it has been suggested that it is from 
the effect of placental and adipose tissue hormones. Placental hormones such as 
human placental lactogen, progesterone, cortisol, placental growth hormone and 
prolactin decreases phosphorylation of insulin receptor substrate 1, which leads to 
insulin resistance. Decreased adiponectin and increased tumor necrosis factor-α 
(TNF-α) and leptin during pregnancy are also associated with insulin resistance 
during pregnancy. 
d) Other specific types 
In addition to the causes of type 1 and type 2 diabetes mellitus and gestational 
diabetes mellitus, there are many causes that can lead to diabetes mellitus.  
i) Genetic defects of β -cells function result in impaired insulin secretion 
because β-cells lose the function to convert pro-insulin to insulin. (e.g. 
maturity-onset diabetes of the young (MODY), mitochondrial disorders, 
et al.). 
ii) Genetic defects in insulin action result from the mutation of insulin 
receptor, which leads to hyperinsulinemia and hyperglycemia. (e.g. 
Leprechaunism, congenital lipoatrophic disorders). Moreover, other 
genetic syndromes associated with diabetes include chromosomal 
abnormalities such as Prader-Willi syndrome, Wolfram’s syndrome, 
Turner syndrome, etc.). 
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iii) Diseases of the exocrine pancreas such as pancreatitis, trauma, 
pancreatectomy, neoplasia, fibrocalculous pancreatopathy, pancreatic 
carcinoma, et al., result in damaged β-cells. Decreased β-cells in the 
pancreas lead to reduced insulin secretion. 
iv) Endocrinopathies related to an excess amount of hormones antagonizing 
insulin action such as growth hormone, cortisol, glucagon, epinephrine, 
etc. (e.g. acromegaly, Cushing’s syndrome, thyrotoxicosis). 
v) Drug- or chemical-induced diabetes occurs when drugs and chemicals 
impair insulin action or damage β-cells. (e.g. glucocorticoids, thiazides, 
phenytoin, antiretroviral therapy). 
vi) Infections, especially viral infections, destroy β-cells. (e.g. congenital 
rubella, Cytomegalovirus, HIV/AIDS, coxsackievirus B, mumps, et al.). 
Uncommon forms of immune-mediated diabetes are the autoimmune disorder 
interfering with the insulin receptor, such as anti-insulin receptor antibodies. 
2.2.2 Criteria for diagnosis of type 2 diabetes mellitus 
The American Diabetes Association updated the criteria for the diagnosis of type 
2 diabetes mellitus in 2010 (145). Persons having HbA1c ≥ 6.5% or Fasting Plasma 
Glucose (FPG) ≥ 126 mg/dl (7.0 mmol/l) or 2-hr plasma glucose ≥ 200 mg/dl (11.1 
mmol/l) during an oral glucose tolerance test (OGTT) or random plasma glucose ≥ 200 
mg/dl with hyperglycemic symptoms is diagnosed as having diabetes mellitus. In 2006 
the World Health Organization (WHO) and the International Diabetes Federation 
(IDF)(146) recommended Fasting Plasma Glucose (FPG) ≥ 126 mg/dl (7.0 mmol/l) or 2-
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hr plasma glucose ≥ 200 mg/dl (11.1 mmol/l) as the diagnostic criteria for diabetes. 
Moreover, HbA1c ≥ 6.5% was recommended in 2011 by WHO for diagnosing diabetes 
mellitus (147). WHO/IDF suggested Fasting Plasma Glucose (FPG) ≥ 126 mg/dl (7.0 
mmol/l) and 2-hr plasma glucose ≥ 140 and 200 mg/dl (7.8-11.1 mmol/l) as the 
diagnostic criteria for Impaired Glucose Tolerance (IGT), and Fasting Plasma Glucose 
(FPG) > 110-125 mg/dl (6.1-6.9 mmol/l) for Impaired Fasting Glucose (IFG) (146). 
2.2.3 Criteria for diagnosis of GDM 
The American Diabetes Association (148) proposed one-step and two-step 
approaches for diagnosing GDM.  The one-step approach is based on a 75 gram OGTT at 
24-28 weeks of gestation with fasting. The diagnosis of GDM is made when the plasma 
glucose level ≥ 92 mg/dl (5.1 mmol/L) when fasting, or ≥ 180 mg/dl (10.0 mmol/L) at 1 
hour after loading, or ≥ 153 mg/dl (8.5 mmol/L) at 2 hours after loading. In addition, the 
two-step approach is based on 50 gram at 24-28 weeks of gestation with non-fasting. If 
the plasma glucose level at 1 hour after glucose loading is equal to or over 140 mg/dl (7.8 
mmol/L), 100 gram OGTT is required. The diagnosis of GDM is made if at least two of 
the four measured plasma glucose levels meet the criteria. The GDM criteria for 100 
gram OGTT is ≥ 95 mg/dl (5.3 mmol/L) at fasting, ≥ 180 mg/dl (10.0 mmol/L) at 1 hour 
after loading, ≥ 155 mg/dl (8.6 mmol/L) at 2 hours after loading, and ≥ 140 mg/dl (7.8 
mmol/L) at 3 hours after loading. By the 2006 WHO criteria for diabetes (149), the 
diagnosis of GDM is made if at least one criteria is met ≥ 126 mg/dl (7.0 mmol/L) at 
fasting, and ≥ 140 mg/dl (7.75 mmol/L) at 2 hours after 75 gram OGTT loading. 
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2.2.3 Epidemiology of diabetes mellitus 
The International Diabetes Federation (IDF) reported that the global prevalence of 
diabetes was 366 million in 2011 and estimated that the prevalence will be 552 million in 
2030 (150). Additionally, the IDF estimated the global prevalence of diabetes in 2035 
will be 600 million, which will be a 57% increase over the projection of  382 million for 
2013 (151).  Studies from China, Japan, and Sweden, supported the projected increase in 
the prevalence of diabetes (152-154). Men show a higher prevalence of diabetes than 
women in some but not all studies (198 million for men and 184 million for women) 
(155). The Chinese study by Wang C also reported that the prevalence of diabetes was 
higher in males (42.75%) compared to females (26.9%) in 2012 (153). However, a study 
done in Southern Iraq reported the prevalence of diabetes in women to be slightly higher 
than for men (52.6% for women and 47.3% for men) (156).  
The National Diabetes Statistics Report (157) released in June 2014 stated that in 
2012, 29.1 million or 9.3% of the American population had diabetes, which is a 12.8% 
increase over 2010. Moreover, it is estimated that 8.1 million (27.8%) people have 
undiagnosed diabetes. In the American population, Indians/Alaskan Natives have the 
highest rate of diabetes (15.9%) followed by non-Hispanic blacks (13.2%) and Hispanics 
(12.8%). The IDF (151) reported that the western pacific region has the highest number 
of people with diabetes, but the diabetic population in Africa, the Middle East and North 
America, and South-East Asia will increase 100%, 96%, and 71% respectively by 2035. 
The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) reported that the 
prevalence of diabetes was 10.2% in South Americans and 13.4% in Cubans, increasing 
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to 17.7% in Central Americans, 18.0% in Dominicans and Puerto Ricans, and 18.3% in 
Mexicans. The prevalence of diabetes is negatively associated with educational levels and 
household incomes (158).  
The percentage of women suffering from GDM is close to type 2 diabetes 
mellitus prevalence. The IDF (151) reported the global prevalence of hyperglycemia in 
pregnancy is 16.9%. The International Association of Diabetes and Pregnancy Study 
Groups (IADPSG), an international consensus group with representatives from multiple 
obstetrical and diabetes organizations, including the American Diabetes Association 
(ADA) also reported more than 200,000  GDM cases each year, or around 7% of all 
pregnancies (ranging from 1 to 14%, depending on the population and the diagnostic 
criteria) were diagnosed with GDM (159). The South-East Asian regions have the highest 
prevalence (25%) while the lowest prevalence is found in North America and the 
Caribbean (10.4%).  In addition, the prevalence of GDM in Haryana, India, was 13.9%, 
which is higher than the prevalence in the United States (8.5%) during 2009-2010 (160). 
The GDM prevalence in Australia in 2000-2009 was 5.1% for the indigenous population 
and 4.5% for the non-indigenous, an increase from 1999 (154). The results of these 
studies show that the majority of cases of hyperglycemia during pregnancy occurred in 
low- and middle-income countries. 
2.2.4 Risk factors of diabetes mellitus 
a) Age 
A Turkish study reported on the positive correlation between maternal age 
and the incidence of type 2 diabetes. The incidence of individuals over age 50 
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developing type 2 diabetes is higher than it is for individuals between the ages of 
20-49 years old (OR: 4.53, 95% CI: 1.98-10.33, P 0.0003) (161). The TromsØ 
study reported that increased age increased the risk of diabetes (OR: 1.3, 95% CI: 
1.1-1.5) (162). 
A positive correlation between age and risk of GDM has been reported, 
similar to the correlation seen in type 2 diabetes. IDF reported that the age of the 
mother is associated with the prevalence of hyperglycemia in pregnancy; mothers 
over 45 years old having the highest prevalence (47.7%) (151). The Nurses’ 
Health Study II presented similar results (163). Increased maternal age increased 
the risk of GDM (age ≥ 40 years vs 25-29 years, RR: 2.24, 95% CI 1.26-3.98, p-
trend <0.01).  A Chinese study by Yang H reported that, when compared to 
mothers less than 30 years ole, mothers age 30 years or older had an increased 
risk of GDM (OR: 2.18, 95% CI: 1.88-2.52) (164). This is similar to the results of 
a study done in Iran (OR: 3, 95% CI: 1.8–5) (165). 
b)  Family history 
A study in Japan examined the incident risk of type 2 diabetes over a 7 
year period. The study showed that participants with a family history of diabetes 
had an increased risk of diabetes when compared with participants without a 
family history of diabetes (HR 1.82; 95% CI: 1.36-2.43) (166). Moreover, 
participants with only the mother having diabetes showed a higher rate of type 2 
diabetes than those with a family history of diabetes (HR: 2.6; 95% CI: 1.71-
3.97). The MONICA (Monitoring of Trends and Determinants in Cardiovascular 
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Disease) Augsburge cohort study reported a significant association between 
family history of diabetes and the risk of diabetes (167). 
A family history of diabetes has also been reported as a risk factor for 
GDM (168). Pregnant women with a history of diabetes in their family have a 
higher risk of GDM when compared to women without a family history of 
diabetes (RR: 1.68, 95% CI: 1.39-2.04) (163). Moreover, data from the National 
Health and Nutrition Examination Survey III, provided similar results (169) . 
Women with maternal, paternal, or sibling histories of diabetes had an increased 
risk of developing GDM (OR: 3.0, 95% CI: 1.2- 7.3; OR: 3.3, 95% CI: 1.1-10.2; 
OR: 7.1, 95% CI: 1.6 -30.9, respectively). A history diabetes in family increased 
risk of type 2 diabetes and GDM. 
c)  Body weight 
Many studies have reported the positive correlation between body weight 
and risk of type 2 diabetes. The Nurses’ Health Study reported that both 
overweight (BMI 25-30 kg/m2) and obese (BMI ≥ 30 kg/m2) individuals showed a 
statistically significant increase in the risk of type 2 diabetes (170). The Finnmark 
study followed subjects for 12 years and found that increased BMI increased risk 
of type 2 diabetes in both genders (BMI ≤ 27 as a reference, BMI ≥ 35 kg/m2 RR: 
27.89; 95% CI: 12.27-63.42 for men; RR: 11.07, 95% CI: 4.63-26.46 in women) 
(171). Studies in Lebanon and Qatar also found that mother having BMI ≥ 30 
kg/m2 increased the risk of type 2 diabetes (OR: 2.29, 95% CI: 1.74-3.02, and OR: 
1.5, 95% CI: 1.2-1.9, respectively) (172, 173).  
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Pre-pregnancy bodyweight has been shown to have a strong association 
with the risk of GDM. A meta-analysis study (174) pooling the data from 70 
studies, also revealed that when compared with women of normal weight (20-
24.9kg/m2), the odds ratio for overweight (25-29.9≤ 30 kg/m2), moderate obesity 
(30-34.9kg/m2), morbid obesity (≥ 35 kg/m2) were  1.97 (95% CI 1.77- 2.19), 
3.01 (95% CI 2.34-3.87) and 5.55 (95% CI 4.27- 7.21) respectively. Moreover, 
the study also presented a protective effect of being underweight (≤ 20 kg/m2) on 
the incidence of GDM (OR: 0.75, 95% CI: 0.69-0.82). A retrospective study in 
Poland (175) reported that increased BMI significantly increased the risk of GDM 
(BMI > 35 kg/m2 vs BMI 18.5-20.9 kg/m2, OR 9.01, 95% CI 3.47-23.3, p-trend 
0.027). Many studies have been confirmed that high pre-pregnancy BMI increases 
the risk of GDM (164, 165, 168, 176-179). Nevertheless, a study in Thailand 
(180) reported the obese women did not have an increased risk of GDM when 
compared with normal weight women (RR: 0.9, 95% CI: 0.6-1.4). Individuals 
with overweight or obesity have a tendency to increase risk of type 2 diabetes and 
GDM. 
d)  Hypertension 
The 8 year follow up of the San Antonio Heart Study, reported that 
participants who converted to non-independent diabetes mellitus had higher 
systolic blood pressure than subjects without diabetes in both men and women, 
the results were statistically significant (181). The Augsburge study showed a 
similar correlation between high blood pressure and the risk of diabetes. The 
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study stated that diabetic subjects had both higher systolic and diastolic blood 
pressure than non-diabetic subject (167). A study in Norway showed that subjects 
developing diabetes had higher systolic blood pressure than non-diabetics (162). 
A study from Qatar reported the positive association of type 2 diabetes with 
systolic blood pressure (SBP) (OR = 1.5, 95% CI = 1.2 – 2.0 for SBP 120–
139 mmHg, OR = 2.2, 95% CI = 1.6-3.1 for SBP 140–159 mmHg, and OR = 3.2, 
95% CI = 2.0 – 5.3 for SBP > 160 mmHg) (172). In addition, the study in Western 
Asia, Lebanon, also suggested that hypertension is a predictor of type 2 diabetes 
(OR: 1.75, CI: 1.54-2.00, p-value < 2 × 10-16) (173). The association between high 
blood pressure and GDM has not been reported. Hypertension is strongly 
associated with diabetes. Both hypertension and type 2 diabetes are related to 
metabolic syndrome, and have common risk factors (obesity, diet, and inactivity). 
e)  Smoking 
Many cohort studies have reported the positive association between 
smoking and the risk of type 2 diabetes and GDM. The studies showed that 
tobacco smoking was correlated with the impairment of glucose metabolism, 
insulin sensitivity, and insulin secretion (182, 183).  Willi et al. (184) analyzed 25 
cohort studies and reported that current smoking increases the risk of type 2 
diabetes (OR: 1.44, 95% CI: 1.31-1.58). Moreover, heavy smokers (≥ 20 
cigarettes/day) showed the highest incidence of diabetes (OR: 1.61, 95% CI: 1.43-
1.80) when compared to lighter smoking (<20 cigarettes/day) (OR: 1.29, 95% CI: 
1.13-1.48) and former smokers (RR: 1.23, 95% CI: 1.14-1.33). The high 
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incidence of type 2 diabetes in heavy smokers was confirmed by studies in Japan 
(OR: 1.37, 95% CI: 1.05-1.80)(185), Finland (OR: 1.57, 95% CI: 1.34-1.84 in 
men and OR: 1.87, 95% CI: 1.36-2.59 in women) (186), and China (OR: 1.25, 
95% CI: 1.00-1.56) (187). In addition, Kim et al. reported that early onset of 
smoking increased the risk of type 2 diabetes in both Korean and US populations 
(188). 
However, some studies showed that the risk of type 2 diabetes increased 
after 3-5 years of smoking cessation (189-191). As a consequence, smoking 
cessation was associated with increased body weight, which is a risk factor of 
type 2 diabetes. However, increased duration of smoking cessation significantly 
decreased the risk of type 2 diabetes (191). A meta-analysis analyzing 4 cohort 
studies reported that passive smoking increased the risk of type 2 diabetes (OR: 
1.28, 95% CI: 1.14-1.44)(192). 
A prospective study in the United States (163) reported that women who 
smoked cigarettes had an increased risk of GDM (RR: 1.43, 95% CI: 1.14-1.80). 
A prospective cohort study in Massachusetts (193) showed that women who 
smoked prior to pregnancy had an increased risk of GDM when compared with 
non-smokers, but the results did not show statistical significance. 
f)  Gestational diabetes mellitus (GDM) and subsequent risk of DM 
Women with previous GDM show increased risk of type 2 diabetes 17-
63% in 5-16 years after diagnosis of GDM (194). A study in northwestern Ontario 
(195) reported that 70% of the women diagnosed with GDM developed type 2 
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diabetes, and the average duration from diagnosis of GDM to type 2 diabetes was 
three years. Sivaraman et al. (196) showed that women diagnosed with GDM had 
a significantly increased risk of type 2 diabetes, finding 6.9% at five years (95% 
CI: 3.8%-9.9%) and 21.1% at ten years (95% CI: 14.1%-27.5%) after diagnosis of 
GDM. Lui et al. (197) showed that increased postpartum body weight (>7 kgs) 
increased the risk of diabetes by 86% and pre-diabetes, impaired glucose 
tolerance or impaired fasting glucose, by 32%, whereas decreased postpartum 
body weight reduced the risk of pre-diabetes by 45%. 
g)  Dietary intake 
The association between food intake and incidence of diabetes has been 
showed to have both positive and negative effects.  The Nurses’ Health Study 
(198) reported the inverse association between dietary fiber intake and risk of type 
2 diabetes (RR=0.72, 95% CI, 0.58-0.90, P trend=.001), this was confirmed by 
the Health Professionals Follow-up Study (199), the Iowa Women’s Health Study 
(200), and the Black Women's Health Study (201). The protective effect of fiber 
intake against GDM was reported in the Nurses’ Health Study II, showing that the 
risk of GDM was 0.67 (RR: 0.67, 95% CI: 0.51-0.9) when comparing the highest 
quintile with the lowest quintile of total daily fiber intake (202). Moreover, each 
10 g/day increase in total fiber intake decreased the risk of GDM 26% (RR: 0.74, 
95% CI: 0.51-0.91). A study focusing on the association between fruit intake and 
the risk of GDM reported that whole fruit consumption reduced the GDM risk 
without statistical significance (203). 
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The association between total carbohydrate intake and the risk of type 2 
diabetes is controversial (198, 199, 204-206). The Nurses’ Health Study (207) 
reported a positive correlation between glycemic index and the risk of type 2 
diabetes (p-trend 0.001), and no association between glycemic load and the risk of 
type 2 diabetes. However, the Health Professionals Follow-up Study (199), the 
Japan Public Health Center-based Prospective Study (208), and a study in China 
(204) reported that both glycemic index and glycemic load increased the risk of 
type 2 diabetes. A cohort study in a US population, The Health Professionals 
Follow-up Study and the Nurses’ Health Study I and II, stated that the high white 
rice intake (≥ 5 serving per week) increased the risk of type 2 diabetes (OR: 1.17, 
95% CI: 1.02-1.36), while high brown rice intake (≥ 2 serving per week) reduced 
the risk of type 2 diabetes (OR: 0.89, 95% CI: 0.81-0.97) (209). This result 
demonstrated the adverse effect of high glycemic index foods and the benefit of 
fiber on the incidence of type 2 diabetes. The correlation between carbohydrate 
intake and GDM was reported on a study by Bao W. and colleagues. The study 
found that a low carbohydrate dietary pattern, with high protein and fat from 
animals, has a negative association with the risk of GDM (p-trend 0.03) (210). 
Additionally, the association between dietary fat intake (total, saturated, 
polyunsaturated, and monounsaturated fat) and occurrence of diabetes is 
inconsistent. The 14 year follow up of the Nurses’ Health Study (211) reported 
the protective effect of polyunsaturated fat on type 2 diabetes; on the contrary, the 
Health Professionals Follow-up Study (199) reported no correlation between 
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polyunsaturated fat intake and the risk of type 2 diabetes. Bowers K. and 
colleagues (212) reported that increased total fat intake, especially animal fat 
increased the risk of GDM (p-trend 0.05). Analyzing the association between fatty 
acid intake and GDM risk revealed that MUFA and cholesterol significantly 
increased the risk of GDM (p-trend 0.04 for both MUFA and cholesterol). The 
Alpha Case-Control Study (213) also showed an association between 
consumption of cholesterol and the risk of GDM (Q4 (≥294 mg/day) vs Q1 (<151 
mg/day) OR: 2.35, 95% CI: 1.35, 4.09, p-trend 0.021).  
High fiber and low carbohydrate intake reduce the risk of both type 2 
diabetes and GDM. The association dietary fat intake and risk of diabetes is 
controversial.  
h)  Dietary pattern 
The Multi-Ethnic Study of Atherosclerosis, MESA, (214) reported that a 
dietary pattern characterized by high intake of tomatoes, beans, refined grains, 
high-fat dairy, and red meat was associated with increased the risk of type 2 
diabetes (OR: 1.18, 95% CI: 1.06-1.32, p-trend 0.004). This study showed that the 
pattern characterized by high intake of whole grains, fruit, nuts/seeds, green leafy 
vegetables, and low-fat dairy decreased the risk of type 2 diabetes (OR: 0.85, 95% 
CI: 0.76-0.95, p-trend 0.005). The insulin Resistance Atherosclerosis Study 
followed non-diabetics for five years and reported that food intake pattern (high 
intake of dried beans, low-fiber bread and cereal, fried potatoes, tomato 
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vegetables, red meat, eggs, and cheese and including low intake of wine) was 
associated with the risk of the type 2 diabetes (215). 
A cohort study in the US showed an association between the western 
dietary pattern or a prudent dietary pattern and the risk of type 2 diabetes. The 
study showed that the western dietary pattern increased the incidence of type 2 
diabetes (OR: 1.59, 95% CI: 1.32-1.93), while the prudent dietary pattern 
decreased the occurrence of type 2 diabetes (OR: 0.84, 95% CI: 0.70-1.00) (216). 
The effect of prudent dietary pattern on the risk of type 2 diabetes was confirmed 
by a study in Finland (217). The MESA study (218) reported that the 
Mediterranean dietary pattern (high consumption of monounsaturated fatty acids, 
fruits, vegetables, and whole grains as well as low fat dairy products intake) 
reduced insulin levels, but had no significant association with incidence of 
diabetes. 
The effect of dietary pattern on the risk of GDM has been shown to be 
similar to the effect seen on type 2 diabetes risk (protective effects:  Prudent diet 
and Mediterranean diet and negative effect: Western Diet).  The Nurses’ Health 
Study II (219) reported a protective effect of the prudent pattern (high intake of 
fruit, green leafy vegetables, poultry and fish) on the GDM risk (p-trend 0.018). 
In addition, the western dietary pattern, which is characterized by high intakes of 
red meat, processed meat, sugary desserts, high-fat foods, and refined grains, is 
positively associated with the risk of GDM (P-trend 0.0011). Tobias DK. and 
colleagues (220) examined the association between GDM risk and dietary 
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patterns, namely the alternate Mediterranean (aMED), Dietary Approaches to 
Stop Hypertension (DASH), and alternate Healthy Eating Index (aHEI). When 
comparing the highest with the lowest quartile of dietary pattern score, aMED, 
DASH, and aHEI significantly decreased the risk of GDM (RR: 0.76, 95% CI: 
0.60-0.95, P-trend = 0.004 for aMED; RR: 0.66, 95% CI: 0.53-0.82, P-trend = 
0.0005 for DASH; RR: 0.54, 95% CI: 0.43-0.68, P-trend < 0.0001 for aHEI). The 
cohort study in China (221) reported the protective effect of a vegetable dietary 
pattern on the risk of GDM (T3 vs T1: RR: 0.79, 95% CI: 0.64-0.97, p-trend 
0.036). Moreover, sweets and seafood dietary patterns increased the risk of GDM 
(T3 vs T1: RR: 1.23, 95% CI: 1.02-1.49, p-trend 0.01). 
Dietary patterns characterized by high fiber intake (whole grain, fruit, and 
vegetable), and low animal fat such as Prudent diet, DASH diet, and 
Mediterranean diet reduces risk of type 2 diabetes and GDM.  The Western 
dietary pattern (low intake of fiber (fruit and vegetable) and high intake of red 
meat, high-fat foods, processed meat and sugar) increased the risk of diabetes.   
i)  Physical inactivity 
Several studies have reported the protective effect of physical activity and 
the adverse effect of sedentary behaviors on the incidence of type 2 diabetes. The 
Nurses' Health Study (222) showed that sedentary behaviors increased the risk of 
type 2 diabetes. The studies showed that increased duration of sitting while 
watching television increased the risk of diabetes (0-1 hr/week is reference, OR: 
1.22; 95% CI: 1.06-1.42 for 2-5 hrs/week), OR: 1.42; 95% CI: 1.24-1.63 for 6-20 
52 
 
 
 
hrs/week, OR: 1.65; 95% CI: 1.41-1.93 for 21-40 hrs/week, OR: 1.94; 95% CI: 
1.51-2.49 for >40 hrs/week; p-trend <0.001), whereas increased standing or 
walking around at home decreased the risk (0-1 hr/week is reference, OR: 0.99; 
95% CI: 0.79-1.24 for 2-5 hrs/week), OR: 0.87; 95% CI: 0.70-1.08 for 6-20 
hrs/week, OR: 0.78; 95% CI: 0.63-0.97 for 21-40 hrs/week, OR: 0.77; 95% CI: 
0.61-0.97 for >40 hrs/week; p-trend <0.001). A survey in Lebanon (173) showed 
that physical inactivity significantly increased the risk of type 2 diabetes. In 
addition, physical activity significantly decreased the risk of type 2 diabetes (OR: 
0.55, 95% CI: 0.37-0.81 for moderate activity, OR: 0.46, 95% CI: 0.24-0.88 for 
heavy activity). The study in urban Shanghai, China (187) also showed a 
significant inverse association between the incidence of type 2 diabetes and 
metabolic equivalent values (METs), which is used to estimate intensity of 
physical activity. Physical activity reduces the incidence of type 2 diabetes by 
decreasing insulin resistance and improving insulin sensitivity (223). 
However, the effect of physical activity on GDM development is 
controversial. The Nurses' Health Study II (224) reported that the physical activity 
score was inversely associated with the risk of GDM (p-trend 0.01). The study 
showed that brisk or very brisk walking 4 hours a week decreased the risk of 
GDM when compared with casual walking of the same duration (RR: 0.66, 95% 
CI: 0.46-0.95). However, the Australian Longitudinal Study found no association 
between physical activity and GDM risk (225). A case-control study determining 
the relation between recreational physical activity and risk of GDM (226) showed 
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an effect similar to brisk walking. For distances of ≤ 2 miles/day, brisk walking 
significantly reduced the GDM risk when compared with casual walking, but 
there was no significant protective effect in distances over 2 miles a day for either 
intensity. This study also reported that women participating in recreational 
physical activity during the year before pregnancy and during the first 20 weeks 
of pregnancy reduced the risk of GDM (OR: 0.45, 95% CI: 0.28-0.74 and OR: 
0.52, 95% CI: 0.33-0.80 respectively). Physical activity can prevent diabetes both 
type 2 diabetes and GDM while physical inactivity increases the risk of diabetes. 
2.3 Metabolic Syndrome  
2.3.1 Overview  
Metabolic syndrome is a major public health issue because it increases the risk of 
cardiovascular diseases (CVD), type 2 diabetes mellitus, stroke, etc. Metabolic syndrome 
is the grouping of visceral obesity, insulin resistance, hyperglycemia, dyslipidemia 
(hypertriglyceridemia and hypo-HDL cholesterolemia), and hypertension. The definitions 
of metabolic syndrome have been proposed by the World Health Organization (WHO), 
the National Cholesterol Education Program, Adult Treatment Panel III (NCEP/ATP III), 
the International Diabetes Federation (IDF), the American Heart Association/National 
Heart, Lung and Blood Institute (AHA-NHLBI), the American Association of Clinical 
Endocrinology (AACE), and the European Group for the Study of Insulin Resistance 
(EGIR) (Table 3.1). AACE proposed the definition of metabolic syndrome by using 
insulin resistance syndrome. The definition given by AACE can be applied to the 
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diagnosis of metabolic syndrome; relying on clinical judgment in non-diabetic patients. 
Genetic, hormonal, and lifestyle factors lead to the development of the syndrome. 
Risk of metabolic syndrome among obese persons can be split into two groups: 
metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUHO) 
(227). Metabolically healthy obesity (MHO) means obese people without metabolic 
abnormalities and have normal blood pressure, normal glucose tolerance, and normal 
lipid profiles. MHO results from the interaction between genetic, environmental, dietary, 
and behavioral factors associated with the accumulation and distribution of fat and insulin 
resistance (228). Subcutaneous adipose tissue of MHO individuals has the propensity to 
accumulate peripheral fat rather than visceral fat depots in MUHO which leads to insulin 
resistance (227). A study of weight-discordant monozygotic twins  (229) reported that the 
obese co-twins in the  ≥ 2% liver fat group presented significantly higher adipocyte 
volume, AUC insulin and glucose, LDL-cholesterol, leptin, and CRP and lower HDL- 
cholesterol than the non-obese co-twins. In the group with different liver fat <2%, obese 
co-twin had higher adipocyte volume and leptin than lean co-twins. This study stated that 
the MHO group (those with a low percentage of liver fat), had less inflammation, while 
the excess liver fat group presented with insulin resistance, dyslipidemia, and 
inflammation. This study of discordance among monozygotic twins indicates a role for 
non-genetic factors influencing the risk of metabolic syndrome.      
Metabolically unhealthy obesity is characterized by abdominal visceral fat 
disposition, visceral and ectopic fat accumulation, and insulin resistance (228). Visceral 
fat is intra-abdominal fat and a marker of ectopic fat which means the fat accumulating in 
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and around the organs in abdominal cavity including the heart (230). Abdominal obesity 
has an effect on metabolic processes by the intra-abdominal visceral fat which has higher 
lipolysis rate than any other depots. Abdominal adipose tissue elevates free fatty acids 
(FFA), cytokines (tumor necrosis factor alpha (TNF-𝛼) and interleukin-6 (IL-6)), 
adipokines, and angiotensin II.  Excess FFA circulation induces insulin resistance, which 
results from reduced hepatic insulin clearance, decreased skeletal muscle insulin 
sensitivity, increased hepatic cholesterol production with elevated triglycerides and very 
low density lipoprotein (VLDL), and altered endothelial function. Elevated levels of 
cytokines also impair insulin sensitivity. A similar result is seen with decreased 
adiponectin level. Adiponectin has a protective effect by regulating lipid and glucose 
metabolism, controlling energy metabolism, and increasing insulin sensitivity (231, 232). 
Obesity increases not only adipose tissue but also the systemic renin angiotensin system, 
which increases angiotensin II circulation. Angiotensin II causes decreased insulin 
sensitivity and vasoconstriction (233). 
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Table 2.1 Definition of metabolic syndrome 
Criteria 
WHO1(234) NCEP/ATP III2(235) IDF3(236) 
Abnormal glycemia plus 2 or more 
other criteria 
3 or more criteria Abdominal obesity plus 2 or 
more other criteria 
Abdominal obesity BMI > 30 kg/m2 and/or Waist to hip 
ratio > 0.9 (men)  
> 0.85 (women) 
Waist circumference 
> 102 cm (men)  
> 88 cm (women) 
Waist circumference for US 
population > 94 cm (men) 
> 80 cm (women) 
Glucose  Insulin resistance or impaired 
glucose regulation or diabetes 
Fasting plasma glucose > 110 
mg/dL or previous diabetes 
Fasting plasma glucose > 100 
mg/dL or previous diabetes 
HDL-C < 35 mg/dL (men)  
< 39 mg/dL(women) 
< 40 mg/dL (men)  
< 50 mg/dL(women) 
< 40 mg/dL (men) 
< 50 mg/dL(women) 
Hypertension ≥ 140/90 mmHg ≥ 130/85 mmHg ≥ 130/85 mmHg 
Triglyceride ≥ 150 mg/dL ≥ 150 mg/dL ≥ 150 mg/dL 
Other microalbuminuria (urinary albumin 
excretion rate ≥ 20 µg/min or 
albumin:creatinine ratio ≥ 30 mg/g) 
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Table 2.1 Definition of Metabolic Syndrome (Cont.) 
Criteria 
AHA-NHLBI4(237) AACE5(238) EGIR6(239) 
3 or more criteria No specific number of criteria for 
diagnosis; based on clinical judgment 
(only for non-diabetic subjects) 
Insulin resistance plus 2 or more 
criteria (only for non-diabetic 
subjects) 
Abdominal 
obesity 
Waist circumference 
> 102 cm (men) 
> 88 cm (women) 
BMI ≥ 25 kg/m2 Waist circumference 
> 94 cm (men) 
> 80 cm (women) 
Glucose  Fasting plasma glucose > 110 
mg/dL or mediation treatment for 
controlling glucose 
Fasting plasma glucose 110-125 
mg/dL or 2 hr post glucose challenge 
140-200 mg/dL 
Insulin resistance or impaired glucose 
regulation (but not diabetes) 
HDL-C < 40 mg/dL (men) 
< 50 mg/dL(women) 
< 40 mg/dL (men) 
< 50 mg/dL(women) 
< 39 mg/dL  
Hypertension ≥ 130/85 mmHg ≥ 130/85 mmHg ≥ 140/90 mmHg 
Triglyceride ≥ 150 mg/dL ≥ 150 mg/dL ≥ 150 mg/dL 
Other  Other features of insulin resistance  
1World Health Organization 
2 National Cholesterol Education Program, Adult Treatment Panel III  
3International Diabetes Federation 
4American Heart Association/National Heart, Lung and Blood Institute 
5 American Association of Clinical Endocrinology, American College of Endocrinology 
6European Group for the Study of Insulin Resistance 
59 
 
 
 
5
9
 
   
Figure 2.1 The difference between metabolically healthy and unhealthy obesity (227, 
228) 
 
BP, blood pressure; LDL, low density lipoprotein; TG, triglyceride; HDL, high density 
lipoprotein; TNF-α, tumor necrosis factor alpha; IL-1, interleukin 1; IL-1B, interleukin 1 
beta; IL-6, interleukin 6  
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Figure 2.2 Mechanism of metabolic unhealthy obesity 
FFA, free fatty acid; VLDL, very low density lipoprotein: TNF-α, tumor necrosis factor 
alpha; IL-6, interleukin 6  
 
2.3.2 Epidemiology of metabolic syndrome 
Global prevalence of metabolic syndrome is around 10% to 84%, which depends 
on region, sex, age, and the definition of metabolic syndrome used (232). The prevalence 
of metabolic syndrome in the United States was 27% during 1999-2000, and increased to 
34.2% during 1999-2006 (240), 36.1% during 2007-2008, 34.2% during 2009-2010, and 
34.7% during 2011-2012 (241). The MARE consortium collaborating among 10 
countries in Europe (Lithuania, Greece, Spain, Germany, Netherlands, United Kingdom, 
Italy, Portugal, Belgium, and Sweden) and the United States reported that overall 
prevalence of metabolic syndrome is 24.3% (24.6% in women and 23.9% in mem) (242). 
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This study also found that Lithuania had the highest prevalence of metabolic syndrome 
(around 63%) and Italy presented the lowest prevalence (around 7%). Misra and Khurana 
reported the prevalence of metabolic syndrome in developing countries (33.5% in South 
Africa, 16.3% in Morocco, 21% for Oman, 33.4% in Turkey, 31.2% in Venezuela, 25.4 
in Brazil, and 33.7% in Iran.) (243). The China Health and Nutrition Survey in 2009 
presented that metabolic syndrome prevalence is 21.3% (95%CI: 20.3-22.2) for NCEP 
ATPIII criteria and 18.2% (95%CI: 17.3-19.1) for IDF criteria after adjustment for age 
(244). The prevalence of metabolism of rural women in Bangladesh and India is also as 
high as the prevalence in other developing and developed countries (36.4% in India and 
31.25% in Bangladesh) (245, 246).   
Higher prevalence of metabolic syndrome in women than in men has been 
reported in the United States, Germany, France, Greece, Finland, and Sweden (241, 242, 
247) , but not in Northeast of China, Spain, Netherlands, Portugal (242, 247, 248). Data 
from the National Health and Nutrition Examination Survey (NHANES) (2003-2012) in 
the United States reported that the highest prevalence of metabolic syndrome was 38.6% 
in Hispanic population, and 37.4% in Non-Hispanic Whites, 35.5% in Blacks, and 23.4 in 
other races (241). 
2.3.3 Risk factors of metabolic syndrome 
a) Age 
The NHANES (2003-2012) reported that prevalence of metabolic 
syndrome increased when ages increased (18.3% among ages 20-39 years, and 
46.7 among ages 60 years or over (241). The prevalence of metabolic syndrome is 
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considered to increase with age. The LATIN America METabolic Syndrome 
(LATINMETS) multicenter study in Brazil reported that increased age groups 
increases risk of metabolic syndrome (20-29 years: OR:1.3, 95% CI: 0.5-3.2; 30-
39 years: OR:5.6, 95% CI: 0.8-11.9; and ≥ 40 years: OR:26.3, 95% CI: 4.5-48.1) 
(249). The Chinese survey in 2009 (244) reported that risk of metabolic syndrome 
increased three time in age ≥ 60 years (OR: 36.7, 95% CI: 34.7-38.7) when 
compare with age 18-39 years (OR: 12.4, 95% CI: 10.9-13.9-38.7).    
b) Body weight 
A national Survey in the United States (1988-1994) (250) reported that 
increased BMI increased the incidence of metabolic syndrome in both men and 
women (BMI 18.5-24.9 is a reference, for men: BMI 25-29.9 kg/m2 (OR: 5.2, 
95% CI: 3.9-6.9), BMI 30-34.9 kg/m2 (OR: 25.2, 95% CI: 19.3-32.9), BMI ≥ 35 
kg/m2 (OR: 67.7, 95% CI: 40.5-113.3); for women: BMI 25-29.9 kg/m2 (OR: 5.4, 
95% CI: 3.7-7.9), BMI 30-34.9 kg/m2 (OR: 14.0, 95% CI: 9.1-21.4), BMI ≥ 35 
kg/m2 (OR: 34.5, 95% CI: 22.6-52.7)).  Xi et al. found that overweight and 
obesity significantly increased risk of metabolic syndrome (BMI < 25 kg/m2 is 
reference; BMI 25-27.49 kg/m2: OR: 4.32, 95% CI: 3.77-4.95; BMI ≥ 27.5 kg/m2: 
OR: 11.24, 95% CI: 9.53-13.26) (244). 
c) Smoking 
Smoking is associated with abdominal obesity and insulin resistance 
(251). Studies in Norway and Korean found that smoking more than 20 cigarettes 
per day increased risk of metabolic syndrome (HR:  1.25, 95% CI: 1.02-1.53, and 
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OR: 1.79, 95% CI: 1.10-2.91, respectively) when compared with non-smoker 
(252, 253). A population based cross-sectional study in China found that 
increased smoking increased risk of metabolic syndrome (never is reference; OR: 
0.79, 95% CI: 0.51-1.25 for ≤ 7.5 packs/year; OR: 1.12, 95% CI: 0.69-1.79 for ≤ 
20 packs/year, and OR: 1.81, 95% CI: 1.15-2.84 for > 20 packs/year; p-trend 
0.045) (251). A study in Iran also reported the protective effect of smoking on 
metabolic syndrome. (254)A study in China reported that high incidence of 
metabolic syndrome in heavy smoker (≥11 cigarettes/day) (OR: 1.33, 95% CI: 
1.04-1.71) when compare to lighter smokers (≤ 10 cigarettes/day) (244). 
However, the study in Japan and Portugal that smoking had no association with 
metabolic syndrome (255, 256). 
d) Alcohol consumption 
Light or moderate alcohol consumption can reduce risk of coronary heart 
disease and stroke, but excessive consumption is toxic to many organs (257). The 
association between alcohol consumption and risk of metabolic syndrome is 
inconsistent. A meta-analysis study, analyzing 14 observational studies, found 
that both men having alcohol consumption 0.1-39.9 g/day and women having 
alcohol consumption 0.1-19.9 g/day had a lower prevalence of metabolic 
syndrome when compared with non-drinkers (OR: 0.84, 95% CI: 0.75-0.94 for 
men and OR: 0.75, 95% CI: 0.64-0.89 for women) (258). The Third National 
Health and Nutrition Examination Survey in the United States also reported the 
protective effect of alcohol consumption on the incidence of metabolic syndrome 
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(< 1 drink/month is reference, OR: 0.65, 95% CI: 0.54-0.79 for 1-19 
drinks/month: OR: 0.34, 95% CI: 0.26-0.47 for ≥ 20 drinks/month, p-trend = 
0.0001) (259). A study in China (251) also reported the protective effect of 
alcohol consumption (0 g/day is reference, OR: 0.81, 95% CI: 0.63-1.05 for ≤ 5.7 
g/day: OR: 0.72, 95% CI: 0.56-0.94 for ≤17.7 g/day; OR: 0.73, 95% CI: 0.56-0.95 
for > 17.7 g/day; p-trend <0.0001). However, a survey in China demonstrated that 
increased alcohol intake increased metabolic syndrome risk (<1 time/month is 
reference; 1-3 times/month (OR: 1.82, 95% CI: 1.21-2.75; 1-2 times/week (OR: 
2.03, 95% CI: 1.35-3.05); 3.4 times/week (OR: 2.07, 95% CI: 1.31-3.27); 1 
times/day (OR: 2.16, 95% CI: 1.45-3.22)) (244). A cross-sectional study in 
Portugal reported no association between alcohol consumption and metabolic 
syndrome (255). 
e) Dietary intake 
The NHANES (1988-1994) found that high carbohydrate intake increased 
risk of metabolic syndrome in men (OR: 1.7, 95% CI: 1.2-2.5 in men and OR: 
1.1, 95% CI: 0.8-1.4 in women) (250). A cross-sectional study in Finland found 
that increased fish consumption reduced risk of metabolic syndrome (tertile 1 is 
reference, tertile 2 (OR: 0.52, 95% CI: 0.32-0.83), tertile 3 (OR: 0.63, 95% CI: 
0.4-1.0), p-trend 0.04 (260). This study also reported the protective effect of the 
consumption of berries, legumes and nuts on the incidence of metabolic 
syndrome. Many studies also reported the inverse association between fish 
consumption and risk of metabolic syndrome (261-263). A study in France 
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presented that increased consumption of cereal grains, and dairy products 
decreased risk of insulin resistance (quintile 1 is reference, for cereal grains: 
quintile 2 (OR: 1.24, 95% CI: 0.76-2.00), quintile 3 (OR: 0.79, 95% CI: 0.47-
1.33), quintile 4 (OR: 0.55, 95% CI: 0.30-0.98), quintile 5 (OR: 0.76, 95% CI: 
0.39-1.48), p-trend 0.05; for dairy products: quintile 2 (OR: 0.76, 95% CI: 0.46-
1.23), quintile 3 (OR: 0.64, 95% CI: 0.39-1.07), quintile 4 (OR: 0.49, 95% CI: 
0.28-0.83), quintile 5 (OR: 0.64, 95% CI: 0.37-1.09), p-trend 0.03) (262). This 
study also found that meat consumption was positively associated with insulin 
resistance (quintile 1 is reference, quintile 2 (OR: 0.96, 95% CI: 0.56-1.64), 
quintile 3 (OR: 1.10, 95% CI: 0.64-1.88), quintile 4 (OR: 1.70, 95% CI: 0.99-
2.90), quintile 5 (OR: 2.29, 95% CI: 1.30-4.02), p-trend 0.0007). The protective 
effect of dairy consumption on insulin resistance was also reported in the 
Coronary Artery Risk Development in Young Adults (CARDIA) study (264). 
f) Physical activity 
Increased physical activity has a protective effect on metabolic syndrome 
because increased physical activity improves metabolic parameters by promoting 
weight reduction (251). A population based cross-sectional study in China, The 
Nantong Metabolic Syndrome Study (NMSS), reported that occupational physical 
activity reduced the incidence of metabolic syndrome (no or sedentary work is 
reference; light intensity (OR: 0.77, 95% CI: 0.55-0.88, moderate intensity (OR: 
0.55, 95% CI: 0.57-0.90), and vigorous intensity (OR: 0.76, 95% CI: 0.63-0.91), 
p-trend 0.005) (251). The Tromsø Study (252) reported that increased intensity of 
66 
 
 
 
6
6
 
physical activity significantly decreased risk of metabolic syndrome, which is 
similar to the result from NMSS. However, A study in Portugal reported no 
association between physical activity and metabolic syndrome (255). A study in 
Taiwan found that watching television ≥ 21 hours/week increased the incidence of 
metabolic syndrome when compared with watching television ≤ 5 hours/week 
(OR: 3.69, 95% CI: 1.05-12.95) (265).  The Third National Health and Nutrition 
Examination Survey in the United States (1988-1994) found that physical 
inactivity increase risk of metabolic syndrome (OR: 1.4, 95% CI: 1.0-2.0 for men 
and OR: 1.2, 95% CI: 1.0-1.4 for women) (250). 
2.3.4 Metabolic syndrome and risk of diabetes mellitus  
Pathogenic studies reported that obesity leads to insulin resistance, the 
impairment of insulin sensitivity in sites of glucose disposal, which can develop into type 
2 diabetes mellitus and GDM. Enlarged fat cells lead to increased free fatty acid level, 
which result in insulin resistance and impaired insulin secretion. Enlarged fat cells cause 
fat overflow to muscles, the liver, and the pancreas, which also affects insulin resistance 
and impairs insulin secretion (266). In a study focusing on the correlation between type 
of obesity and risk of diabetes, the presence of visceral fat, or the accumulation of fat in 
the central abdominal area, was associated with diabetes (267).  Moreover, other studies 
presented waist circumference, correlating it with the level of abdominal visceral fat, as a 
predictor of non-insulin independent diabetes mellitus (268-270). 
Metabolic syndrome is a cluster of cardio-metabolic risk factors which increase 
the risk of type 2 diabetes mellitus and cardiovascular disease. Many studies have 
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reported that metabolic syndrome increased the risk of type 2 diabetes mellitus, including 
the West of Scotland Coronary Prevention Study (RR: 7.26, 95% CI: 2.25-23.4 ) (271), 
the Beaver Dam Study (RR: 9.37, 95% CI: 2.22-39.59) (272), the San Antonio Heart 
Study (OR: 3.30, 95% CI: 2.27-4.80) (273), the Framingham Offspring Study (RR: 6.29, 
95% CI: 4.47-10.81) (274), Australian Diabetes, Obesity, and Lifestyle (AusDiab) study 
(RR:7.8, 95% CI: 5.5–11.0) (275), and the Insulin Resistance Atherosclerosis Study (OR: 
4.14, 95% CI: 2.79-6.16) (276). Insulin resistance and dyslipidemia in metabolic 
syndrome are important factors in type 2 diabetes mellitus development. Insulin 
resistance over time will develop to type 2 diabetes mellitus because of the inability of 
pancreatic beta cells to produce sufficient insulin to compensate for insulin resistance 
(232). Moreover, hypertriglyceridemia and hypo HDL-C as a risk factor for pancreatic 
beta cell dysfunction contribute to type 2 diabetes by reducing insulin secretion (277).   
Most studies have reported the development of metabolic syndrome after 
gestational diabetes mellitus (GDM). Studies reported the risk factors of GDM, 
including: high fasting plasma glucose, insulin resistance, high systolic blood pressure, 
high triglyceride level, low HDL-C level at the first trimester of pregnancy, and 
overweight or obesity pre-gestation (174, 278-280). These factors are used for the 
diagnosis of metabolic syndrome. Women with a history of GDM also have increased 
risk of metabolic syndrome. A meta-analysis study (281), analyzing 17 studies, showed 
that the risk of metabolic syndrome increased in women with a history of GDM (OR: 
3.96, 95% CI: 2.98-5.26). In addition, the subgroup analysis by ethnicity showed that 
Caucasian women have higher odds of developing metabolic syndrome after GDM than 
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Asian women (OR: 4.54, 95% CI: 3.78 -5.46 in Caucasian; and OR: 1.28, 95% CI: 0.64 
to 2.56 in Asian). The subgroup analysis by BMI showed that women with prior GDM 
had an increased risk of metabolic syndrome (OR: 5.39, CI: 4.47- 6.50). This result may 
be explained by a study which reported that women with a history of diabetic pregnancy 
had higher CRP levels and lower adiponectin levels compared to controls (282). 
Moreover, higher level of CRP and IL-6 were present in women with metabolic 
syndrome and a history of GDM compared with the control group and women with a 
history of GDM, but who did not have metabolic syndrome (283, 284). Therefore, 
inflammation and adipose tissue relating to insulin sensitivity may be the link between 
GDM and metabolic syndrome.  
 Metabolic syndrome is not only a consequence of, but a risk factor for gestational 
diabetes mellitus. A study in Greece by Chatzi et al. (285) found that women with 
metabolic syndrome in early pregnancy increased the risk of GDM (RR: 3.17, 95% CI: 
1.06-9.50). 
2.3.5 Biochemical markers related to diabetes mellitus and metabolic syndrome 
Biochemical markers are hormones, enzymes, antibodies, or other substances in 
urine, blood, tissue, or other body fluids. These biomarkers have been used to detect 
abnormality or disease. Fasting plasma glucose (FBG), oral glucose tolerance test 
(OGTT), glycated hemoglobin (HbA1c), and random plasma glucose are the common 
biochemical markers for screening and diagnosing diabetes (145). The association 
between first trimester biomarker and the risk of developing GDM has been studied in 
lipid profiles, inflammatory biomarkers, and ferritin levels. 
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a) Glucose and Insulin 
Plasma glucose is a parameter for diagnosing diabetes by the American 
Diabetes Association, WHO, and IDF (145, 146). The homeostatic model 
assessment (HOMA) was proposed to assess insulin resistance (HOMA-IR) and 
β-cells function (HOMA-B) (286). HOMA model has been used to predict type 2 
diabetes development. QUICKI (quantitative insulin sensitivity check index) was 
proposed later by Katz et al. in order to assess insulin sensitivity. Chen et al. 
determining the predictive accuracy of QUICKI concluded that QUICKI is an 
accurate index for assessing insulin sensitivity (287). 
HOMA-IR = [Fasting plasma glucose (mmol/L) x Fasting plasma insulin 
(mU/L)]/22.5 
HOMA-B = [20x Fasting plasma insulin (mU/L)]/ [Fasting plasma glucose 
(mmol/L)-3.5]% 
QUICKI = 1/[log(fasting plasma insulin (μU/ml))+log(fasting plasma glucose 
(mg/dl))] 
The Women’s Health Initiative Observation Study (288), a multiethnic 
cohort of women in the United States, found that diabetic cases had higher 
HOMA-IR and lower HOMA-B than controls. This study reported the strong 
association between diabetes and HOMA-IR and HOMA-B in all ethnic groups 
(HOMA-IR; RR: 3.05, 95% CI: 2.63-3.53 for overall; RR: 3.79, 95% CI: 2.94-
4.88 for Whites; RR: 2.59, 95% CI: 2.03-3.30 for Blacks; RR: 2.66, 95% CI: 
1.80-3.91 for Hispanics; RR: 4.18, 95% CI: 2.18-8.04 for Asians;  HOMA-B; RR: 
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0.52, 95% CI: 0.46-0.58 for overall; RR: 0.50, 95% CI: 0.42-0.59 for Whites; RR: 
0.48, 95% CI: 0.39-0.60 for Blacks; RR: 0.49, 95% CI: 0.35-0.68 for Hispanics; 
RR: 0.59, 95% CI: 0.37-0.93 for Asians). The association between type 2 diabetes 
and HOMA-IR and HOMA-B was reported in many population including 
Mexican-American (289), non-Hispanic White (289), African-American (290), 
Mexican (291), Japanese (292), and Chinese (293). Yokoyama et al. found that 
type 2 diabetic patients had higher QUICKI than the healthy participants (294).  A 
five year follow-up study in Finland (295) found that increased QUICKI 
increased risk of type 2 diabetes in obesity (tertile 1 is reference; tertile 2, OR: 
5.29, 95% CI: 1.39-20.24; tertile 3, OR: 7.77, 95% CI: 1.63-37.04; p-trend 0.002).  
Many studies found that pregnant women with GDM have higher HOMA-
IR and lower QUICKI and HOMA-B than pregnant women with normal glucose 
tolerant (296-299). Ozcimen et al. suggested the cut-point of HOMA-IR in the 
first trimester for predicting GDM is 2.60 (300).  However, a prospective cohort 
study in Turkey reported no association between HOMA-IR, HOMA-B, and 
QUICKI and risk of GDM (301). Therefore, HOMA and QUICKI have 
inconsistent correlations with the prevalence of type 2 diabetes and GDM. 
A study in India conducted by Bhatnagar et al. reported that metabolic 
syndrome group had higher both fasting and post-prandial plasma glucose and 
serum insulin including HOMA-IR than the control group (302).  
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b) Lipid profiles 
Both high triglyceride and low high-density lipoprotein levels are 
associated with a pre-diabetic state, or insulin resistance syndrome (303). The San 
Antonio Heart Study with an 8 year follow up, reported that participants who 
converted to non-insulin dependent diabetes mellitus had higher triglyceride 
levels and lower HDL levels than subjects without diabetes. These results were 
statistically significant for both men and women (181).  A longitudinal study in 
Norway also reported that both high triglyceride and low HDL had a significant 
association on the risk of diabetes (162). The Finnmark study with a 12 year 
follow up, presented a significant inverse correlation between HDL levels and the 
risk of diabetes mellitus only in women at not in men (HDL <1 mmol/l is 
reference, HDL 1.0-1.49 mmol/l :RR = 0.6), HDL ≥ 1.5 mmol/L: RR = 0.17), P-
trend <0.0001)(171). In addition, a positive correlation between total cholesterol 
and risk of diabetes was reported in the study from Qatar (total cholesterol ≥ 240 
mg/dl OR: 1.4, 95% CI: 1.0-1.9) (172). 
The triglyceride and HDL levels have an association with the development 
of GDM. Pregnant women developing GDM have lower HDL levels and higher 
triglyceride levels during the first trimester than control pregnancies when 
adjusted for maternal age, BMI, gestational age at sampling, smoking, ethnicity, 
parity, conception status, and previous GDM (279). Guanghui Li and colleagues 
(304) studied the association between lipid profiles during the first trimester and 
risk of developing GDM. The study reported on two groups, a lean group (BMI < 
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24 kg/m2) and an obese group (BMI ≥ 24 kg/m2). After adjustment for age, parity, 
gravidity, family history of diabetes, and level of education, the risk of developing 
GDM had a positive association with triglyceride, LDL, and LDL/HDL ratio in 
both groups. In addition, the negative correlation between HDL level and the risk 
of GDM was found only in lean women. The results of this study were supported 
by a meta-analysis study which found that higher triglyceride and LDL levels and 
lower HDL levels during first trimester were associated with development of 
GDM (305). 
c) Fatty acids 
Fatty acids have been used as biomarkers for dietary fat intake, obesity, 
insulin resistance and diabetes. The Melbourne Collaborative Cohort Study 
(MCCS), four year follow up, presented a positive association between the 
incidence of type 2 diabetes and some plasma fatty acid proportions such as total 
saturated fatty acid levels (OR: 3.76, 95% CI: 2.43- 5.81), stearic acid levels (OR: 
4.14, 95% CI: 2.65- 6.49), palmitoleic acid levels (OR: 5.61, 95% CI: 3.65-8.60), 
dihomo-γ-linolenic acid levels  (OR: 9.65, 95% CI: 5.48-16.97), and inverse 
association with linoleic acid levels (OR: 0.22, 95% CI: 0.14- 0.36), and trans 
fatty acid levels (OR: 0.20, 95% CI: 0.12- 0.32) when compared highest quintile 
with lowest quintile (306). 
d) Inflammatory markers: cytokines and adipokines 
Inflammatory markers and diabetes can be described with adipose tissue 
functions. Obesity causes adipose tissue to promote inflammatory response 
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(increased leptin, resistin, visfatin, chemerin, tumor necrosis factor alpha (TNF-
α), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), plasminogen 
activator inhibitor 1, monocyte chemoattractant protein-1, and retinol binding 
protein-4, and decreased adiponectin and interleukin-10 (IL-10)) (307). 
Inflammatory markers have been proposed as predictors for the incidence 
of type 2 diabetes. A meta-analysis study conducted by Wang et al. found that 
interleukin-6 (IL-6) and C-reactive protein (CRP) had positive associations with 
the risk of type 2 diabetes (RR: 1.31, 95% CI: 1.17-1.46 and RR: 1.26, 95% CI: 
1.16-1.37, respectively) (308). The population-based MONItoring of trends and 
determinants in CArdiovascular disease (MONICA)/Cooperative Research in the 
Region of Augsburg (KORA) (309) studies found that increased interleukin-18 
(IL-18) raised the risk of type 2 diabetes. The MONICA/KORA studies, however, 
did not observe an association between type 2 diabetes and IL-6 and CRP. A year 
later, the MONICA/KORA studies published result on the novel inflammatory 
markers associated with type 2 diabetes, namely monocyte chemoattractant 
protein-1 (MCP-1), interleukin-8 (IL-8) and interferon-gamma-inducible protein-
10 (IP-10) (310). A cohort study in the United Kingdom found that Interleukin-1 
receptor antagonist (IL-1Ra) was positively associated with the risk of type 2 
diabetes (OR: 1.48, 95% CI: 1.21-1.80) (311). 
Adipokines have been reported to have an association with the incidence 
of type 2 diabetes. The data from the Third National Health and Nutrition 
Examination Survey (NHANES III) (312) showed that increases in leptin levels 
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significantly increased the incidence of diabetes mellitus in both genders (Q4 vs 
Q1; OR: 4.36, 95% CI: 2.15-8.85 for men, OR: 2.76, 95% CI: 1.32-5.77 for 
women, and OR: 3.79, 95% CI: 2.05-7.00 for overall) after adjustment for 
diabetes risk factors (age, sex, race/ethnicity, education, smoking, alcohol intake, 
hypertension, serum cholesterol and C-reactive protein). However, plasma leptin 
level had no association with diabetes mellitus after adjustment for diabetes risk 
factors and body mass index (Q4 vs Q1; OR: 1.07, 95% CI: 0.59–1.94 for men, 
OR: 0.86, 95% CI: 0.49–1.51 for women, and OR: 0.98, 95% CI: 0.56–1.72 for 
overall). A meta-analysis study (313) analyzing 24 articles presented that an 
increase in leptin levels of 1-log ng/ mL significantly increased the risk of type 2 
diabetes only in men (RR: 1.37, 95% CI: 1.13-1.66 in men, and RR: 0.96, 95% 
CI: 0.90-1.03 in women) after adjustment for type 2 diabetes risk factors and body 
mass index. The British Regional Heart Study (314) , a prospective study of 
cardiovascular disease in men aged 60-79 years, reported that type 2 diabetes 
mellitus had a negative correlation with adiponectin (RR: 0.33, 95% CI: 0.19-
0.56) and a positive correlation with leptin (RR: 4.98, 95% CI: 2.75-9.04) after 
adjusting for type 2 diabetes risk factors. The 10 year follow-up study in 
Aboriginal Canadian population (315) showed that type 2 diabetes mellitus had a 
positive association with leptin (OR: 1.50, 95% CI: 1.02-2.21) and a negative 
association with adiponectin (OR: 0.63, 95% CI: 0.48-0.83) and adiponectin-to-
leptin ratio (OR: 0.54, 95% CI: 0.37-0.77), after adjustment for age, sex, 
triglycerides, HDL cholesterol, hypertension, and impaired glucose tolerance. 
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However, only adiponectin significantly correlated with the risk of type 2 diabetes 
(OR: 0.68, 95% CI: 0.51-0.90) after additional adjustment with waist 
circumference and body mass index. 
Prospective studies have found that GDM is related to decreased 
adiponectin and anti-inflammatory cytokines (IL-4 and IL-10) and increased 
leptin and pro-inflammatory cytokines (IL-6 and TNF-α) (316). Pregnancies with 
GDM have higher IL-6 concentrations during the first trimester than pregnancies 
without GDM (317). Adiponectin levels during the first trimester have a negative 
correlation with the risk of developing GDM (OR: 1.13, 95% CI: 1.03-1.24 per 1 
µg/ml decrease) after adjustment for age and waist circumference (318). When 
compared to the highest quantile, pregnant women with first trimester adiponectin 
concentrations ranging in the lowest quantile were 10.2 times (95% CI: 1.13-78.7) 
more likely to develop GDM (319). Other studies confirmed that pregnant women 
developing GDM have lower adiponectin level and higher leptin and CRP levels 
than women in the control group (279, 320-323). Increased first trimester CRP 
concentration increased the risk of developing GDM after adjusting for age, 
race/ethnicity, parity, blood pressure, smoking, and gestational age (T3:T1, OR: 
3.6, 95% CI: 1.2-11.4, p-trend < 0.01) (324). Qui C and colleagues (323) reported 
that leptin levels during the first trimester of pregnancy were positively associated 
with the risk of developing GDM when adjusted for parity, family history of type 
2 diabetes, and pre-pregnancy BMI (T3:T1, OR: 4.90, 95% CI: 1.40-17.5, p-trend 
< 0.02) (325). 
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The positive association between CRP and risk of metabolic syndrome 
was found in studies in the United States (326), Spain (327), Korea (328), India 
(329), and Iran (330). A study in Poland (331) reported the increased hs-CRP, IL-
6, and TNF- α increased a number of metabolic syndrome components. This study 
also presented a negative association between adiponectin and a quantity of 
metabolic syndrome parameters. The Indian Atherosclerosis Research Study 
(IARS) (332) found that hs-CRP levels was associated with risk of developing 
metabolic syndrome (OR: 1.49, 95% CI: 1.14-1.95), but the association between 
IL-6 and metabolic syndrome was not found. A study in Japan by Matsushita et 
al. presented that increased TNF- α and CRP, including deceased adiponectin 
were associated with metabolic syndrome (OR: 1.27; 95% CI: 1.00-1.60, OR: 
1.49; 95% CI: 1.19-1.87, and OR: 2.03, 95% CI: 1.55-2.66, respectively) (333). A 
negative association of adiponectin and positive associations of leptin and CRP on 
metabolic syndrome were reported in a population-based cross-sectional study in 
Kuwait (334) and Spain (335). However, the Framingham Heart Study (336) 
reported no association between risk of metabolic syndrome and inflammatory 
biomarkers (CRP, IL-6, and TNF- α).  
e) Liver enzymes 
Liver functions maintain glucose levels during fasting and in the 
postprandial period. The liver enzymes are used to evaluate of liver function: 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-
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glutamyltransferase (GGT).  AST and ALT are considered as hepatocellular 
health markers while GGT can indicate biliary tract function (337). 
The correlation between liver enzymes and risk of type 2 diabetes has 
been reported for many decades, but the results are still inconclusive. The Insulin 
Resistance Atherosclerosis Study, a multicenter observational epidemiologic 
study (338) showed that AST had a significant positive association with the risk 
of type 2 diabetes (OR: 1.98, 95% CI: 1.23–3.17; Q4 vs Q1–Q3). The association 
between AST and incidence of type 2 diabetes was reported in the Mexico City 
Diabetes Study (339) and the cohort study in China (340), but not in a Korean 
(337),  Japanese (341), or English (342) study. The Namwon study (337) 
presented that after adjusting for diabetes risk factors, serum ALT concentration 
were associated with type 2 diabetes in both males (OR: 1.95, 95% CI: 1.18-3.21) 
and females (OR: 1.49, 95% CI: 1.03-2.16) when comparing the highest quartile 
(ALT ≥ 30 units/l) to the lowest quartile (ALT ≤ 20 units/l). Many studies also 
reported the association between ALT and incidence of type 2 diabetes (338, 340, 
342-345). However, studies of middle-aged Japanese men (341) and a Mexican 
population (339) reported no correlation between ALT and risk of type 2 diabetes 
after adjusting for other diabetes risk factors. The Mexico City Diabetes Study 
(339) reported that GGT was an independent predictor for type 2 diabetes when 
controlling for diabetes risk factors, plasma proinsulin and 2 hour glucose levels 
(OR:1.62, 95% CI:1.08–2.42). The study in Korea (337) also reported that 
females in the highest GGT quartile (GGT ≥ 55 units/l) had a significantly 
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increased risk of type 2 diabetes (OR: 1.85, 95% CI: 1.23-2.79) when compared 
with the lowest quartile (GGT ≤ 19 units/l). Many studies (342, 344-346) 
confirmed that increased GGT increased the risk of type 2 diabetes. The study in 
middle-aged Japanese men (341) reported that increased serum alkaline 
phosphatase significantly raised the risk of type 2 diabetes after adjustment for all 
diabetes risk factors (OR: 2.04, 95% CI: 1.39-3.00 for Q4 vs Q1, p-trend <0.001). 
A 5-year follow-up study in the United Stated (326) presented the 
association between incidence of metabolic syndrome and ALT and AST/ALT 
ratio (OR: 1.43, 95% CI: 1.15-1.77 and OR: 0.72, 95% CI: 0.57-0.90, 
respectively). Meta-analysis studies (347, 348) considering prospective cohort 
studies, reported that the highest category of GGT and ALT increased risk of 
metabolic syndrome when compared with the lowest category (RR: 1.63, 95% CI: 
1.43-1.82 and RR: 1.81, 95% CI: 1.49-2.14, respectively). These studies also 
found that risk of metabolic syndrome was 1.09 per 5U/l increment of GGT levels 
(95% CI: 1.06-1.13) and 1.13 per 5U/l increment of ALT levels (95% CI: 1.11-
1.16). 
f) Iron status 
Body iron stores have been reported as an independent predictor of the 
risk for type 2 diabetes. The EPIC (European Prospective Investigation of 
Cancer)-Norfolk Cohort Study (349) and a study in China (350) reported that a 
raised ferritin level increased the risk of type 2 diabetes during 5 years of follow-
up. Montonen et al. examined the association between body iron stores and risk of 
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type 2 diabetes among 27,548 participants during a 7 year follow-up. This study 
found that serum ferritin concentrations were positively associated with the risk of 
type 2 diabetes (RR: 1.73, 95% CI: 1.15- 2.6, p-trend 0.002), while there was no 
correlation between transferrin receptors and the risk of type 2 diabetes (351). The 
Camden study reported that first trimester serum ferritin levels were positively 
associated with the risk of GDM (OR: 2.35, 95% CI: 1.06- 5.22, p-trend <0.05) 
(322). 
g) Amino acid profiles 
The population-based Metabolic Syndrome in Men (METSIM) Study 
(4.7-year follow-up) reported that alanine (OR 1.02, 95% CI: 1.01-1.04), leucine 
(OR 1.05, 95% CI: 1.01-1.08), Phenylalanine (OR 1.06, 95% CI: 1.00-1.13), 
isoleucine (OR 1.10, 95% CI: 1.05-1.15), tyrosine (OR 1.12, 95% CI: 1.05-1.19), 
and glutamine (OR 0.97, 95% CI: 0.96-0.99) predicted the incidence of type 2 
diabetes (352).  Moreover, the increased level of alanine, leucine, isoleucine, 
valine, phenylalanine, and tyrosine and decreased level of glutamine and histidine 
increased fasting plasma glucose and 2 hour postprandial glucose, and decreased 
insulin sensitivity. 
2.3.6 Genes related to obesity and diabetes mellitus 
Four hundred and sixteen genes were found that were associated with type 2 
diabetes or GDM or obesity. These genes can be divided into two priority groups. 
Twenty-eight genes classified into the first group having association between OFCs and 
type 2 diabetes or GDM or obesity (Table 2.2). In the second group, three hundred and 
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eighty-eight genes have association with significant association with type 2 diabetes or 
GDM or obesity in human studies (Table 2.3). 
The association between gene polymorphisms and the risk of diabetes differs 
among populations. Polymorphisms in genes related to β-cell function, insulin sensitivity, 
glucose transport, glucose homeostasis, cytokine, and obesity have been found to be 
associated with the incidence of diabetes.  Genes related to obesity were associated with 
body mass index, waist circumference, waist-to-hip ratio, and fat distribution. Genes 
classified in first priority group were described more in term of mechanisms and the 
association with diabetes mellitus and obesity.   
a) ABCC8 (ATP-binding cassette, sub-family C (CFTR/MRP), member 8) 
ABCC8 influences the K-ATP channel function, which causes increased 
insulin secretion by pancreatic β-cells. Elbein et al. reported a ABCC8 gene 
mutation that decreased pancreatic β-cell compensation to reduced insulin 
sensitivity (353). 
A candidate gene study in the United States reported that the 
polymorphism of rs4148643 and rs1799854 was associated with the risk of both 
type 2 diabetes and GDM (354). A study in Turkish (355) and Finnish (354) 
populations found that the variation at rs1799854 and rs1799859 in ABCC8 were 
associated with type 2 diabetes. Additionally, the association between rs1799854 
polymorphism and type 2 diabetes mellitus was confirmed in a Japanese 
population (356). 
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b) ADIPOQ (adiponectin, C1Q and collagen domain containing) 
ADIPOQ gene has an influence on adiponectin concentration, which is 
involved in increased glucose uptake via glucose transporter 4 (GLUT-4), and 
increased fatty acid uptake and oxidation (357). Yamauchi reported that 
adiponectin stimulated phosphorylation of acetyl coenzyme A carboxylase, 
glucose uptake, lactate production, and fatty acid oxidation through activated 5-
prime-AMP-activated protein kinase (358). A human study found that low plasma 
adiponectin levels was associated with hyperinsulinemia and insulin resistance 
(359), and increased adiposity in children decreased insulin sensitivity (360).  
The Chennai Urban Rural Epidemiology Study (CURES) in India reported 
that ADIPOQ variation (rs17846866) was associated with type 2 diabetes (361). 
The correlation between two SNPs in ADIPOQ (rs1063537 and rs16861194) and 
the risk of type 2 diabetes was reported in a Chinese Han population (362, 363). 
The meta-analysis from Western Australian cohort studies provided additional 
SNPs (rs12637534, rs16861209, and rs17366568) associated with type 2 diabetes 
(364). The genetic studies in Chinese Han and Japanese populations reported that 
the SNPs rs2241766 and rs1501299 increased the risk of type 2 diabetes (365, 
366). However, the former study in China reported no correlation between the 
polymorphism in ADIPOQ (rs16861194, rs26672, rs12495941, rs2241766, 
rs1501299, rs12629945, rs6444175, rs267729, rs2275738, rs1342387, rs1029629, 
rs11061971, rs12342, and rs1044471) and the incidence of type 2 diabetes 
mellitus. The study in Korea presented no association between type 2 diabetes and 
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rs2241766 and rs1501299 (367).  The association between type 2 diabetes and the 
polymorphism at rs2241766, rs1501299, and rs822396 in ADIPOQ was 
controversial in a Japanese population (368). However, the study in Bulgaria 
(369) reported the association between GDM and ADIPOQ variant at rs266729, 
rs2241766 and rs1501299. On the contrary, the study in Malaysia (370), China 
(371) and Iran (372) reported that rs2241766 had correlation with GDM. 
The genetic association study in Indians presented that ADIPOQ variants 
at rs1501299, rs822396, and 2241767 had significant correlations with obesity 
(373). A study in France reported that obesity was related to rs266729 and 
rs1501299, but no association between obesity and rs17300539 and rs2241766 
was found (374). A meta-analysis study reported that ADIPOQ polymorphism 
(rs1501299, rs2241766, and rs17300539) had no correlation with obesity (375). 
c) ADRB3 (Adrenoceptor beta 3) 
ADRB3 is a member of beta adrenergic receptor family. Adrenergic 
receptors mediates catecholamine-induced activation of adenylate cyclase through 
G protein-coupled receptors (376). ADRB3 regulates energy balance through 
lipolysis in adipocyte, free fatty acid mobilization from adipose cells to portal 
vein and thermogenesis in skeletal muscle (377, 378). The mutation of ADRB3 
gene is associated with decreased resting metabolic rate, obesity, obesity-related 
diseases (diabetes and hypertension), calorigenic dysfunction, early onset of 
diabetes mellitus, and increased body weight with aging (378, 379).   
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The association of ADRB3 (rs4994) polymorphism on the risk of type 2 
diabetes was presented in the Chinese Han (365) and Japanese populations (380). 
Furthermore, the association between the similar SNP (rs4994) and GDM was 
reported in the study in Austria (381). A study in Chinese population (382) 
reported additional SNPs (rs72655364 and rs72655365) in ADRBP3 associated 
with type 2 diabetes. However, the study in Taiwanese (383) and Italian (384) 
populations reported that rs4994 variant had no correlation with GDM. In Asian 
populations (385-387) found that SNP (rs4994) was associated with obesity. 
Gagnon et al. analyzing the data from the Quebec Family Study (QFS) and the 
Swedish Obese Subjects (SOS) reported that rs4994 mutation had no association 
with obesity (377). 
d) CDKAL1 (CDK5 regulatory subunit associated protein 1-like 1) 
CDKAL1 is a marker of impaired insulin secretion, and increases risk of 
type 2 diabetes. The role of CDKAL1 gene in the function of pancreatic β-cells is 
unknown.  A mouse study showed that CDKAL1 knockout mice impaired 
conversion of proinsulin to insulin and decreased ATP generation in mitochondria 
after glucose stimulation (388). 
A genetic study in the Chinese Han population reported the association 
between type 2 diabetes and CDKAL1 variants at rs10946398, but there was no 
association at rs736425  and rs4712527 variant (389). The meta-analysis study 
(390) presented the significant correlation between type 2 diabetes and CDKAL1 
variant at rs7754840 and rs7756992 in Asian, Caucasian, African, and Arab 
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populations, which is similar to the study in Japanese and Lebanese populations 
(391-395). The association between rs10916398 and the diabetes in Asian, 
Caucasian, and African populations was also reported in the meta-analysis study 
(390). In addition, the study in a Caucasian population (the Wellcome Trust Case 
Control Consortium (WTCCC) and Finland-United States Investigation of 
NIDDM genetics (FUSION)) reported that the CDKAL1 variant (rs10916398) 
increased the incidence of type 2 diabetes (396, 397). Additional SNPs 
(rs4712524, rs9295475, and rs9460546) associated with type 2 diabetes were 
reported in East Asian and European populations (398). A GWAS of a Japanese 
population reported the association between type 2 diabetes and rs2237892 (399).  
Moreover, a GWAS of a Caucasian population found that rs7754840 variant 
increased the risk of type 2 diabetes (400). 
The polymorphisms in CDKAL1 at rs7756992 and rs7754840 increase 
risk of GDM (401). The association between the SNP in CDKAL1 (rs7754840) 
and GDM was confirmed in GWAS in a Korean population (402). However, the 
study in the Chinese population reported that the SNP rs7754840 had no 
association with GDM (403).  In addition, the study in Danish populations added 
more SNP (rs7756992) which have a correlation with GDM (404).  
The GWA study in a Japanese population reported the association between 
CDKAL1 (rs2206734) and BMI (405). The study in a Chinese population found 
that the polymorphism at rs10946398 was not associated with BMI (406). 
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e) CDKN2A/2B (Cyclin-dependent kinase inhibitor 2A/B) 
CDKN2A/2B gene is located on chromosome 9p2, which is located 
between CDKN2A and CDKN2B. CDKN2A and CDKN2B genes are involved in 
cell cycling control in tumor of lung, breast, brain, bone, skin, bladder, kidney, 
ovary, and lymphocyte (407, 408). The function of CDKN2A/2B on diabetes has 
not reported. 
A study of a Dutch population reported the association between the risk of 
type 2 diabetes and rs1412829 in CDKN2A/2B (409). A study of a Japanese and 
Malay populations (395, 410) reported an additional SNP (rs10811661) associated 
with type 2 diabetes. The association between type 2 diabetes and rs10811161 
mutation was found in the Chinese, Indian, Korean, and Han Chinese populations 
(394, 411-413), but not in the African American and Lebanese populations (392, 
414). Both WTCCC and FUSION studies reported that variation at rs10811661 
and rs564398 increased the risk of type 2 diabetes (396, 397). Moreover, the 
meta-analysis study also reported an association between type 2 diabetes and 
rs10811661 in Asian and Caucasian populations, and rs564398 in Caucasian 
populations (390). In GWA study, the association between type 2 diabetes and 
rs10811661 was found in Caucasian populations (400). 
Wang Y. reported the association of the CDKN2A/2B variant at 
rs2383208 with GDM in a Chinese population (403). The study found 
CDKN2A/2B variation (rs10811661) associated with GDM, which was 
confirmed by a study in a Korean population (401). However, no association 
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between GDM and rs10811661 (Danish population) (404) and rs10757261 
(Korean population) (402) was reported. 
f) FTO (Fat mass and obesity associated) 
Gerken et al. (415) reported that FTO shared sequence with iron- and 2-
oxoglutarate-dependent oxygenases, and FTO mRNA level found in 
hypothalamus was regulated by feeding and fasting. A mouse study by Gao et al. 
(416) found that mice with FTO mutation had postnatal growth retardation (lower 
body weight, shorter body length, and lower bonne mineral density) and 
decreased insulin-like growth factor 1 (IGF-1) levels. FTO variants disrupt AT 
rich interactive domain 5B (MRF1-like) (ARID5B)-mediated repression of 
iroquois homeobox 3 (IRX3) and iroquois homeobox 5 (IRX5). The depression of 
IRX3 and IRX5 leads to a cell-autonomous shift from white adipocyte browning 
and mitochondrial thermogenesis, which result in increased fat storage and body 
weight (417).  
The Wellcome Trust Case Control Consortium (WTCCC) and Finland-
United States Investigation of NIDDM Genetics (FUSION) reported that the 
variation in FTO (rs8050136) was associated with the risk of type 2 diabetes in 
European populations (396, 397). The correlation between type 2 diabetes and 
FTO polymorphism (rs8050136 and rs17817449, except rs1121980) was reported 
in a Lebanese Arab population (418). The meta-analysis study based on European 
and East Asian populations (419) found the association between type 2 diabetes 
and variation in FTO at rs9939609, which is similar to the study in Norwegian 
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and Swedish populations after adjusting for age, sex, and BMI (420).  In addition, 
polymorphism at rs9939609 increased the risk of GDM in the study in Spain 
(421). The study in a Chinese population reported additional SNPs associated 
with type 2 diabetes, namely rs6499640 and rs3751812 (422). However, the 
genetic studies reported no association between the diabetic risk and rs9939609 in 
a Japanese population (391), including rs8050136 in African American and 
Chinese populations (411, 414). The study in Denmark found that there was no 
association between the SNP rs9939609 and GDM (404). 
A large prospective study in the United States found the association 
between obesity and rs9939609 in white-Americans and rs1421085 in African-
Americans (423).A meta-analysis confirmed that polymorphism in the FTO gene 
at rs9939609 increased the risk of both overweight and obese subjects (424-426). 
The GWAS study of Scuteri A and colleagues found the correlation between 
obesity and many SNPs in FTO namely rs9930506, rs8050136, rs1121980, 
rs7193144, rs9939609, rs9926289, rs6602024, rs7907949, rs965670, rs1188445, 
and rs6965526 (427). Later GWAS in a European population provided another 
FTO variant (rs1421085) that was associated with obesity (428). 
g) GCK (Glucokinase) 
GCK gene has an important role in glucose homeostasis by censoring 
insulin release in pancreatic β cells (429). In mouse study, mice with isolated 
pancreatic islets of heterozygous GCK knockout had impaired glucose sensitivity 
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and impaired ability of β cells to secrete insulin for maintaining glucose 
homeostasis (430, 431). 
The association between rs2284779 variant and the risk of type 2 diabetes 
was stated in the genetic study of a population with Caucasian ancestry (432). The 
study of Finns reported other GCK polymorphism correlated with type 2 diabetes 
(rs2244164, rs12534623, rs2268573, and rs882020) (433).  
Moreover, studies in Sweden (434) and China (435) presented the 
association of the variant rs1799884 with risk of GDM. The HAPO 
(Hyperglycemia and Adverse Pregnancy Outcome) study, a collaboration among 
United Kingdoms, Australia and Thailand, confirmed the association between the 
SNP rs1799884 and GDM (436).  However, studies in the United States (437) and 
the United Kingdom (438), found no significant association between rs1799884 
mutation and GDM. The variation at rs4607517 has no association with GDM in a 
study of a Chinese population (403). 
h) GNPDA2 (Glucosamine-6-phosphate deaminase 2) 
GNPDA2 gene encodes an enzyme catalyzing the reversible action: 
converting D-glucosamine-6-phosphate into D-fructose-6-phosphate and 
ammonium (439). GNPDA2 is involved in nucleotide metabolic process of 
nucleotide sugar, amino sugar, carbohydrate, and N-acetylglucosamine (439).  
The association between GNPDA2 variant at rs10938397 and type 2 
diabetes was reported in the meta-analysis study in European and East Asian 
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population (419) and the study in a Chinese population (422). The association of 
GNPDA2 on the risk of GDM has not been presented. 
The candidate gene study in Chinese proposed the rs10938397 variant has 
significant association with central obesity (426).  The meta-analysis of GWA 
data reported that GNPDA2 (rs10938397) was associated with BMI (425).  The 
meta-analysis in African ancestry found the additional SNP (rs348465) to be 
associated with body mass index (440). 
i) HHEX (Haematopoietically expressed homeobox) 
HHEX gene encodes a transcription factor related to Wnt signaling for cell 
growth and development. A mouse study found that HHEX knockout mice had 
impaired forebrain, cardiovascular, thyroid, and liver development (441, 442). 
The variation at rs1111875, rs7923837, and rs5015480 in HHEX 
associated with both type 2 diabetes in Han Chinese, Korean, Chinese, and 
Japanese populations (389, 391, 394, 395, 410), and GDM in  a Korean 
population (401). A genetic study in India confirmed that rs1111875 variant 
increased the risk of type 2 diabetes (413). Moreover, the WTCC study reported 
that the SNP rs5015480 was associated with type 2 diabetes (396). Nevertheless, 
no correlation between HHEX (rs1111875) variation and type 2 diabetes was 
reported by the study in the Netherlands (409). The GWA study in French and 
Finnish, Caucasian populations reported the association between type 2 diabetes 
and the polymorphism in HHEX (rs1111875 and rs7923837) (397, 400, 443). 
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j) HNF1A (Hepatocyte Nuclear Factor 1 homeobox A) 
HNF1A, a homeodomain containing transcription factor, is expressed in 
liver, pancreas, intestine, and kidney (444). Mutation of HNF1A gene related to 
hepatic adenomas familial (HEPAF), maturity-onset diabetes of the young 3 
(MODY3), and insulin-dependent diabetes mellitus (IDDM).  According to 
HNF1A mutation, β-cell dysfunction in MODY3 results from impaired DNA 
binding, reduced transcriptional activation, and impaired subcellular localization 
of pancreatic β-cells (444, 445). 
HNF1A (rs1169288) variant was associated with both type 2 diabetes and 
GDM (434, 446, 447). The GWA study in a Hispanic population reported that two 
SNPs in HNF1A (rs7305618 and rs21573907) were associated with type 2 
diabetes (448). The Finnish case-control study reported additional SNP 
(rs2701175) variant increased the risk of type 2 diabetes (449). A study 
combining GWA data of European population found that that variant rs7957197 
increased the incidence of type 2 diabetes (450). 
k) HNF1B (Hepatocyte nuclear factor 1-beta) 
HNF1B, a member of homeodomain containing transcription factor, is 
expressed in liver, pancreas, bile ducts, thymus, genital tract, lung, and gut (451). 
Many studies reported functions of HNF1B including epithelial differentiation 
during human organogenesis (452), renal tubulogenesis regulation (453), hepatic 
insulin sensitivity control (454), and pancreatic endocrine cell generation (455). 
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Moreover, HNF1B gene is also associated with pancreatic β cell dysfunction and 
insulin resistance (454). 
The study in Caucasian reported the association between type 2 diabetes 
and five SNPs in HNF1B (rs6422978, rs11263755, rs2285741, rs10962, and 
rs3110641) (432). The genetic study in the United States found that the 
polymorphism in HNF1B (rs12450628 and rs1008284) was associated with type 2 
diabetes (433). The study in a Japanese population presented the association 
between type 2 diabetes and the SNPs rs1016991 and rs2688, not at rs757210, 
rs757211, rs718960, and rs2689 (356). The cohort study in the United States 
present no association between type 2 diabetes and the variation in HNF1B 
(rs11649743, rs4430796, and rs7501939) (456). However, the association 
between the SNP rs4430796 and type 2 diabetes was reported in the GWAS of a 
European population (450). Only polymorphism in rs7903146 is associated with 
GDM in a Danish population (404). 
l) IGF2BP2 (Insulin-like growth factor 2mRNA binding protein 2) 
IGF2BP2 is a family of mRNA-binding protein (IMP1, IMP2, and IMP3), 
which relates to RNA stability, localization, and translation.  IMPs are expressed 
in developing cells, especially in neuronal and epithelial cells in mid-gestation. 
IGF2BP2 mRNA is found in many organs (brain, gut, testis, liver, pancreas, bone 
marrow, kidney, lung, and muscle) during perinatal period and in adult tissues 
(457). IGF2BP2 variant was associated with impaired pancreatic β cell function 
(458, 459), and impaired insulin sensitivity (460). 
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Genetic studies presented the association between type 2 diabetes and the 
polymorphism in IGF2BP2 at rs4402960 and rs1470579 in Japanese, Chinese, 
Korean and Indian populations (391, 394, 395, 410, 461), and at rs7651090 in a 
Chinese population (411). The genetic study in East Asian and European 
populations found that the IGF2BP2 variation (rs4376068 and rs6769511) 
increased the risk of type 2 diabetes (398). However, The WTCC and FUSION 
study (396, 397) and the genetic studies in Dutch, Chinese Han, and Japanese 
populations (368, 389, 409) reported no association between type 2 diabetes and 
the SNP rs4402960. The correlation between the variant rs1470579 in IGF2BP2 
and type 2 diabetes was confirmed by the GWAS in a Japanese population (399). 
The GWAS in a Caucasian population also reported that type 2 diabetes was 
associated with the SNPs rs1470579 and rs4402960 (400). 
The association between the rs4402960 polymorphism and GDM was 
reported in the candidate gene approach in China (403) and Korea (462). The 
GWAS in the Korean population reported that the SNP in IGF2BP2 (rs1470579) 
was correlated with GDM (402). The association between rs4402960 and GDM 
was not significant in the Danish population (404). 
m) IL-10 (Interleukin-10) 
IL-10 gene encoded anti-inflammatory cytokine, a T helper 2 mediated 
cytokine, which inhibits cytokine production by t helper 1 cells (463). Il-10 gene 
expression is important for inflammatory response and disease progression. 
Dysregulation of IL-10 increased inflammatory response and risk of developing 
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autoimmune diseases such as Crohn’s disease, hepatitis, Systemic Lupus 
Erythematosus (SLE), and allergic asthma (464). A mouse study by Pennline et 
al. (465) found that IL-10 can prevented the onset of diabetes in non-obese 
diabetic (NOD) mice by inhibiting interferon-γ synthesis. This study reporter that 
NOD mice receiving IL-10 treatment reduce the severity of insulitis, prevent 
pancreatic islet cell infiltration, and promote normal insulin production. Esposito 
et al. (466) found that low IL-10 levels was associated with metabolic syndromes 
while high IL-10 concentration was associated with obesity. 
A meta-analysis study, based on Asian and European populations, 
presented that the variation at rs1800872 was associated with type 2 diabetes 
(467). The association between GDM and the polymorphism in IL-10 
(rs1800872) was reported in a Malaysian population (468). However, the genetic 
study in North Indian and Taiwanese population reported no correlation between 
type 2 diabetes and two SNPs in IL-10 (rs1800872 and rs1800871) (469, 470).  
A candidate gene study in Caucasians reported that the variant in IL-10 at 
rs1800872 was associated with increased BMI and waist-to-hip ratio (471). 
n) IRS (Insulin receptor substrate-1) 
IRS1 gene, the insulin receptor substrate protein family, encoded a 
signaling adapter protein. IRS1 has a key role in transmitting signals from the 
insulin and insulin-like growth factor 1 receptors to intracellular phosphoinositide 
3-kinase/protein kinase B pathway and extracellular signal-regulated kinases 
mitogen-activated protein kinase pathway (472). A mouse study found that IRS 
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knockout mice reduced insulin content of β-cells and decreased glucose-
stimulated insulin secretion leading to glucose intolerance (473).  
The genetic studies in Mexican (474), Indian (475) , and Dutch (476) 
populations reported the variant rs1801278 in IRS1 was associated with type 2 
diabetes. A meta-analysis study analyzing data from ten articles (3428 GDM and 
4637 controls) showed that the polymorphism in IRS1 (rs1801278) also related to 
GDM (477). This was also reported in Greek (478), Italian (384), and Saudi (479) 
populations. Moreover, the meta-analysis study in French found that the 
rs2943641 variant increased the risk of type 2 diabetes (480). However, there is 
no association between the IRS1 variation (rs1801278) and type 2 diabetes in the 
African-American population (481), and GDM in the Scandinavian population 
(482). A case-control study in the African-American population reported that the 
polymorphism in IRS1 at rs1801278 was associated with higher BMI (481). 
o) KCNJ11 (Potassium channel, inwardly rectifying subfamily J, member 
11) 
KCNJ11 gene is a family of the potassium channel gene. KCNJ11 gene 
encodes an inward-rectifier potassium ion channel (Kir6.2) protein, which is 
subunit of the ATP-sensitive potassium (KATP) channel. Increased glucose 
concentration increases potassium flow into cell through the KTAP channel, and 
ATP binds to Kir6.2 in order to increase intracellular potassium ion concentration. 
Increased intracellular potassium concentration activating calcium ion channel 
leads to increase intracellular free calcium ion levels which trigger other 
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components of insulin secretion pathway.  KCNJ11 gene mutation can lead to 
diabetes by disrupting Kir6.2 protein activity, reducing ATP sensitivity of KTAP 
channel activity and suppression of insulin secretion (483).  
The association between type 2 diabetes and KCNJ11 polymorphism at 
rs5215 was reported in the Chinese Han population (389) and at rs5219 in 
Chinese (411), Japanese (410), and Indian (461) populations. However, the study 
in Turkey reported no association between type 2 diabetes and the SNPs in 
KCNJ11 (rs5215, rs5219, rs5218, rs5216, and rs1800467) (355). The GWA study 
in a Caucasian population found that the variant rs5219 in KCNJ11 increased the 
incidence of type 2 diabetes (400). In addition, the GWA study in a Finnish 
population (397) confirmed the correlation between type 2 diabetes and the SNP 
rs5215. 
The variation at rs5219 also has a correlation with GDM in a Scandinavian 
population (482). However, the studies in Korea (401)  and Denmark (404) 
presented no significant association between GDM and two SNPs in KCNJ11 
(rs5215 and rs5219). 
p) KCNQ1 ((Potassium channel, voltage gated KQT-like subfamily Q, 
member 1) 
KCNQ1 encodes a pore-forming alpha-subunit of the voltage-gated K 
channel (KvLQT1). KCNQ1 is expressed in a wide variety of tissue including: 
heart, lung, liver, kidney, adipose tissue, brain, skeleton muscle and pancreas 
(484). KCNQ1 controls ventricular repolarization process, which lead to cardiac 
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conduction abnormality (485). A complex interaction between ATP-sensitive K+ 
(KATP) channels and voltage-dependent K
+ (Kv) channels regulated insulin 
secretion from pancreas. The Electronic mechanism at KATP and Kv channels 
triggers and maintains glucose-stimulated insulin secretion. This effect may lead 
to impair pancreatic β-cell function (486). 
A meta-analysis of GWAS in African American population reported the 
association between two SNP (rs231356 and rs2283228) in KCNQ1 and type 2 
diabetes (487). A meta-analysis in Mexican-American population (448) and a 
GWAS in Japanese population (488) found that rs2237892 variation increased 
risk of type 2 diabetes. Another meta-analysis study including Japanese, Chinese, 
and Korean population also reported that rs2074196, rs2237892 and rs2237895 
polymorphisms (SNP) was significantly associated with type 2 diabetes (489). 
The association between rs2237895 and type 2 diabetes was reported in a GWAS 
in Han Chinese population (490) and the Punjabi cohort study (Indians living in 
India and the United States) (484). A case-control study in Lebanese population 
also found that KCNQ1 variation (rs2237892 and rs2237895) was associated with 
type 2 diabetes (418). 
A-meta-analysis study from multi-ethnic population (Korean, Chinese, 
French, Greek, Swede, Brazilian, Dane, Turkish, and American), reported that 
rs2237892 associated with GDM (491). A candidate gene study in Chinese 
population found that KCNQ1 polymorphism at rs2237895 and 2237896) 
increased risk of GDM but there is no association between rs2237892 had GDM 
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(492).  Candidate gene studies in Korean population presented that the KCNQ1 
polymorphism at rs2074196 and rs2237892 and rs2237895 increased risk of 
GDM (493, 494). 
q) LEP (Leptin) 
LEP gene encodes leptin hormone regulating body weight through leptin 
receptors. The more fat accumulates, the more leptin is produced because fat cells 
release leptin in proportion to their size. Leptin is involved in food intake 
inhibition, energy expenditure regulatory, energy and glucose homeostasis, bone 
formation, immune and inflammatory response, angiogenesis, hematopoiesis, and 
would healing. The activation of leptin receptor mediates transcriptional 
regulation of the melanocortin pathway in hypothalamus and downregulates 
endocannabinoid expression in order to control food intake and energy balance 
(495). The peripheral actions of leptin are inhibition of insulin synthesis and 
secretion in pancreatic β-cell insulin biosynthesis (496). A study found that 
obesity may result from downregulation of leptin receptor expression and 
unresponse of leptin signal. A mouse study reported that leptin deficient mice 
(obese mice and lipodystrophic mice) presented hyperinsulinemia leading to 
downregulate insulin receptor in liver and adipose tissue (497). 
LEP gene has correlation with obesity and BMI. Leptin regulates glucose 
uptake and fatty acid oxidation and inhibits insulin secretion. The study in Korean 
women showed that the polymorphism of LEP at rs10954173 and rs11761556 
increased the risk of type 2 diabetes (498). The LEP variation (rs7799039) had no 
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association with type 2 diabetes in a Chinese population (499). Enquobahrie DA 
and colleagues, analyzing genotype from placenta, reported the LEP expression in 
GDM group was significantly different from the control (500).  
A candidate gene study in South Africans found the association between 
BMI and LEP polymorphism (rs10954174 and rs6966536) (501). However, the 
study in Finland (502), and Italy (503) presented no association between 
rs2167270 and obesity. A meta-analysis study reported no association between 
obesity and rs2167270 and rs7799039 (375). 
r) LEPR (Leptin receptor) 
LEPR encoded a single transmembrane protein mediating the action of 
leptin. LEPR gene mutation causes impaired receptor signaling of leptin, and 
related to obesity, hyperleptinemia, and atherogenic lipid profiles (504). A study 
found that LEPR mutation in obese patients resulted in severe obesity, immune 
dysfunction, pituitary dysfunction, hyperphagia, and delayed puberty (505, 506).  
The meta-analysis study, analyzing data form 16 studies, presented the 
significant correlation between polymorphism at rs1137101 in LEPR and the risk 
of type 2 diabetes (507). The polymorphisms at rs1892534 and rs2211651 are 
associated with early onset type 2 diabetes mellitus in a Taiwanese population 
(508). No association between LEPR polymorphism was reported in Korean or 
Chinese Han populations (362, 498). Moreover, the correlation between LEPR 
and GDM has not been reported. 
99 
 
 
 
9
9
 
The gene association study found that BMI was significantly related to the 
polymorphism in LEPR at rs1137100, rs1137101, rs12033452, rs3790419, and 
rs7518632 (498). Other candidate gene studies in Caucasians presented the 
correlation between rs1137101 and rs9436746 and BMI (509, 510). Meta-analysis 
studies found that the LEPR gene (rs1137101, rs1137100, rs8179183, and 
rs62589000, rs10889567, rs3790437) was not associated with obesity (375, 510). 
s) MTNR1B (Melatonin receptor 1B) 
MTNR1B encodes melatonin 2 protein (MT2), a receptor for melatonin, 
which is expressed in β-cells. MT2 is involved in insulin secretion in β-cells 
because melatonin inhibits adenylate cyclase/cyclic the guanylate cyclase/cyclic 
adenosine monophosphate (AC/cAMP), guanosine monophosphate (GC/cGMP), 
and 1,4,5-trisphosphate (IP3) signal pathways (511). Many studies reported that 
MT2 receptor was associated with decreased glucagon secretion and alterative 
glucose metabolism (512-515). Therefore, MTNR1B polymorphisms affect 
pancreatic glucose sensing, insulin secretion, and glucose tolerance (513, 514).  
MTNR1B is associated with fasting plasma glucose levels in type 2 diabetes 
(514). 
A meta-analysis study reported the MTNR1B (rs10830963) increases the 
risk of type 2 diabetes (514). This SNP is also associated with GDM in a Czech 
Republic study (516). Other candidate gene approaches in Han Chinese (517) and  
Greek (518) populations found similar SNP results to the study from the Czech 
Republic. In addition, the study in the Korean population (519) showed that the 
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variation at rs10830963 and rs1387153 in MTNR1B was associated with GDM. 
This was  supported  by the results of a meta-analysis of ten articles (3428 GDM 
and 4637 controls) with the same SNPs (477).  The GWAS in the Korean 
population proposed the new SNP (rs10830962) associated with GDM (402). 
However, Wang Y presented no association between MTNR1B (rs10830963) and 
GDM (403). 
t) PPARG (Peroxisome proliferator-activated receptor gamma) 
The PPARG gene is associated with insulin action, adipocyte 
differentiation, lipid storage, and fat-specific gene expression (520). Kim et al. 
(521) reported that PPARG activates glucose transporter 2 and glucokinase in 
liver and pancreatic β-cells, which improves glucose homeostasis. Moreover, 
PPARG increases insulin sensitive in peripheral tissue and glucose sensitivity of 
liver and pancreatic β-cells. In a mouse study, PPARG knockout mice higher 
insulin-induced increase in glucose disposal rate and greater insulin-induced 
suppression of hepatic glucose production than in wildtype mice (522). 
The candidate gene studies in Chinese (411), Japanese (523), and Indian 
(461) populations and the GWAS in Finnish (397) and Caucasian populations 
(400) found that the PPARG variant (rs1801282) increased the risk of type 2 
diabetes.  However, a genetic study in the Chinese Han population reported no 
association between type 2 diabetes and PPARG variants at rs1801282, 
rs12636454, and rs11128597 (389). The WTCCC study in England, reported a 
controversial association between rs1801282 and type 2 diabetes mellitus (396). 
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The association between GDM and PPARG variant (Both rs1801282 and 
rs3856806) was found in the study in French (524). However, a candidate gene 
approach in Sweden, Denmark and Korea did not report the association between 
PPARG variation (rs3856806 and rs1801282) and GDM (401, 404, 525). The 
association between rs1801282 and total body fat mass was proposed in 
menopause women (526). 
u) SLC30A8 (Solute carrier family 30 (zinc transporter), member 8) 
SLC30A8, a member of zinc transporter (ZNT) family, encodes zinc 
transporter (ZnT8). ZnT proteins transport zinc out of cells when zinc is excess, 
and sequester cytoplasmic zinc into cell when zinc is replete. Zinc facilitates the 
formation of dense core granules for insulin crystallization in pancreatic β-cell 
and has a positive influence on insulin gene transcription (527). A mouse study 
(528) showed that ZnT8 knockout mice reduced zinc content in pancreatic β-cell 
insulin-secretory granules affecting insulin processing and crystallization. 
Reduced zinc concentration in the secretory granules leads to increased proinsulin 
to insulin ratio in blood circulation and decreased glucose-induced insulin 
secretion (527). 
Studies in Lebanese (418), Japanese (391) and Dutch (409) populations  
reported no association between  type 2 diabetes and the polymorphism in 
SLC30A8 (rs3802177 and rs13266634). Studies of Chinese, British and Indian 
populations (396, 411, 461) including the GWAS in French and Caucasian 
populations (400, 443) found that the polymorphism at rs13266634 was 
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associated with type 2 diabetes. This SNP was also associated with GDM in a 
Korean population (401). In addition, the genetic study of the Han Chinese 
population found an association between type 2 diabetes and SLC30A8 at 
rs3802177 rs11558471, and rs13266634 (389). However, the rs13266634 
mutation had no significant association with type 2 diabetes in an African 
American population (414). 
v) TCF7L2 (Transcription factor 7-like 2) 
The TCF7L2 gene encodes a high mobility group box-containing 
transcription factor related to blood glucose homeostasis. Yi et al. reported that 
TCF7L2 regulated proglucagon by repressing the glucagon gene in 
enteroendocrine cells via Wnt signaling pathway (529). TCF7L2 gene is related to 
pancreatic cells development and glucose-induced insulin secretion (530). A study 
in human found that patients with type 2 diabetes decreased TCF7L2 protein 
levels in pancreas when compared with healthy controls. This study proposed that 
interaction between TCF7L2 and glucagon-like peptide-1 (GLP1R) and glucose-
dependent insulinotropic polypeptide (GIPR) may regulate pancreatic β-cell 
function and survival (531). 
In Dutch, Han Chinese, British, Korean, Chinese, African American, 
Arabic and Indian populations, the polymorphism in TCF7L2 (rs7903146) 
increases the risk of type 2 diabetes (394, 396, 409, 412, 414, 461, 532) and 
increases in risk of GDM in Scandinavian (525), Korean (401), Danish  (404), and 
Czech (533) women. The study in China (389) also reported an association 
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between type 2 diabetes and two SNP (rs7903146 and rs6585205).  The 
association between the SNP rs10885409 and type 2 diabetes was reported in a 
North Indian population (413). However, a study in Netherland reported no 
correlation between the variant rs4430796 in TCF7L2 gene (450). The association 
between type 2 diabetes and rs7903146 was confirmed in the GWAS in French, 
Finnish and Caucasian population (397, 400, 443). Moreover, the Japanese 
GWAS reported that additional SNP rs7901695 increased the incidence of type 2 
diabetes (399). A Meta-analysis of GWAS in African American population found 
additional SNP (rs114748339) associated with type 2 diabetes (487).  
Candidate gene studies in Austria (534), Spain (421), and the Czech 
Republic (533) reported additional SNPs (rs12255372, rs4506565, and 
rs7901695, respectively) related to GDM. However, the same study in Korea 
(401) and Denmark (404) also showed that variation at rs12255372 in TCF7L2 
had no correlation with GDM. 
w) TNF-α (Tumor necrosis factor alpha) 
TNF-α encoded a cell signaling protein produced at inflammatory site. 
TNF-α also activates multiple protein kinases and phosphoprotein phosphatases. 
A mouse study found that TNF-α caused insulin resistance because TNF-α 
infusion activated protein kinase A, which inhibited the tyrosine kinase activity of 
insulin receptor (535). TNF-α is interferes insulin signaling in adipose cell, 
muscle, and liver. TNF-α inhibit glucose-induced insulin secretion (536). A cell 
study by Tsiotra et al. (537) found that TNF-α suppressed both basal and glucose-
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induced insulin secretion and proinsulin mRNA transcription. Hotamisligil et al. 
(535)described the mechanism of TNF-α-induced insulin resistance, TNF-α 
reduced GLUT4 mRNA levels in adipocyte and myocyte and inhibited insulin-
stimulated glucose transport.  
The study in a Finnish population reported that the polymorphism in TNF-
α at rs1800610 increased the risk of type 2 diabetes (449). Additional SNP 
(rs361525) associated with type 2 diabetes was found in a Mexican population 
(538), but not in Taiwanese and British populations (539, 540). The study in 
China (541) and Mexico (542) presented that GDM was associated with the 
variant rs1800629 in TNF-α. However, the study in Malaysia (468) and Brazil 
(543), reported no significant association between TNF-α variation (rs1800629) 
and GDM. Additionally, the study in Tunisia, Taiwan, and Mexico presented no 
association between the variant rs1800629 in TNF-α and type 2 diabetes mellitus 
(538, 539, 544). A meta-analysis study based on Asian and Caucasian population 
and the large-scale study in a British population confirmed the association 
between the SNP rs1800629 and the diabetes (540, 545).  
The study in a European population (Ireland and France) reported that the 
TNF-α polymorphism (rs1800629) increased the risk of obesity (BMI >30 kg/m2) 
(546). The association between rs1800629 and obesity was confirmed with a 
meta-analysis study (375).  However, other studies in Caucasian population 
presented no correlation between TNF-α variation and obesity (544, 547-549). 
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2.4 Genetic Study in Epidemiology 
2.4.1 Overview 
Genetic epidemiology aims to explain the role of genetic variation leading to 
disease risk in populations. The study of genetic epidemiology relies on biometrical work 
and statistical methods (segregation analysis, linkage analysis, association analysis, and 
simulation methods). Genetically influenced diseases can be divided into monogenic 
diseases (diseases resulting from a single gene mutation) and complex or multifactorial 
diseases (diseases occurring with genetic and environmental factors) and each uses a 
different method of analysis.  
When information about DNA was unavailable, scientists used the Mendelian 
laws of inheritance to study the correlation between genetic variation and diseases. 
Nowadays, with extensive data on the human genome, the genome scan and candidate 
genes approach have been used to analyze the association between complex diseases and 
genes. 
2.4.2 Genetic epidemiology approaches 
a) Candidate gene approaches 
i) Segregation analysis 
Segregation analysis is useful in the study of monogenic diseases. 
This approach uses phenotypic data within pedigrees to determine the 
pattern of inheritance of major genes influencing a phenotype and to 
estimate the parameters of the genetic model (recessive, dominant, co-
dominant), which is based on a probability calculation to observe the 
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phenotype on parameters in genetic models and on family structure. The 
most likely model nested within a general model is selected by likelihood-
ratio test.  Moreover, complex segregation analysis may be used for 
multifactorial disease. However, segregation analysis is not useful in the 
case of non-major genes and a few moderately influenced genes (550).  
ii) Linkage analysis 
Linkage studies assess on which part of the chromosome a disease 
gene is located. Linkage analysis investigates the association between a 
marker and a disease in related individuals. This approach aims to 
examine the linkage between a susceptible locus and disease, and 
estimates the recombination rate. There are two methods for linkage 
analysis namely model-based (parametric or “lod score”) and model free 
(nonparametric). The lod score method is based on the likelihood of the 
observed marker and disease in a family under the model for distribution 
of the unobserved disease gene. Nonparametric methods compare the 
proportion of alleles shared IBD (identical by descent) by pairs of affected 
relatives with the proportion expected based on their relationship.  The 
degree of complexity of the disease has an effect on the genetic model 
assumption (550).  
iii) Linkage disequilibrium (genetic association methods) 
Association studies investigate which allele or genotype of genes 
are associated with disease. The case-control study design compares allele 
107 
 
 
 
1
0
7
 
or genotype frequencies in a group of unrelated affected individuals with a 
group of unrelated unaffected individuals.  However, populations 
consisting of two or more subgroups with different allele frequencies, 
different confounding factors, and different baseline rates of disease, may 
cause increased false positive associations and biased relative risk 
estimation.  Therefore, matching or adjusting for race can be used to 
control for the problems arising from a variety in a population 
stratification. 
The family-based study design was created to determine the 
association between suspected alleles of diseases with internal control of 
confounding. There are two types of controls in family-based study 
designs; sibling controls or case-parent-trios (parental control or pseudo-
siblings). The data analysis is based on a standard conditional logistic 
regression model. The case-sibling study design asserts that affected 
individuals are cases and their unaffected siblings are controls.  In a case-
parent-trio study design, only cases and their parents are genotyped and 
form the set of hypothetical pseudo-sibling consisting of the three other 
genotypes which could have been transmitted from the parents. The case-
pseudo sibling sets are analyzed as 1:3 matched case-control design. The 
internal control in the model comes from the two parental alleles that are 
not transmitted to the affected child.  The common test for case-parent-trio 
study design is the Transmission Disequilibrium test (TDT), which 
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compares the transmitted alleles with non-transmitted alleles from 
heterozygous parents to child. The TDT is a test of both likage and 
association together. This design avoids possible bias from inadequate 
controls and population stratifications (550). 
b) Genome-Wide Association Studies (GWAS) 
GWAS is a standard approach for exploring the basis of complex genetic 
diseases from hundreds of thousands of single-nucleotide polymorphisms (SNPs) 
by the case-control, population-based prospective and cross-sectional study 
designs. Due to the ability to assay more than a million SNPs, GWAS has become 
a new and powerful tool in searching for novel biological insights to explain 
susceptibility for diseases (550). 
The power of GWAS to identify true genetic associations depends on the 
quality of the database. In the beginning of GWAS, the most associations 
discovered in GWAS were indirectly casual because a small fraction of the 
genetic variation in the genome was detected. With the extensive availability of 
genome variation data, GWAS can infer the genotypes for most of the common 
variants in the genome by using an imputation technique. However, many 
associations between SNPs and diseases are weak with the odd ratios around 1.2-
1.6. In order to avoid false positive claims, the genome-wide level of significance 
(p-value < 5 x 10-8) was calculated from the Bonferroni correction for one million 
SNPs. Moreover, ethnic variation in a population also may result in a biased 
interpretation. To help deal with this problem the STRUCTURE program (the 
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adjustment for an estimate of global ancestry from a finite set of founding 
populations using ancestry informative marker), and the EIGENSTRAT program 
(applying the principal components from all or subset of the markers) have been 
proposed to control for false positives in a heterogeneous population. Due to a 
limited genome database and statistic dependency, GWAS requires a large sample 
size and multiple replications of similarly large samples in order to effectively 
provide evidence of genetic association (215). 
The associations between genes and disease from GWAS explain a small 
proportion of the genetic causes of disease. Therefore, secondary analysis of 
GWAS data including targeted hypothesis testing, gene-gene interaction, and 
gene-environment interaction analysis may further our understanding of the 
etiology of genotype and phenotype and improve the ability to detect relevant 
genetic polymorphisms. 
c) Gene-Environment interaction 
The effects of genetic variants may depends on environment exposures or 
the effect of an environment factors depends on an individual genotype. G-E 
interaction model may increase the power to detect novel genes or environmental 
factors that influence the trait through the interaction. In term of statistics, G-E 
interaction is defined as a deviation from a model on a particular scale by using 
linear regression models for quantitative traits and logistic regression models for 
binary traits (551). 
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d) Gene-Gene (G-G) interaction 
G-G interaction may be analyzed by pathway-based approaches. Pathway 
analysis determines association between phenotype and sets of genes 
corresponding to biological pathways, which provide larger effects, the greater 
power of discovery, and natural connections to biological mechanisms. Pathway-
based approaches may determine environmental factors interacting with the set of 
genes, which leads to a complex phenotype (552). 
 
 
 
Figure 2.3 Guideline for pathway analysis (552). 
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Table 2.2 Summary of candidate genes with established associations with orofacial clefts found in dissertation literature review to 
have published links with  type 2 diabets, gestational diabetes mellitus, or obesity. 
 
Gene ID Gene name Chromosome OFCs1 T2DM2 GDM3 Obesity 
ADAMTS9 ADAM metallopeptidase with 
thrombospondin type 1 motif, 9 
3p14.1 (553)a (409, 418, 
554) 
- (555) 
CBS Cystathionine-beta-synthase 21q22.3 (556, 557)b (558) - (559) 
COMT Catechol-O-methyltransferase 22q11.21 (560, 561)b - - (562) 
CYP1B1 Cytochrome P450, family 1, 
subfamily B, polypeptide 1 
2p22.2 (563)b - - (564) 
ESR1 Estrogen receptor 1 6q25.1 (565)b (566) - - 
ETV5 Ets variant 5 3q28 (422, 567, 
568)b 
- - (569) 
F13A1 Coagulation factor XIII, A1 
polypeptide 
6p25.3-p24.3 (570-572)b - - (573) 
FAF1 Fas (TNFRSF6) associated factor 
1 
1p33 (574)a (575) - - 
GDF15 Growth differentiation factor 15 19p13.11 (576)b - (500) - 
GSTT1 Glutathione S-transferase theta 1 22q11.23 (134, 577)b (578) - - 
HLA-B Major histocompatibility 
complex, class I, B 
6p21.3 (579)b (487) - - 
KLF9 Kruppel-like factor 9 9q13 (580)b - - (405) 
LMX1B LIM homeobox transcription 
factor 1, beta 
9q33.3 (581)a - - (582) 
MAF V-maf avian musculoaponeurotic 
fibrosarcoma oncogene homolog 
16q22-q23 (139)b - - (428) 
MTHFR Methylenetetrahydrofolate 
reductase (NAD(P)H) 
1p36.3 (583-586)b (558, 587) - (559) 
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Table 2.2 Summary of candidate genes with established associations with orofacial clefts found in dissertation literature review to 
have published links with  type 2 diabets, gestational diabetes mellitus, or obesity (Cont.) 
 
1OFCs Orofacial clefts; 2T2DM, type 2 diabetes mellitus; 3GDM, gestational diabetes mellitus 
Genes associated with OFCs: a, animal study; b, human study  
Genes associated with T2DM, GDM, and obesity base on human study 
 
Gene ID Gene name Chromosome OFCs1 T2DM2 GDM3 Obesity 
MTR 5-methyltetrahydrofolate-
homocysteine methyltransferase 
1q43 (588, 589)b (558) - (558, 559) 
PAX6 Paired box 6 11p13 (590)b - - (569, 591) 
PCYT1A Phosphate cytidylyltransferase 1, 
choline, alpha 
3q29 (592, 593)b - - (594) 
PEMT Phosphatidylethanolamine N-
methyltransferase 
17p11.2 (592)b (587) - (594) 
RBP4 Retinol binding protein 4, plasma 10q23.33 (595)b - (596) - 
RPS7 Ribosomal protein S7 2p25 (597)b - (500) - 
SLC8A1 Solute carrier family 8 
(sodium/calcium exchanger), 
member 1 
2p22.1 (598)b (599) - - 
STK11 Serine/threonine kinase 11 19p13.3 (600)b (601) - - 
TCN2 Transcobalamin II 22q12.2 (602)b (558, 559) - (558, 559) 
TFAP2B Transcription factor AP-2 beta 
(activating enhancer binding 
protein 2 beta) 
6p12 (603)b - - (569, 591) 
TGFB1 Transforming growth factor, beta 
1 
19q13.1 (604-606)b - (541) (607) 
THADA Thyroid adenoma associated 2p21 (139, 608)b (609-611)   
VEGFA Vascular endothelial growth 
factor A 
6p12 (612)a - - (555) 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus. 
 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
AATF Apoptosis antagonizing transcription factor 17q12 - - (573) 
ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 1 
16p13.1 
- - (573) 
ABCC8 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 8 
11p15.1 
(354-356) (354)  
ACE Angiotensin I converting enzyme 17q23.3 (613) - (614, 615) 
ACTN2 Actinin, alpha 2 1q42-q43 (616) - - 
ADAM12 ADAM metallopeptidase domain 12 10q26 - (500) (573) 
ADCY10 Adenylate cyclase 10 (soluble) 1q24 (611, 617) - - 
ADCY3 Adenylate cyclase 3 2p23.3 - - (440) 
ADCY5 Adenylate cyclase 5 3q21.1 (618) - - 
ADD2 Adducin 2 (beta) 2p13.3 - (500) - 
ADIPOR1 Adiponectin receptor 1 1q32.1 (619) - - 
ADIPOQ Adiponectin, C1Q and  collagen domain  
containing 
3q27 
(361-366) (369-372) (373, 374) 
ADRB2 Adrenoceptor beta 2, surface 5q31-q32 (620) - (385) 
ADRB3 Adrenoceptor beta 3, surface 8p12 (365, 380, 
382) 
(381) (385, 386) 
AGPAT4 1-acylglycerol-3-phosphate O-acyltransferase 4 6q26 - (500) - 
AGRP Agouti related neuropeptide 16q22 - - (621) 
AGT Angiotensinogen (serpin peptidase inhibitor, clade 
A, member 8) 
142.2 (622) - (623) 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.) 
 
 
  
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
AGTR1 Angiotensin II receptor, type 1 3q24 (622) -  
AKAP1 A kinase (PRKA) anchor protein 1 17q22 - - (582, 624) 
ALX4 ALX homeobox 4 11p11.2 (418) -  
ANAPC13 Anaphase promoting complex subunit 13 3q22.2 - - (582) 
ANGPTL6 Angiopoietin-like 6 19p13.2 - - (625) 
ANKRD50 Ankyrin repeat domain 50 4q28.1 (616) - - 
ANXA4 Annexin A4 2p13 (449) (500) - 
AP3S2 Adaptor-related protein complex 3, sigma 2 
subunit 
15q26.1 (626) - - 
APCS Amyloid P component, serum 1q21-q23 - - (625) 
APLP2 Amyloid beta (A4) precursor-like protein 2 11q24 - - (582) 
APOC1 Apolipoprotein C-I 19q13.2 - - (582) 
APOE Apolipoprotein E 19q13.2 (627) - (607, 628) 
AQP3 Aquaporin 3 (Gill blood group) 9p13 - (500) - 
ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat 
and PH domain 1 
11q13.4 (450) - - 
ARHGAP44 Rho GTPase activating protein 44 17p12 (599) - - 
ARID1B AT rich interactive domain 1B (SWI1-like) 6q25.1  - (582) 
ARL15 ADP-ribosylation factor-like 15 5p15.2 (575) - - 
AZGP1 alpha-2-glycoprotein 1, zinc-binding 7q22.1 - - (629) 
BCDIN3D BCDIN3 domain containing 12q13.12 - - (582) 
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 2p16.1 (450) - - 
BCL2 B-cell CLL/lymphoma 2 18q21.3 (630) - - 
BCL2A1 BCL2-related protein A1 15q24.3 - - (426) 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
 
  
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
BDNF Brain-derived neurotrophic factor 11p13 (419, 631, 
632) 
- (426, 591, 
633, 634) 
BHLHE40 Basic helix-loop-helix family, member e40 3p26 - (500) - 
C15orf41 Chromosome 15 open reading frame 41 15q14 - - (582) 
C16orf62 Chromosome 16 open reading frame 62 16p12.3 - - (573) 
C1D C1D nuclear receptor corepressor 2p13-p12 - (500) - 
C2CD4A/4B C2 calcium-dependent domain containing 4A/4B 15q22.2 (450) - - 
CADM2 Cell adhesion molecule 2 3p12.1 - - (569) 
      
CALM1 Calmodulin 1 (phosphorylase kinase, delta) 14q32.11 - (500) (569, 591) 
CAPN10 Calpain 10 2q37.3 (475, 635) - (636) 
CARHSP1 Calcium regulated heat stable protein 1, 24kDa 16p13.2 - (500) - 
CASP9 Caspase 9, apoptosis-related cysteine peptidase 1p36.21 (617) - - 
CCDC102B Coiled-coil domain containing 102B 18q22.1 (617) - - 
CCDC80 Coiled-coil domain containing 80 3q13.2  - (573) 
CCL2 CD276 molecule 15q23-q24 - - (573) 
CD63 CD63 molecule 12q12-q13 - (500) - 
CD93 CD93 molecule 20p11.21 - (500) - 
CD96 CD96 molecule 3q13.13-q13.2 (599) - - 
CDH12 Cadherin 12, type 2 (N-cadherin 2) 5p14.3 - - (582) 
CDKAL1 CDK5 regulatory subunit  associated protein 1-
like 1 
6p22.3 (389-398, 
400, 405) 
(401, 402, 
404) 
 
CDKN2A Cyclin-dependent kinase inhibitor 2A 9p21 (461) - - 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
CDKN2A/2B Cyclin-dependent kinase inhibitor 2A/2B 9p21 (390, 394-
397, 400, 
409-413) 
(401, 403) - 
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha 19q13.1 - (500) - 
CES1 Carboxylesterase 1 16q22.2 - - (624) 
CFB Complement factor B 6p21.3 - - (637) 
CHCHD2P9 Coiled-coil-helix-coiled-coil-helix domain 
containing 2 pseudogene 9 
9q21.31 (450) - - 
CHDH Choline dehydrogenase 3p21.1 (558) - (558) 
CHRNA5 Cholinergic receptor, nicotinic, alpha 5 (neuronal) 15q24 (638) - - 
CHRNB2 Cholinergic receptor, nicotinic, beta 2 1q21.3 (638) - - 
CHRNB4 Cholinergic receptor, nicotinic, beta 4 15q24 (638) - - 
CIDEA Cell death-inducing DFFA-like effector a 18p11.21; 18 - - (573) 
CLDN7 Claudin 7 17p13.1 - (500) - 
CLMN Calmin (calponin-like, transmembrane) 14q32.13 - - (569, 573) 
CMIP C-Maf inducing protein 16q23 (639) - - 
CNGB3 Cyclic nucleotide gated channel beta 3 8q21.3 - - (582) 
CNPY2 Canopy FGF signaling regulator 2 12q15 - (500) - 
CNTN1 Contactin 1 12q11-q12 (599) - - 
CNTNAP4 contactin associated protein-like 4 16q23.1  - (582) 
COL13A1 Collagen, type XIII, alpha 1 10q22 (599) - - 
COL17A1 Collagen, type XVII, alpha 1 10q24.3 - (500) - 
COL8A1 Collagen, type VIII, alpha 1 3q12.3 (418) - - 
CPE Carboxypeptidase E 4q32.3 - - (621) 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
 
  
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
CPEB4 Cytoplasmic polyadenylation element binding 
protein 4 
5q21 - - (555) 
CPVL Carboxypeptidase, vitellogenic-like 7p15.1 - (500) (573) 
CRTC2 CREB regulated transcription coactivator 2 1q21.3 (601) - - 
CSN3 Casein kappa 4q21.1 (599, 616) - - 
CTSA Cathepsin A 20q13.1 - - (629) 
CWC22 CWC22 spliceosome-associated protein 2q31.3 (599) - - 
CXCL12 Chemokine (C-X-C motif) ligand 12 10q11.1 - - (564) 
DAPK2 Death-associated protein kinase 2 15q22.31 - - (573) 
DARS Aspartyl-tRNA synthetase 2q21.3 - - (582) 
DBC1 Ddeleted in bladder cancer 1 chromosome: 
15 
(616) - (582) 
DBI Diazepam binding inhibitor (GABA receptor 
modulator, acyl-CoA binding protein) 
2q12-q21 - - (564) 
DNAJC15 DnaJ (Hsp40) homolog, subfamily C, member 15 13q14.1 - - (582) 
DNAJC27 DnaJ (Hsp40) homolog, subfamily C, member 27 2p23.3 - - (569) 
DRD2 Dopamine receptor D2 11q23 - - (640, 641) 
DUSP9 Dual specificity phosphatase 9 Xq28 (450) - - 
DYNLL1 Dynein, light chain, LC8-type 1 12q24.23 - (500) - 
DYT7 Dystonia 7, torsion (autosomal dominant) 18p (642) - - 
EFNA5 Ephrin-A5 5q21 - - (582) 
EGR2 Early growth response 2 10q21.1 (616) - - 
EIF4B Eukaryotic translation initiation factor 4B 12q13.13 - (500) - 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
EIF4E3 Eukaryotic translation initiation factor 4E family 
member 3 
3p14 - - (582) 
EIF4EBP1 Eukaryotic translation initiation factor 4E binding 
protein 1 
8p12 - - (573) 
ENPP1 Ectonucleotide pyrophosphatase/ 
phosphodiesterase 1 
6q22-q23 (365, 449, 
643) 
- - 
EPB41L3 Erythrocyte membrane protein band 4.1-like 3 18p11.32 (616) - - 
ESRRG Estrogen-related receptor gamma 1q41 (599) - - 
ETV5 Ets variant 5 3q28 - - (569) 
EXT2 Exostosin glycosyltransferase 2 11p12-p11 (644) - - 
FABP2 Fatty acid binding protein 2, intestinal 4q28-q31 (645) - (628) 
FAIM2 Fas apoptotic inhibitory molecule 2 12q13 (419) - (569, 582, 
646) 
FAM129A Family with sequence similarity 129, member A 1q25 (599) - - 
FAM19A5 Family with sequence similarity 19 (chemokine 
(C-C motif)-like), member A5 
22q13.32 
- - (582) 
FANCL Fanconi anemia, complementation group L 2p16.1  - (569) 
FBXL17 F-box and leucine-rich repeat protein 17 5q21.3 (599) - - 
FERMT1 Fermitin family member 1 20p12.3 - (500) - 
FHIT Fragile histidine triad 3p14.2 (599) - - 
FHOD3 Formin homology 2 domain containing 3 18q12 - - (582) 
FLT1 Fms-related tyrosine kinase 1 13q12 - (500) - 
FOSL2 FOS-like antigen 2 2p23.3 - (500) - 
FOXA2 Forkhead box A2 20p11 - - (582) 
FOXN3 Forkhead box N3 14q31.3 (397) - (582) 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
FTO Fat mass and obesity associated 16q12.2 (396, 397, 
418-420, 
422, 423) 
(421) (423-428) 
FXYD5 FXYD domain containing ion transport regulator 5 19q13.12 - (500) - 
GABRA4 Gamma-aminobutyric acid (GABA) A receptor, 
alpha 4 
4p12 (647) - - 
GALNT10 Polypeptide N-acetylgalactosaminyltransferase 10 5q33.2 - - (440) 
GALNT2 Polypeptide N-acetylgalactosaminyltransferase 2 1q41-q42 - (500) (440) 
GAS6 Growth arrest-specific 6 13q34 - - (564) 
GATAD2A GATA zinc finger domain containing 2A 19p13.11 (630) - - 
GBA Glucosidase, beta, acid 1q21 - (500) - 
GCK Glucokinase 7p15.3-p15.1 (432, 433) (434-436) - 
GCKR Glucokinase (hexokinase 4) regulator 2p23 (611, 618) - - 
GDNF Glial cell derived neurotrophic factor 5p13.1-p12 (616) - - 
GFM1 G elongation factor, mitochondrial 1 3q25 (599) - - 
GHRL Ghrelin/obestatin prepropeptide 3p26-p25 - - (621, 648) 
GIPR Gastric inhibitory polypeptide receptor 19q13.3 - - (405, 591) 
GLIS3 GLIS family zinc finger 3 9p24.2 (356, 639) - - 
GLP1R Glucagon-like peptide 1 receptor 6p21 - - (621) 
GNG7 Guanine nucleotide binding protein (G protein), 
gamma 7 
19p13.3 - (500) - 
GNPDA2 Glucosamine-6-phosphate deaminase 2 4p12 (419, 422) - (425, 426, 
440) 
GP2 Glycoprotein 2 (zymogen granule membrane) 16p12 - - (591) 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
GPC5 Glypican 5 13q32 (599) - - 
GPRC5B G protein-coupled receptor, class C, group 5, 
member B 
16p12 - - (569) 
GRB10 Growth factor receptor-bound protein 10 7p12.2 (599) - - 
GRB14 Growth factor receptor-bound protein 14 2q22-q24 (626) - (555) 
GRIK1 Glutamate receptor, ionotropic, kainate 1 21q22.11 (616) - - 
GRIN2B Glutamate receptor, ionotropic, N-methyl D-
aspartate 2B 
12p12 - - (582) 
GRK5 G protein-coupled receptor kinase 5 10q26.11 (649) - - 
GRM3 Glutamate receptor, metabotropic 3 7q21.1-q21.2 - - (582) 
GYPC Glycophorin C (Gerbich blood group) 2q14-q21 (616) - - 
HADHA Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (trifunctional 
protein), alpha subunit 
2p23 - - (564) 
HCN4 Hyperpolarization activated cyclic nucleotide 
gated potassium channel 4 
15q24.1 - - (582) 
HDGF Hepatoma-derived growth factor 1q23.1 - (500) - 
HES1 Hes family bHLH transcription factor 1 3q28-q29 - - (564) 
HHEX Haematopoietically expressed homeobox 10q23.33 (389, 391, 
394-397, 
400, 410, 
413, 443) 
(401) - 
HMG20A High mobility group 20A 15q24 (626) - - 
HMGA2 High mobility group AT-hook 2 12q15 (450, 487) - - 
HNF1A HNF1 homeobox A 12q24.2 (446-450) (434) - 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
HNF1B Hepatocyte nuclear factor 1-beta 17q12 (356, 432, 
433, 450) 
(404) - 
HNF4A Hepatocyte nuclear factor 4-alpha 20q13.12 (450, 626) - - 
HOXB1 Homeobox B1 17q21.3 - - (582) 
HOXB5 Homeobox B5 17q21.3 - - (650) 
HOXC13 Homeobox C13 12q13.3 - - (555) 
HPSE2 Heparanase 2 (inactive) 10q23-q24 (616) -  
HSPA1B Heat shock 70kDa protein 1B 6p21.3 - - (547) 
HTR2A 5-hydroxytryptamine (serotonin) receptor 2A, G 
protein-coupled 
13q14-q21 - - (621) 
IDE Insulin-degrading enzyme 10q23-q25 (651) (402) - 
IFI30 Interferon, gamma-inducible protein 30 19p13.1 - (500) - 
IGKC Immunoglobulin kappa constant 2p12 (652) - - 
IGF2BP2 Insulin-like growth factor 2mRNA binding protein 
2 
3q27.2 (391, 394, 
395, 398-
400, 410, 
411, 461) 
(402, 403, 
462) 
- 
IL10 Interleukin-10 1q31-q32 (467) (468) (471) 
IL18RAP Interleukin 18 receptor accessory protein 2q12 - - (564) 
IL1β Interleukin-1 beta 2q14 (653, 654) - - 
IL1R1 Interleukin 1 receptor, type I 2q12 - - (564) 
IL1RN Interleukin-1 receptor antagonist 2q14.2 (654, 655) - - 
IL4 Interleukin-4 5q31.1 (655, 656) - - 
IL6 Interleukin-6 7p21 (449, 544, 
657, 658) 
- (375, 544, 
659) 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
IL6ST Interleukin 6 signal transducer 5q11.2 - - (564) 
INHA Inhibin, alpha 2q35 - (500) - 
INS Insulin 11p15.5 - (384) - 
IRF5 Interferon regulatory factor 5 7q32 - - (629) 
IRS1 Insulin receptor substrate-1 2q36 (474, 475, 
480) 
(384, 477-
479) 
(481) 
IVNS1ABP Influenza virus NS1A binding protein 1q25.1-q31.1 - - (573) 
JAZF1 JAZF zinc finger 1 7p15.2-p15.1 (409, 609, 
651) 
- - 
JUN Jun proto-oncogene 1p32-p31 - - (564) 
KCND2 Potassium channel, voltage gated Shal related 
subfamily D, member 2 
7q31 (599) - - 
KCNIP3 Kv channel interacting protein 3, calsenilin 2q21.1 (651) (500) - 
KCNJ11 Potassium channel, inwardly rectifying subfamily 
J, member 11 
11p15.1 (389, 397, 
400, 410, 
411, 461) 
(482) - 
KCNK16 Potassium channel, two pore domain subfamily K, 
member 16 
6p21.2-p21.1 (356, 639) - - 
KCNQ1 Potassium channel, voltage gated KQT-like 
subfamily Q, member 1 
11p15.5-p15.4 (489) (491-494) - 
KCTD15 Potassium channel tetramerization domain 
containing 15 
19q13.11 - - (569) 
KCTD8 Potassium channel tetramerization domain 
containing 8 
4p13 (611, 647) - - 
KIF1C Kinesin family member 1C 17p13.2 - (500) - 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
KLF9 Kruppel-like factor 9 9q13 - - (405) 
KLF14 Kruppel-like factor 14 7q32.3 (450) - - 
KLHL32 Kelch-like family member 32 6q16.1 - - (440) 
LEP Leptin 7q31.3 (498) (660, 661) (501-503) 
LEPR Leptin receptor 1p31 (507, 508) - (498, 509, 
510) 
LIMCH1 LIM and calponin homology domains 1 4p13 - - (582) 
LINGO2 Leucine rich repeat and Ig domain containing 2 9p21.2 (616) - (569) 
LPIN1 Lipin 1 2p25.1 - - (625) 
LPL Lipoprotein lipase 8p22 - - (628) 
LPP LIM domain containing preferred translocation 
partner in lipoma 
3q28 (575) - - 
LRP1B Low density lipoprotein receptor-related protein 
1B 
2q21.2 - - (569, 646) 
LTA Lymphotoxin alpha 6p21.3 (397, 662) - - 
LY86 Lymphocyte antigen 86 6p25.1 - - (555) 
LYPLAL1 Lysophospholipase-like 1 1q41 - - (555) 
MARCH4 Membrane-associated ring finger (C3HC4) 4, E3 
ubiquitin protein ligase 
2q35 - - (582) 
MAEA Macrophage erythroblast attacher 4p16.3 (663) - - 
MAGEA9 Melanoma antigen family A9 Xq28 - (500) - 
MAP2K5 Mitogen-activated protein kinase kinase 5 15q23 - - (569, 591) 
MAPRE2 Microtubule-associated protein, RP/EB family, 
member 2 
18q12.1 (664) - - 
MATN3 Matrilin 3 2p24-p23 - - (582, 591) 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
 
  
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
MBL2 Mannose-binding lectin (protein C) 2, soluble 10q11.2 - (665) - 
MCF2L2 MCF.2 cell line derived transforming sequence-
like 2 
3q27.1 (368) - - 
MC4R Melanocortin 4 receptor 18q22 (611) - (405, 428, 
440, 569, 
591, 666) 
MC5R Melanocortin 5 receptor 18p11.2 - - (667) 
MIF Macrophage migration inhibitory factor 
(glycosylation-inhibiting factor) 
22q11.23 - (500) - 
MINA MYC induced nuclear antigen 3q11.2 - - (582) 
MMADHC Methylmalonic aciduria (cobalamin deficiency) 
cblD type, with homocystinuria 
2q23.2 (611) - - 
MPHOSPH9 M-phase phosphoprotein 9 12q24.31 (575) - - 
MRC1 Mannose receptor, C type 1 10p12.33 - - (573, 629) 
MSH6 MutS homolog 6 2p16 (599) - - 
MSRA Methionine sulfoxide reductase A 8p23.1 (478, 668) - - 
MT1A Metallothionein 1A 16q13 (669) - - 
MTCH2 Mitochondrial carrier 2 11p11.2 - - (569) 
MTHFD1L Methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 1-like 
6q25.1 (558) - (558) 
MTIF3 Mitochondrial translational initiation factor 3 13q12.2 - - (569) 
MTHFSD Methenyltetrahydrofolate synthetase domain 
containing 
16q24.1 (599) - - 
MTNR1A Melatonin receptor 1A 4q35.1 - (517) - 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
MTNR1B Melatonin receptor 1B 11q21-q22 (514, 517, 
518) 
(402, 477, 
516, 519) 
- 
MYT1L Myelin transcription factor 1-like 2p25.3 - - (582) 
NAA25 N(alpha)-acetyltransferase 25, NatB auxiliary 
subunit 
12q24.13 - - (573) 
NAP5 Non-intrinsic ABC protein 5 chromosome: 
1 
- - (582) 
NCKAP5 NCK-associated protein 5 2q21.2 (599) - - 
NCOA1 Nuclear receptor coactivator 1 2p23 - - (564) 
NEGR1 Neuronal growth regulator 1 1p31.1 - - (569, 634) 
NEUROD1 Neuronal differentiation 1 2q32 (433, 449) - - 
NEUROG3 Neurogenin 3 10q21.3 (670) - - 
NFE2L3 Nuclear factor, erythroid 2-like 3 7p15.2 - - (555) 
NKX2-2 NK2 homeobox 2 20p11.22 (356) - - 
NKX6-1 NK6 homeobox 1 4q21.33 (356) - - 
NOTCH2 Notch 2 1p13-p11 (609, 610) - - 
NPC1 Niemann-Pick disease, type C1 18q11.2 - - (428) 
NPY Neuropeptide Y 7p15.1 - - (509, 623) 
NPY1R Neuropeptide Y receptor Y1 4q32.2 - - (621, 624) 
NPY2R Neuropeptide Y receptor Y2 4q31 - - (386, 671) 
NPY5R Neuropeptide Y receptor Y5 4q32.2 - - (621) 
NRF1 Nuclear respiratory factor 1 7q32 (672) - - 
NRP1 Neuropilin 1 10p12 (599) - - 
NRXN1 Neurexin 1 2p16.3 - - (582) 
NRXN3 Neurexin 3 14q31 - - (569, 582) 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
NUDT3 Nudix (nucleoside diphosphate linked moiety X)-
type motif 3 
6p21.2 - - (569) 
OLFM4 Olfactomedin 4 13q14.3 - - (646, 650) 
OR13D1 Olfactory receptor, family 13, subfamily D, member 
1 
9q31.1 (616) - (440) 
OSTF1 Osteoclast stimulating factor 1 9q13-q21.2 - - (582) 
OVCH2 Ovochymase 2 (gene/pseudogene) 11p15.4 - - (582) 
PALLD Palladin, cytoskeletal associated protein 4q32.3 - - (573) 
P2RX4 Purinergic receptor P2X, ligand gated ion channel, 4 12q24.32 - - (673) 
PANK4 Pantothenate kinase 4 1p36.32 (617) - - 
PARD3B Par-3 family cell polarity regulator beta 2q33.3 - - (582) 
PCDH20 Protocadherin 20 13q21 - - (582) 
PCK1 Phosphoenolpyruvate carboxykinase 1 (soluble) 20q13.31 (449) - - 
PCSK1 Proprotein convertase subtilisin/kexin type 1 5q15-q21 - - (591, 674, 
675) 
PCSK2 Proprotein convertase subtilisin/kexin type 2 20p11.2 (676) - - 
PDX1 Pancreatic and duodenal homeobox 1 13q12.1 (432) - - 
PEPD Peptidase D 19q13.11 (356, 639) - - 
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 
10p15.1 - - (629) 
PHLDB1 Pleckstrin homology-like domain, family B, 
member 1 
11q23.3 (616) - - 
PKHD1 Polycystic kidney and hepatic disease 1 6p12.2 - - (582) 
PKP1 Plakophilin 1 1q32 - - (582) 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
PLA2G16 Phospholipase A2, group XVI 11q12.3 - (500) - 
PLA2G1B Phospholipase A2, group IB (pancreas) 12q24.31 - - (673) 
PLIN2 Perilipin 2 9p22.1 - (500) - 
PMEPA1 Prostate transmembrane protein, androgen induced 
1 
20q13.31-
q13.33 
- - (629) 
PMS2P3 PMS1 homolog 2, mismatch repair system 
component pseudogene 3 
7q11.23 - - (637) 
POC5 POC5 centriolar protein 5q13.3 - - (569, 582) 
POLG2 Polymerase (DNA directed), gamma 2, accessory 
subunit 
17q - (500) - 
PON1 Paraoxonase 1 7q21.3 (559) - (559) 
PPARA Peroxisome proliferator-activated receptor alpha 22q13.31 - (462) - 
PPARD Peroxisome proliferator-activated receptor delta 6p21.2 - - (677) 
PPARG Peroxisome proliferator-activated receptor gamma 3p25 (396, 397, 
400, 411, 
461, 523) 
(524) (526) 
PPARGC1A Peroxisome proliferator-activated receptor gamma, 
coactivator 1 alpha 
4p15.1 (365) - (625) 
PPIB Peptidylprolyl isomerase B (cyclophilin B) 15q21-q22 - (500) - 
PPP1R3A Protein phosphatase 1, regulatory subunit 3A 7q31.1 (652) - - 
PPP1R3B Protein phosphatase 1, regulatory subunit 3B 8p23.1 (652) - - 
PRC1 Protein regulator of cytokinesis 1 15q26.1 (450) - - 
PRKD1 Protein kinase D1 14q11 (647) - (569, 646) 
PRKG2 Protein kinase, cGMP-dependent, type II 4q13.1-q21.1 (599) - - 
PRLR Prolactin receptor 5p13.2 - (678) - 
  
 
1
2
8
 
Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
PROCR Protein C receptor, endothelial 20q11.2 - (500) - 
PROX1 Prospero homeobox 1 1q41 (618) - - 
PSMD6 Proteasome 26S subunit, non-ATPase 6 3p14.1 (356, 449, 
639) 
- - 
PTBP2 Polypyrimidine tract binding protein 2 1p21.3 - - (569) 
PTDSS2 Phosphatidylserine synthase 2 11p15.5 - - (594) 
PTER Phosphotriesterase related 10p12 - - (428) 
PTPRD Protein tyrosine phosphatase, receptor type, D 9p23-p24.3 (490) - - 
PYY Peptide YY 17q21.1 - - (671) 
QPCTL Glutaminyl-peptide cyclotransferase-like 19q13.32 - - (569) 
RALGPS2 Ral GEF with PH domain and SH3 binding motif 2 1q25.2 (616) - - 
RASGRP1 RAS guanyl releasing protein 1 (calcium and 
DAG-regulated) 
15q14 (649) - - 
RAPGEF1 Rap guanine nucleotide exchange factor (GEF) 1 9q34.3 (672) - - 
RBFOX1 RNA binding protein, fox-1 homolog (C. elegans) 
1 
16p13.3 - - (679) 
RBMS1 RNA binding motif, single stranded interacting 
protein 1 
2q24.2 (680) - - 
RFNG RFNG O-fucosylpeptide 3-beta-N-
acetylglucosaminyltransferase 
17q25 - (500) - 
RIMS1 Regulating synaptic membrane exocytosis 1 6q12-q13 (599) - - 
RNASE4 Ribonuclease, RNase A family, 4 14q11 - (500) (573) 
RNF13 Ring finger protein 13 3q25.1 - - (629) 
RNF138 Ring finger protein 138, E3 ubiquitin protein ligase 18q12.1 (433) - (582) 
RNLS Renalase, FAD-dependent amine oxidase 10q23.31 (599) - - 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
 
  
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
RORA RAR-related orphan receptor A 15q22.2 (616) - - 
RPL27A Ribosomal protein L27a 11p15 - - (569) 
RPS29 Ribosomal protein S29 14q - (500) - 
RSPO3 R-spondin 3 6q22.33 - - (555) 
SASH1 SAM and SH3 domain containing 1 6q24.3 (664) - - 
SAMD12 Sterile alpha motif domain containing 12 8q24.12 (599) - - 
SCG3 Secretogranin III 15q21 - - (637) 
SDCCAG8 Serologically defined colon cancer antigen  81q43 - - (666) 
SDF2L1 Stromal cell-derived factor 2-like 1 22q11.21 (616) - - 
SEC16B SEC16 homolog B, endoplasmic reticulum export 
factor 
1q25.2 - - (405, 440, 
569, 591, 
646) 
SGCG Sarcoglycan, gamma (35kDa dystrophin-
associated glycoprotein) 
13q12 (681) - - 
SH2B1 SH2B adaptor protein 1 16p11.2 (419) - (569, 634, 
682) 
SH3BGRL SH3 domain binding glutamate-rich protein like Xq13.3 - - (573) 
SIDT1 SID1 transmembrane family, member 1 3q13.2 (599) - - 
SLC15A4 Solute carrier family 15 (oligopeptide transporter), 
member 4 
12q24.32 (368) - - 
SLC24A3 Solute carrier family 24 
(sodium/potassium/calcium exchanger), member 3 
20p13 (616) - - 
SLC2A1 Solute carrier family 2 (facilitated glucose 
transporter), member 1 
1p34.2 (573, 683) - - 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
SLC2A2 Solute carrier family 2 (facilitated glucose 
transporter), member 2 
3q26.1-q26.2 (449, 672) - - 
SLC30A8 Solute carrier family 30 (zinc transporter), member 8 8q24.11 (389, 391, 
396, 400, 
409, 411, 
418, 443, 
461) 
(401) - 
SLC39A8 Solute carrier family 39 (zinc transporter), member 8 4q24 - - (569, 646) 
SLC44A3 Solute carrier family 44, member 3 1p21.3 (664) - - 
SMPD1 Sphingomyelin phosphodiesterase 1, acid lysosomal 11p15.4-
p15.1 
- (500) - 
SNHG11 Small nucleolar RNA host gene 11 20q11.23 - - (573) 
SOCS3 Suppressor of cytokine signaling 3 17q25.3 - - (621) 
SOD1 Superoxide dismutase 1, soluble 21q22.11 (684) - - 
SORBS1 Sorbin and SH3 domain containing 1 10q23.33 (616) - - 
SPCS3 Signal peptidase complex subunit 3 4q34.2 - (500) - 
SPECC1 Sperm antigen with calponin homology and coiled-
coil domains 1 
17p11.2 (599, 611) - - 
SPSB3 SplA/ryanodine receptor domain and SOCS box 
containing 3 
16p13.3 - - (573) 
SREBF1 Sterol regulatory element binding transcription 
factor 1 
17p11.2 - - (685) 
SRI Sorcin 7q21.1 - (500) - 
SRR Serine racemase 17p13 (490) (403) - 
SRRT Serrate, RNA effector molecule 7q21 - (500) - 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 3q12.1 - - (573) 
ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 3q27.3 (626) - - 
STAT3 Signal transducer and activator of transcription 3 
(acute-phase response factor) 
17q21.31 - - (621) 
STEAP4 STEAP family member 4 7q21.12 - (500) - 
STRIP1 Striatin interacting protein 1 1p13.3 - - (582) 
SV2C Synaptic vesicle glycoprotein 2C 5q13.3 - - (582) 
TAZ Tafazzin Xq28 - - (629) 
TCEB1 Transcription elongation factor B (SIII), polypeptide 
1 (15kDa, elongin C) 
8q21.11 (599) - (607) 
TCF7L2 Transcription factor 7-like 2 10q25.3 (389, 394, 
396, 397, 
399, 400, 
409, 412-
414, 443, 
461, 487, 
532) 
(401, 404, 
421, 525, 
533, 534) 
 
TFAP2B Transcription factor AP-2 beta (activating enhancer 
binding protein 2 beta) 
6p12 - - (569, 591, 
646) 
THSD7B Thrombospondin, type I, domain containing 7B 2q22.1 - - - 
TLE4 Transducin-like enhancer of split 4 9q21.31 (450) - - 
TMBIM6 Transmembrane BAX inhibitor motif containing 6 12q13.12 - - (436, 634) 
TMEFF2 Transmembrane protein with EGF-like and two 
follistatin-like domains 2 
2q32.3 (397, 616) - - 
TMEM101 Transmembrane protein 101 17q21.31 - - (573) 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
TMEM154 Transmembrane protein 154 4q31.3 (575) - - 
TMEM160 Transmembrane protein 160 19q13.32 - - (569) 
TMEM163 Transmembrane protein 163 2q21.3 (686) - (582) 
TMEM18 Transmembrane protein 18 2p25.3 (419) - (569, 634, 
646, 666, 
687) 
TNF-α Tumor necrosis factor alpha 6p21.3 (449, 538, 
540, 545) 
(541, 542) (375, 546) 
TNNI3K TNNI3 interacting kinase 1p31.1 - - (569, 646) 
TP53 Tumor protein p53 17p13.1 (672) - - 
TP53INP1 Tumor protein p53 inducible nuclear protein 1 8q22 (450) - - 
TRPS1 Trichorhinophalangeal syndrome I 8q24.12 (599) - - 
TSPAN8 Tetraspanin 8 12q14.1-q21.1 (610) - - 
TUSC3 Tumor suppressor candidate 3 8p22 - (500) - 
UBE2E2 Ubiquitin-conjugating enzyme E2E 2 3p24.2 (399) (688) - 
UCK2 Uridine-cytidine kinase 2 1q23 - (500) - 
UCK3 None 3p24.2 - (500) - 
UCP1 Uncoupling protein 1  4q28-q31 - - (625, 689) 
UCP2 Uncoupling protein 2 (mitochondrial, proton 
carrier) 
11q13 - - (385, 628, 
685, 690) 
UTRN Utrophin 6q24 (616) - - 
UCP3 Uncoupling protein 3 (mitochondrial, proton 
carrier) 
11q13.4 (691) - (385, 628) 
UTS2 Urotensin 2 1p36 - (500, 692) - 
VLDLR very low density lipoprotein receptor 9p24 - - (624) 
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Table 2.3 Summary 416 genes found in dissertation literature review to be associated with type 2 diabetes, gestational diabetes 
mellitus, or obesity  related to obesity and/or diabetes mellitus (Cont.). 
  
1T2DM, type 2 diabetes mellitus 
2GDM, gestational diabetes mellitus 
Genes associated with T2DM, GDM, and obesity base on human study 
Gene ID Gene name Chromosome T2DM1 GDM2 Obesity 
VPS13B Vacuolar protein sorting 13 homolog B (yeast) 8q22.2 - - (637) 
VPS26A VPS26 retromer complex component A 10q21.1 (626) - - 
WFS1 Wolfram syndrome 1 
 
4p16.1 (409, 418, 
693) 
- - 
WWOX WW domain containing oxidoreductase 16q23 (639) - - 
ZBED3 Zinc finger, BED-type containing 3 5q13.3 (450) - - 
ZC3H4 Zinc finger CCCH-type containing 4 19q13.32 - - (582) 
ZFAND3 Zinc finger, AN1-type domain 3 6p21.2 (356, 639) - - 
ZFAND6 Zinc finger, AN1-type domain 6 15q25.1 (450) - - 
ZNF169 Zinc finger protein 169 9q22.32 - - (405) 
ZNF608 Zinc finger protein 608 5q23.2 - - (569) 
ZNF718 Zinc finger protein 718 4p16.3 - - (582) 
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CHAPTER 3 
 
THE ASSOCIATION BETWEEN MATERNAL PRE-PREGNANCY WEIGHT AND  
 
MATERNAL DIABETES AND OROFACIAL CLEFTS IN THE UTAH POPULATION 
 
 
3.1 Abstract 
Background: The inconsistent association between pre-pregnancy weight and 
maternal diabetes and risk of orofacial clefts has been reported in a few studies. 
Objective: To determine the association between maternal pre-pregnancy weight 
and maternal diabetes mellitus and the risk of orofacial clefts (OFCs) in a population-
based case-control study of birth certificate data in Utah. 
Methods: Cases of OFCs during 1995-2011 were ascertained by the state-wide 
Utah birth defects registry. Controls were randomly selected from Utah birth certificates 
at a ratio of 4:1 to cases, matched by birth month and year. Odds ratios (ORs) and 95% 
confidence intervals (CIs) were calculated to estimate the relative risk for cleft subtypes 
associated with maternal pre-pregnancy weight and maternal diabetes. Multiple logistic 
regression analysis was used to adjust for the potential confounding effects of maternal 
age, education, body mass index (BMI), depression, and maternal diabetes. Pre-existing 
diabetes, gestational diabetes mellitus (GDM), and all diabetes were evaluated as 
mediating variables in the association between maternal obesity and risk of OFCs. 
Results: Results are based on 1,451 live-born cases with registry diagnoses. 
Obesity increased risk of both non-isolated and isolated OFCs (adjusted odds ratios 
(aOR): 1.41, 95%CI: 1.07-1.87 and aOR: 1.23, 95% confidence interval (CI): 1.01-1.50, 
respectively). Underweight mothers had a reduced risk of cleft lip only (CLO) (aOR: 
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0.46, 95%CI: 0.24-0.88), and an increased risk of cleft palate only (CPO) (aOR: 1.50, 
95%CI: 1.04-2.16). Maternal depression increased risk of all OFCs (aOR: 1.31, 95%CI: 
1.00-1.73). Pre-existing diabetes increased risk of all OFCs (aOR: 2.19, 95% CI: 1.18-
4.09) with a larger effect for non-isolated OFCs (aOR: 3.83, 95%CI: 1.71-8.58) vs 
isolated OFCs (aOR: 1.54, 95%CI: 0.70-3.41). GDM mothers had an increased risk of all 
OFCs (aOR: 1.48, 95%CI: 1.05-2.09) with a larger effect for non-isolated OFCs (aOR: 
2.29, 95%CI: 1.41-3.72) vs isolated OFCs (aOR: 1.15, 95%CI: 0.75-1.77). Mediation 
analysis indicated that obesity had a direct effect of increasing the risk of OFCs without 
the mediating effect of known maternal diabetes. 
Conclusion: Extremes of maternal pre-pregnancy weight were associated with 
risk of OFCs in Utah with obese mothers having an increased risk of all types of OFCs, 
while underweight mothers having a decreased risk of CLO and increased risk of CPO. 
Maternal depression was also associated with OFC risk.  Both pre-existing and 
gestational diabetes were associated with OFC risk, with strongest effects for non-
isolated OFCs. Both stratification and mediation analyses suggest an effect of obesity on 
OFCs apart from known maternal diabetes. The growing epidemics of obesity and 
diabetes and the challenge of early detection and treatment of GDM underscore the 
public health importance of further research in this area. 
3.2 Introduction 
Orofacial clefts (OFCs) are congenital deformations of the lip, palate, or both. 
Genetic and environmental factors and interaction between both have been reported as 
the causes of OFCs.  OFCs are an important health issue in both developed and 
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developing countries. The global incidence of OFCs is one in every 500-2500 births 
depending on geographic location, racial and ethnic groups, maternal age, environmental 
exposures, and socioeconomic status (1). OFCs affect on average one in every 750 births 
in the United States and the highest incidence among states with state-wide birth defect 
registers is in Utah (1 in 450 births) (2).  
Maternal obesity increases health risks for both mother and child (3, 4). Maternal 
obesity has been associated with fetal malformations such as neural tube defects, 
congenital heart defects, and orofacial clefts (4). Obesity-related birth defect mechanisms 
include hyperglycemia, insulin resistance, and poor folate status (4, 5). Case-control 
studies (6-8) and a meta-analysis study (9) reported a positive association between 
maternal obesity and the occurrence of OFCs while other studies have not (10-12). 
However, the associations with various cleft phenotypes and the role of maternal 
underweight are less well studied. An international consortium of OFC case-control 
studies found associations between both maternal obesity and underweight risk of cleft 
palate with or without cleft lip, but not with cleft lip alone (13).   
Diabetes mellitus is a disorder of the regulation of blood glucose. Hyperglycemia 
is a characteristic of diabetes mellitus resulting from a defect in insulin secretion or 
insulin action or both (14). Diabetes mellitus also stimulates the production of adverse 
metabolic factors including ketone bodies, branched chain amino acid and advanced 
glycation end products and these factors may disrupt normal embryonic development (15, 
16). Maternal diabetes leads to altered expression levels of specific genes and increases 
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the variation of gene expression levels which may also disrupt embryonic development 
(17, 18).  
Human studies have reported associations between maternal diabetes and the risk 
of OFCs. Data from a large international consortium from the U.S., Denmark, and 
Norway confirmed that maternal diabetes increased the incidence of OFCs after adjusting 
for maternal age, education levels, multivitamin use, maternal BMI categories, and 
history of smoking (19). The Atlanta Birth Defects Case-Control Study (20) showed that 
being an insulin-dependent diabetic mother increased the risk of cleft palate. The data 
from the National Birth Defect Prevention Study (NBDPS) found that both pre-
gestational (type 1 or 2) and gestational diabetes mellitus increased the risk of isolated 
cleft lip with or without cleft palate (CL/P) and cleft palate only (CPO) (21). Moreover, 
two large studies reported that maternal diabetes increased the incidence of OFCs (19, 
22). However, another study from NBDPS did not find an association between gestation 
diabetes mellitus (GDM) and risk of cleft lip with cleft palate or cleft lip only (23). 
 The inconsistent association between pre-pregnancy weight and maternal 
diabetes and risk of OFCs has been reported in a few studies. Few studies have presented 
the association between maternal obesity and diabetes and risk of OFCs based on 
subtypes of clefts (non-isolated vs isolated and combinations of lip and palate). 
Moreover, there is no previous study that has reported the effect of maternal obesity on 
risk of OFCs mediated by maternal diabetes. The investigation of maternal weight and 
diabetes may confirm or provide additional information regarding OFC associations. 
Thus, this study aims to determine the association between pre-pregnancy weight and 
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maternal diabetes and risk of OFCs in the Utah population using a complete sample from 
a state-wide birth defects registry linked to birth certificates. 
3.3 Subjects and Methods 
3.3.1 Study design, population, and data sources 
The study design is a case-control study.  The study protocol was reviewed and 
approved by the institutional review boards of Utah State University (USU), the 
University of Utah, and the Utah Department of Health. 
Cases of OFCs were ascertained by the Utah Birth Defect Network (UBDN), 
operated by the Utah Department of Health (UDOH). UBDN, a statewide population-
based surveillance system, identifies all prenatal or postnatal major structural birth 
defects in fetuses and neonates (24). The OFC classifications used in the data analyses 
were based on the final UBDN diagnoses based on a review by a medical geneticist. OFC 
cases resulting from pregnancy outcomes (live birth, stillbirth, or pregnancy termination) 
were divided into cleft lip alone, cleft palate alone, cleft lip without cleft palate, and cleft 
lip with cleft palate and classified as isolated, syndromic, or multiple birth defect cases. 
The case mothers of a child with an OFC during 1995-2011 were linked to the Utah 
Population database (UPDB) (24). The UPDB provides information for research on 
genetics, epidemiology, demography, and public health. The database represents Utah’s 
population appearing in administrative records from the late 18th century to the present 
and receives annual updates from birth and death certificates, hospitalization and 
ambulatory surgery records, and driver licenses. Controls were randomly selected from 
Utah birth certificates at a ratio of 4:1 to live-born cases matched by birth month and 
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year. The anonymized identification numbers of cases and controls from UPDB were 
linked to the Utah Birth Certificate database. In addition, the UPDB provided information 
on OFC cases noted in fetal and neonatal death records. 
Utah birth certificate forms were revised in 1991, 1997, 2003, and 2009 and these 
were used to collect data on cases and controls born during 1995-2011. The birth 
certificate data consists of information on newborns (sex, date of birth, birth weight and 
length, and birthplaces) and their parents (race/ethnicity, ages, and marital status, and the 
number of children born to the mother, etc.), including delivery complications, maternal 
medical risk factors, congenital malformations, and birth injuries. 
Relevant changes in birth certificates were in the classification of maternal and 
paternal education, maternal alcohol consumption, maternal smoking, maternal medical 
risk factors, and notation of congenital anomalies. In the years of 1991- 2008, maternal 
and paternal education levels were recorded as the number of highest grades completed, 
and changed to be eight categories of the highest degree of school completed in 2009 (8th 
grade or less, 9th-12th grade, high school graduate, some college credit but no degree, 
associate degree, Bachelor’s degree, Master’s degree, and Doctorate or professional 
degree). Maternal smoking and alcohol consumption were recorded as average number of 
cigarettes per day and average number of drinks per week in each trimester of gestation. 
In 2009, a question about maternal tobacco use three months before pregnancy was added 
and a question on maternal alcohol use was deleted. Questions on history of gestational 
diabetes mellitus and pre-existing diabetes were added in 1997 in order to replace a more 
general question on unspecified diabetes. Many medical risk factors were added in 2009 
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including depression. Cleft lip, cleft palate, and cleft lip and palate were separately coded 
after 2008 on birth certificate instead of cleft lip/palate in previous forms under the 
question of congenital anomalies of child. Medical risk factors were noted primarily by 
text fields and ICD-9-CM codes.  Due to the non-specific question on diabetes mellitus 
on birth certificate forms during 1995-1996, these years were excluded from analyses. 
3.3.2 Statistical analysis 
The Statistical Package for Social Sciences (IBM SPSS) statistics version 22 for 
Windows was used for data analyses.  Descriptive analyses were conducted to determine 
the distribution of maternal characteristics (age, body mass index (BMI), smoking status, 
education level, and diabetic status) by OFC case-control status. Chi-square testing was 
used to assess the association between OFCs and categorical variables. Multivariable 
logistic regression was used to determine the odds ratio estimating the association 
between maternal BMI categories, diabetes mellitus, gestational diabetes mellitus, and 
depression and the risk of orofacial clefts with adjustment for potentially confounding 
variables. Stratified analyses were conducted to evaluate effect measure modification.  
Mediation analysis was conducted using the approach introduced by Vanderweele 
et al. (25). This approach is based on the counterfactual framework of mediation analysis 
(26), and extends mediation analysis for a dichotomous outcome with exposure-outcome 
confounders, mediator-outcome confounders, and exposure-mediator interaction. Pre-
gestational diabetes mellitus, GDM and hyperglycemia combined during pregnancy were 
considered as mediators of the association between maternal overweight and obesity and 
risk of OFCs. 
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3.4 Results 
A total of 1,750 cases of OFCs were ascertained from the UBDN including live 
births (n=1596, 91.2%), stillbirths (n=59, 3.4%), terminations (n=81, 4.6%), and 
spontaneous abortions (n=14, 0.8%)). 1,611 OFC live-born cases were linked to the birth 
certificate records; 139 cases were excluded from the case-control study because they 
were not live-births (n=136) or non-Utah maternal residences (n=3). Overall prevalence 
of OFCs based on the UBDN registry data, trended to decline over the period 2000-2011 
(average 2.09 per 1000 live births) and the decline appeared to be due to a decline in 
isolated OFCs while the prevalence of non-isolated OFCs appeared relatively constant 
(Figure 3.1). Birth certificates reported 77.6% OFC cases (n=1,250) determined by the 
UBDN registry (n=1,611) and the completeness of reporting improved from 71.1% 
during 1995 to 91.9% during 2011. 
Among OFC cases born during 1997-2011, non-isolated OFCs accounted for 
29.8% (n=432), isolated OFCs accounted for 70.2% (n=1091) of all OFC cases; 34.3% 
were cleft palate only (CPO) (n=497), 25.3% were cleft lip only (CLO) (n=367), and 
40.5% were cleft lip with cleft palate (CLP) (n=587).  
Mean of maternal age at birth of non-isolated cases but not isolated cases was 
higher than controls (27.65.9 years vs 27.15.5 years). There was no significant 
difference between controls and all OFCs cases in the mean of paternal age at birth of 
index child or parity. Maternal age greater than 35 years increased risk of non-isolated 
OFCs when compared with mother age of 20-35 years (OR: 1.62, 95% CI: 1.18-2.23). 
The association between paternal age and risk of OFCs was not found. There was no 
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association between mothers and fathers of age nineteen or younger and risk of OFCs 
(Table 3.2). Mothers of all OFCs and isolated OFCs had higher mean BMI than control 
mothers (Table 3.1). The prevalence of depression, pre-existing DM and GDM in both 
non-isolated and isolated OFCs were higher than controls.  
Higher maternal and paternal education levels (higher than bachelor degree vs 
high school diploma or less) were associated with a decreased risk of both all and isolated 
OFCs (maternal education; OR: 0.85, 95% CI: 0.73-0.98, p-trend = 0.03 and OR: 0.82, 
95% CI: 0.69-0.98, p-trend = 0.03 respectively and paternal education: OR: 0.76, 95% 
CI: 0.63-0.92, p-trend = 0.01 and OR: 0.75, 95% CI: 0.60-0.95, p-trend = 0.01 
respectively) (Table 3.2). The education associations appeared stronger for isolated OFCs 
compared to non-isolated OFCs.   
The birth certificate data for maternal smoking and alcohol consumption after 
1999 had missing rates over than 90%, thus, these data after 1999 were excluded from 
analysis. Mothers with depression had an increased risk of all OFCs (OR: 1.38; 95% CI: 
1.06-1.80) and the estimates were similar, but with wider confidence intervals for the 
sub-groups of non-isolated OFCs (OR: 1.60; 95% CI: 1.60 -2.43) (Table 3.2).  
Obesity (BMI > 30 kg/m2) compared to normal weight increased risk of all OFCs, 
non-isolated, and isolated OFCs with p-trends < 0.0001, 0.01, and 0.01, respectively 
(Table 3.2). The adjusted odds ratio for obese mothers (BMI ≥ 30 kg/m2) was 1.29 (95% 
CI: 1.09-1.53) for all OFCs, 1.41 (95% CI: 1.07-1.87) for non-isolated OFCs, and 1.23 
(95% CI: 1.01-1.50) for isolated OFCs when compared to mothers with normal BMI. 
Maternal underweight was associated with a decreased risk of isolated CLO (aOR 
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(adjusted odds ratio): 0.42; 95% CI: 0.20-0.85) and increased risk of all CPO (aOR: 1.50; 
95% CI: 1.04-2.16) after adjustment for maternal age, education, depression, and all 
diabetes (Table 3.3). The associations between maternal obesity and all, non-isolated, and 
isolated OFCs were only slightly less after adjustment for maternal age, education, 
depression, and all diabetes (Table 3.4). Linear regression analysis showed that the slope 
of prevalence of maternal obesity during 1997-2011increased every year for both OFC 
groups and controls. The slope of the regression line of case mothers was significantly 
higher than the slope of control mothers (p-value = 0.028) (Figure 3.2). 
Mother with pre-existing diabetes had an increased risk of all OFCs (aOR: 2.19; 
95% CI: 1.18-4.09) with a stronger effect for non-isolated OFCs (aOR: 3.83; 95% CI: 
1.71-8.58) vs isolated OFCs (aOR: 1.54; 95% CI: 0.70-3.41) when adjustment for 
maternal age, maternal education, depression, and BMI (Table 3.5). Based on cleft 
subtypes, pre-existing diabetes increased risk of non-isolated CLP, CL/P (cleft lip 
with/without cleft palate) and cleft palate with or without cleft lip (CP/L) (aOR: 6.23; 
95% CI: 2.31-16.81, aOR: 4.64; 95% CI: 1.74-12.40, and aOR: 4.41; 95% CI: 1.96-9.90, 
respectively). GDM mothers had an increased risk of all OFCs (aOR: 1.48, 95%CI: 1.05-
2.09) with a larger effect for non-isolated OFCs (aOR: 2.29, 95%CI: 1.41-3.72) vs 
isolated OFCs (aOR: 1.15, 95%CI: 0.75-1.77) (Table 3.6). Associations between GDM 
and risk of non-isolated CPO and CP/L were found (aOR: 2.91; 95% CI: 1.59-5.32, and 
aOR: 2.22; 95% CI: 1.32-3.73, respectively). All diabetes had an increased risk of all 
OFCs (aOR: 1.52; 95% CI: 1.14-2.04) with a stronger effect for non-isolated OFCs (aOR: 
2.38; 95% CI: 1.58-3.59) vs isolated OFCs (aOR: 1.18; 95% CI: 0.82-1.71) (Table 3.7).  
269 
 
In addition, all diabetes increased risk of non-isolated CPO, CLP, CL/P, and CP/L (aOR: 
2.71; 95% CI: 1.59-4.62, aOR: 2.08; 95% CI: 1.06-4.07, aOR: 2.05; 95% CI: 1.13-3.72 
and aOR: 2.43; 95% CI: 1.58-3.74, respectively) 
Mediation analyses adjusting for maternal age and education indicated that there 
are direct effects of maternal obesity on all, non-isolated, and isolated OFCs not mediated 
through maternal diabetes (OR: 1.31; 95% CI: 1.11-1.55, OR: 1.45; 95% CI: 1.09-1.92, 
OR: 1.25; 95% CI: 1.03-1.53, respectively) (Table 3.8). There was no apparent 
interaction between obesity and maternal diabetes. The odds ratio for the indirect 
(mediation) effect of pre-existing diabetes was 1.02 (95% CI: 1.00-1.04) for all OFCs and 
1.06 (95% CI: 1.01-1.12) for non-isolated OFCs. However, there was no apparent 
mediation effect of GDM and all DM on risk of OFCs (all, non-isolated, and non-non-
isolated OFCs). Stratified analyses based on logistic regression with the same covariates 
revealed similar associations between obesity and OFC risk for both non-diabetic (aOR: 
1.33; 95%CI: 1.12-1.57) and diabetic (aOR: 1.38; 95%CI: 0.67-2.85). Moreover, 
maternal diabetes increased risk of OFCs in both normal weight and obese mothers (aOR: 
1.45; 95% CI: 0.83-2.52 and aOR: 1.37; 95% CI: 0.86-2.19, respectively)   
3.5 Discussion 
This study found that obese mothers had an increased risk of both non-isolated 
and isolated OFCs, while underweight mothers had a decreased risk of CLO and an 
increased risk of CPO. An association between maternal depression and risk of OFCs was 
also found in this study.  In addition, mothers with pre-existing diabetes had an increased 
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risk for having a child with non-isolated CLP, CL/P, and CP/L, and GDM mothers were 
associated with non-isolated CPO and CP/L.  
The study was population-based and relatively robust against selection bias. OFC 
cases were drawn from the state-wide Utah birth defects registry, which provided 
exhaustive case-finding from multiple sources and determination of OFC diagnosis by 
medical geneticist review. Birth certificates were obtained for 99.7 percent of live-born 
registry cases. OFC cases that were not live-born were excluded from the case-control 
analysis because of the difficulty of selecting appropriate controls but were included in 
the estimates of overall rates of OFCs in Utah. Cleft diagnoses from birth certificate 
records included 77.6% of cases found by the registry over the entire study period, 
however the completeness of cleft diagnoses from birth certificate records tended to 
improve over time thus birth certificate diagnoses may be used to analyze OFC 
occurrence in areas that lack registries but that have high-quality completion of birth 
certificates. Data on maternal medical conditions (diabetes mellitus, GDM, depression, 
and hypertension) and potential confounders were obtained from birth certificate records, 
and these conditions are likely under-reported. We found a large amount of missing data 
on smoking and alcohol use, thus we were unable to control for the potential confounding 
by these factors. The prevalence of OFCs has been decreasing, yet the rate of OFC risk 
factors including obesity, and diabetes have been increasing. This indicates that only one 
environmental risk factor cannot explore or predict the OFC occurrence. 
This study found that underweight mothers had a significantly decreased risk of 
CLO, but increased risk of CPO. To our knowledge the protective effect of maternal 
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underweight on risk of CLO has not been previously reported and is inconsistent with the 
previous study by Kutbi et al (27), which reported that maternal underweight marginally 
increased risk of isolated CLO and CPO. The characteristic of underweight mothers in 
OFCs requires further study. Moreover, we found an increased risk of CPO, CLP, CL/P, 
and CP/L with maternal obesity, which is consistent with a previous study by Kutbi et al 
suggesting that obesity has a specific effect on palate formation but not lip formation 
(27). A recent meta-analysis by Blanco et al also presented that maternal obesity 
increased risk of CPO and CL/P (28).  
The association between maternal diabetes and risk of non-isolated OFCs is 
consistent with limited previous studies (19, 21). Correa et al. using the data from the 
National Birth Defect Prevention Study (NBDPS) during 1997-2003 showed an 
association between both pre-existing diabetes (type 1 or 2) and GDM and risk isolated 
OFCs, while only pre-existing diabetes was associated with syndromic OFCs (21). 
Correa et al. also reported higher estimates of odds ratios and wider confidence intervals 
than our Utah study (non-isolated CPO, OR: 10.73, 95% CI: 3.99-28.86 and non-isolated 
CL/P, OR: 8.07, 95% CI: 3.05-21.39). Data from a large international consortium of 
case-control studies from the U.S., Denmark, and Norway (19) found an association 
between GDM and syndromic OFCs and CPO. A prospective study by Moore et al (10) 
reported suggestive associations between pre-existing (type 1 or 2) and GDM and risk of 
OFCs but also with very wide confidence intervals that included 1.0 (prevalence ratios 
(PR): 8.9, 95% CI: 0.85-46.5; and PR: 2.6, 95% CI: 0.82-8.5, respectively).  
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The data on pre-existing diabetes and GDM in our Utah study are based on the 
birth certificate record and may be underreported. A study by DeSisto et al. (29) 
comparing prevalence of GDM in the United States from birth certificates and the 
Pregnancy Risk Assessment Monitoring System (PRAMS) reported that prevalence of 
GDM in Utah from PRAMS (6.4%) was higher than the prevalence from birth certificates 
(4.0%) in 2010.  A study by Owen-Gary and War reported that only 44.8% of the 
confirmed GDM cases had a GDM diagnosis in their medical records (30). The 
discrepancies among birth certificates, PRAMS, and medical records may result from 
under diagnosis and from poor quality of transcription or documenting medical record 
data on birth certificates. The current gold standard for GDM screening, oral glucose 
tolerance tests (OGTT), is applied during 24th -28th week of gestation. However, there is 
no clear agreement on the diagnostic criteria for GDM using oral glucose tolerance tests 
(OGTT) because different organizations have provided different guidelines and 
thresholds (31). These reasons lead to under-diagnosing and unclear-documenting of 
GDM on birth certificates. Therefore, the association between GDM and risk of non-
syndromic OFCs may be underestimated because of underreported GDM on birth 
certificates.  
We found a direct effect of obesity and small indirect (mediating) effect of pre-
existing diabetes on risk of OFCs. Both stratification and mediation analyses indicated 
that the effect of obesity on increasing risk of OFCs apart from the presence of known 
maternal diabetes. However, mediation analysis may not be a powerful method when 
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there is a small sample size of pregnancies exposed to diabetes and the presence of 
undetected diabetes in the population.  
Based on stratified analysis, diabetic mothers with normal BMI (18.5-24.9 kg/m2) 
also have an increased risk of OFCs. This relevance of this further finding can be 
appreciated by considering studies of non-obese diabetics (BMI 18-24.9 kg/m2). A cohort 
study in the United States minority populations (32) found that about 13% of participants 
were normal weight diabetics (BMI 17-25 kg/m2); Asians had a five-times higher 
prevalence of diabetes in the normal weight group when compared to the obese group 
(17% vs 4%). This study also reported that normal weight diabetics had more rapid 
pancreatic beta cell failure than obese diabetics, which is also supported by the 
observation of  impaired pancreatic insulin secretion in normal weight diabetics from a 
prospective study in the United Kingdom (33). Moreover, a case-control study in 
Portugal (34) reported that normal weight diabetic patients had higher chemerin levels 
than controls. Chemerin is an adipokine regulating adipocyte development and 
differentiation and glucose metabolism in liver and skeletal muscle tissue. The 
pathophysiology of normal weight diabetes and the association between chemerin and 
other metabolic factors require further study. 
Due to the complex relationship between BMI and diabetes it is difficult to 
establish that BMI and diabetes are entirely independent causes of effects on OFCs. From 
stratified analysis, maternal underweight had a protective effect on the formation of lip 
alone which happens during 4th-8th week of gestation, while both maternal diabetes and 
obesity had an effect of an increased risk of cleft palate which occurs during 6th-12th week 
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of gestation. BMI and maternal diabetes might have effects on facial formation in a 
variety of pathways. BMI is a rather crude measurement of body composition and is not a 
precise indicator of fat mass, fat distribution, or metabolic status. Abdominal obesity has 
a higher lipolysis rate than peripheral fat depots and is associated with adverse conditions 
of the metabolic syndrome including elevated free fatty acids (FFA), cytokines, and 
adipokines (35, 36). In addition, obesity increases activity of cytochrome P450 (CYP) 
2E1, which may lead to poor folate status (37). Several epidemiological studies have 
reported that obesity increases the risk of inadequate folate status (38-41); BMI may have 
an adverse effect on cellular uptake and tissue distribution of folate. Obesity leads to 
insulin resistance, the impairment of insulin sensitivity in sites of glucose disposal, which 
can develop to type 2 diabetes mellitus and GDM (42). Many studies (43-45) reported 
that obese women increased risk of developing GDM. 
The mechanisms explaining the relationship between maternal diabetes and 
orofacial clefts are unknown. Elevated blood glucose and insulin stimulates the 
production of many adverse metabolic factors including ketone bodies, branched chain 
amino acid, inflammatory markers, advanced glycation end products, altered expression 
levels of specific genes, and increase the variation of gene expression levels (15-18). 
These factors may disrupt normal embryonic development.  
Our results suggest that in Utah maternal obesity, depression, and diabetes are 
associated with increased risk of OFCs, and underweight mothers had a decreased risk of 
CLO. Mechanistic studies are needed to understand the causal effects of maternal obesity, 
underweight, depression, metabolic abnormalities, and diabetes on OFCs risk. Effective 
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interventions are needed for promoting healthy body weight and metabolic status in 
reproductive age women in order to reduce the risk of OFCs.  Effective early screening 
for GDM risk is needed for the periconceptional period and in the first month of gestation 
in order to allow early interventions for controlling hyperglycemia, hyperinsulinemia and 
other associated metabolic abnormalities to prevent OFCs and other congenital 
malformations. 
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Table 3.1 Demographic characteristics of orofacial cleft cases and controls (1997-2011) 
Parameters Control 
N = 5804 
All_OFCs 
n = 1451 
Non-isolated OFCs 
n = 432 
Isolated OFCs 
n = 1091 
Age of father 29.66.0 29.66.2 29.75.9 29.56.2 
Age of mother 27.15.5 27.25.6 27.65.9* 27.05.5 
Number of previous live births now 
still live 
1.41.4 1.41.5 1.41.6 1.31.4 
Maternal BMIa 24.55.5 25.05.7** 25.05.9 24.95.6** 
Maternal BMIa category 
  Underweight (<18.5 kg/m2) 
  Normal (18.5-24.9 kg/m2) 
  Overweight (25-29.9 kg/m2) 
  Obese (≥30 kg/m2) 
 
348 (6.2%) 
3252 (58.2%) 
1212 (21.7%) 
777 (13.9%) 
 
78 (5.7%) 
757 (55.1%) 
293 (21.3%) 
245 (17.8%) 
 
27 (6.7%) 
219 (54.8%) 
73 (18.3%) 
81 (20.3%) 
 
51 (5.2%) 
538 (55.3%) 
220 (22.6%) 
164 (16.9%) 
Maternal Race/ethnicity 
  White, non-Hispanic 
  Black, non-Hispanic 
  Asian or Pacific Islander 
  American Indian 
  Hispanic 
  Unknown 
 
4668 (80.4%) 
45 (0.8%) 
118 (2.0%) 
71 (1.2%) 
833 (14.4%) 
58 (1.0%) 
 
1150 (79.3%) 
6 (0.4%) 
28 (1.9%) 
29 (2.0%) 
210 (14.5%) 
17 (1.2%) 
 
330 (76.4%) 
2 (0.5%) 
8 (1.9%) 
12 (2.8%) 
69 (16.0%) 
8 (1.9%) 
 
820 (75.2%) 
4 (0.4%) 
20 (1.8%) 
17 (1.6%) 
141 (12.9%) 
9 (0.8%) 
Paternal Race/ethnicity 
  White, non-Hispanic 
  Black, non-Hispanic 
  Asian or Pacific Islander 
  American Indian 
  Hispanic 
  Unknown 
 
4392 (75.7%) 
56 (1.0%) 
89 (1.5%) 
38 (0.7%) 
683 (11.8%) 
155 (2.7%) 
 
1089 (75.1%) 
7 (0.5%) 
20 (1.4%) 
15 (1.0%) 
168 (11.6%) 
31 (2.1%) 
 
308 (71.3%) 
1 (0.2%) 
8 (1.9%) 
7 (1.6%) 
59 (13.7%) 
11 (2.5%) 
 
781 (71.6%) 
6 (0.5%) 
12 (1.1%) 
8 (0.7%) 
109 (10.0%) 
20 (1.8%) 
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Table 3.1 Demographic characteristics of orofacial cleft cases and controls (1997-2011) (Cont.) 
Parameters Control 
N = 5804 
All_OFCs 
n = 1451 
Non-isolated OFCs 
n = 432 
Isolated OFCs 
n = 1091 
Maternal education 
  High school or less 
  Some college or bachelor 
  Higher than bachelor 
 
2402 (41.9%) 
1812 (31.6%) 
1520 (26.5%) 
 
633 (44.6%) 
447 (31.5%) 
340 (23.9%) 
 
184 (43.9%) 
129 (30.8%) 
106 (25.3%) 
 
449 (44.9%) 
318 (31.8%) 
234 (23.4%) 
Paternal education 
  High school or less 
  Some college or bachelor 
  Higher than bachelor 
 
1924 (36.4%)  
2526 (47.8%) 
831 (15.7%) 
 
502 (38.9%) 
623 (48.3%) 
165 (12.8%) 
 
149 (39.0%) 
183 (47.9%) 
50 (13.1%) 
 
353 (38.9%) 
440 (48.5%) 
115 (12.7%) 
Hypertensiona 373 (6.4%) 93 (6.4%) 31 (7.2%) 62 (6.1%) 
Depression 224 (3.9%) 76 (5.2%) 26 (6.0%) 50 (4.9%) 
Pre-existing diabetes mellitusb 29 (0.5%) 16 (1.1%) 8 (2.0%) 8 (0.8%) 
Gestational diabetes mellitusb 133 (2.3%) 49 (3.4%) 22 (5.2%) 27 (2.7%) 
All diabetes mellitusc 181 (2.8%) 69 (4.3%) 31 (6.5%) 38 (3.4%) 
a Hypertension refers to chronic hypertension, pregnancy induced hypertension, pre-eclampsia, eclampsia, and toxemia   
bBased on data during 1997-2011 
c All diabetes mellitus refers to combination between pre-existing DM and GDM 
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Table 3.2 Association between demographic factors and risk of OFCs  
Characteristic All OFCs  
(N=1451) 
Non-isolated OFCs  
(N=432) 
Isolated OFCs  
(N=1091) 
OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value 
Maternal age 
  Less than 19 years 
  20-35 years 
  More than 35 
 
0.89 [0.70-1.11] 
1 [Reference] 
1.21 [0.98-1.50] 
 
0.29 
 
0.08 
 
0.78 [0.52-1.19] 
1 [Reference] 
1.62 [1.18-2.23] 
 
0.25 
 
0.003 
 
0.93 [0.72-1.20] 
1 [Reference] 
1.04 [0.81-1.34] 
 
0.56 
 
0.77 
Paternal age 
  Less than 19 years 
  20-35 years 
  More than 35 
 
0.68 [0.44-1.06] 
1 [Reference] 
1.11 [0.94-1.30] 
 
0.09 
 
0.22 
 
0.39 [0.14-1.07] 
1 [Reference] 
1.06 [0.80-1.40] 
 
0.07 
 
0.68 
 
0.81 [0.50-1.31] 
1 [Reference] 
1.13 [0.94-1.36] 
 
0.38 
 
0.21 
Maternal BMIa 
  Underweight (<18.5 kg/m2) 
  Normal (18.5-24.9 kg/m2) 
  Overweight (25-29.9 kg/m2) 
  Obese (≥30 kg/m2)  
    
 
0.96 [0.74-1.25] 
1 [Reference] 
1.04 [0.89-1.21] 
1.36 [1.15-1.60] 
p-trend1 0.001 
 
0.77 
 
0.62 
<0.001 
 
1.15 [0.76-1.74] 
1 [Reference] 
0.89 [0.68-1.18] 
1.55 [1.19-2.02] 
p-trend1 0.01 
 
0.50 
 
0.42 
0.001 
 
0.89 [0.65-1.21] 
1 [Reference] 
1.10 [0.93-1.30] 
1.28 [1.05-1.56] 
p-trend1 0.01 
 
0.44 
 
0.29 
0.01 
Maternal education  
  High school or less 
  Some college or bachelor 
  Higher than bachelor 
 
1 [Reference] 
0.94 [0.82-1.07] 
0.85 [0.73-0.98] 
p-trend 0.03 
 
 
0.34 
0.03 
 
1 [Reference] 
0.93 [0.74-1.17] 
0.91 [0.71-1.17] 
p-trend 0.43 
 
 
0.54 
0.46 
 
1 [Reference] 
0.94 [0.80-1.10] 
0.82 [0.69-0.98]   
p-trend 0.03 
 
 
0.43 
0.03 
Father education  
  High school or less 
  Some College or bachelor 
  Higher than bachelor 
 
1 [Reference] 
0.95 [0.83-1.08] 
0.76 [0.63-0.92] 
p-trend 0.01 
 
 
0.40 
0.01 
 
1 [Reference] 
0.94 [0.75-1.17] 
0.78 [0.56-1.08] 
p-trend 0.15 
 
 
0.56 
0.13 
 
1 [Reference] 
0.95 [0.82-1.11] 
0.75 [0.60-0.95] 
p-trend 0.03 
 
 
0.50 
0.01 
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Table 3.2 Association between demographic factors and risk of OFCs (Cont.). 
Characteristic All OFCs  
(N=1451) 
Non-isolated OFCs  
(N=432) 
Isolated OFCs  
(N=1091) 
OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value 
Hypertension  1.00 [0.79-1.26] 0.97 1.13 [0.77-1.65] 0.66 0.95 [0.72-1.25] 0.69 
Depression 1.38 [1.06-1.80] 0.02 1.60 [1.05-2.43] 0.03 1.29 [0.94-1.76] 0.11 
a BMI (Body mass index) calculated as body weight (kg)/height (m2) 
1 excluding underweight 
Control = 5804 
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Table 3.3 Association between maternal underweight and risk of orofacial clefts (1997-2011)a 
Cleft Group  Odds Ratios and 95% Confidence Intervals by Cleft Subtypes 
OFCs CLO CPO CLP CL/P CP/L 
All Crude 0.96  
[0.74-1.25] 
0.50   
[0.27-0.92] 
1.45  
[1.01-2.08] 
0.89   
[0.60-1.32] 
0.73  
[0.52-1.03] 
1.14  
[0.86-1.50] 
 Model1 0.96  
[0.74-1.24] 
0.46  
[0.24-0.88] 
1.50  
[1.04-2.16] 
0.86  
[0.58-1.29] 
0.71  
[0.50-1.00] 
1.14  
[0.86-1.50] 
 Model2 0.95  
[0.74-1.24] 
0.46  
[0.24-0.88] 
1.50  
[1.04-2.16] 
0.86  
[0.58-1.29] 
0.71  
[0.50-1.00] 
1.14  
[0.86-1.50] 
Non-isolated Crude 1.15  
[0.76-1.74] 
0.67  
[0.16-2.81] 
1.46  
[0.86-2.46] 
0.91  
[0.44-1.90] 
0.85  
[0.44-1.64] 
1.22  
[0.80-1.88] 
 Model1 1.21 
 [0.80-1.85] 
0.80  
[0.19-3.42] 
1.54  
[0.91-2.62] 
0.91  
[0.44-1.91] 
0.89  
[0.46-1.73] 
1.26  
[0.82-1.95] 
 Model2 1.22 
 [0.80-1.85] 
0.80  
[0.19-3.41] 
1.54  
[0.91-2.63] 
0.92  
[0.44-1.92] 
0.89  
[0.46-1.73] 
1.27  
[0.82-1.96] 
Isolated Crude 0.89  
[0.65-1.21] 
0.47  
[0.24-0.93] 
1.44  
[0.90-2.32] 
0.88  
[0.56-1.40] 
0.70  
[0.47-1.03] 
1.09  
[0.78-1.53] 
 Model1 0.86  
[0.63-1.17] 
0.42  
[0.20-0.85] 
1.46  
[0.91-2.36] 
0.84  
[0.53-1.34] 
0.66  
[0.44-0.98] 
1.07  
[0.76-1.51] 
 Model2 0.86  
[0.63-1.17] 
0.42  
[0.20-0.85] 
1.47  
[0.91-2.36] 
0.84  
[0.53-1.34] 
0.66  
[0.44-0.98] 
1.07  
[0.76-1.51] 
OFCs: orofacial clefts; CL: cleft lip only; CP: cleft palate only; CLP: cleft lip with cleft palate; CL/P: cleft lip with/without cleft 
palate; CP/L: cleft palates with or without cleft lip.  
a All diabetes refers to combination between pre-existing DM and GDM 
Model1: Covariates in multiple logistic regression models included maternal age, maternal education levels, and depression. 
Model2:  Covariates in multiple logistic regression models included maternal age, maternal education levels, depression, and all 
diabetes. 
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Table 3.4 Association between maternal obesity and risk of orofacial clefts (1997-2011)a 
Cleft Group  Odds Ratios and 95% Confidence Intervals by Cleft Subtypes 
OFCs CLO CPO CLP CL/P CP/L 
All Crude 1.36  
[1.15-1.60] 
1.25  
[0.93-1.68] 
1.37  
[1.05-1.78] 
1.41  
[1.12-1.79] 
1.35   
[1.11-1.63] 
1.39  
[1.16-1.68] 
 Model1 1.33  
[1.12-1.57] 
1.27  
[0.94-1.72] 
1.33  
[1.01-1.74] 
1.36  
[1.07-1.73] 
1.33  
[1.09-1.61] 
1.35  
[1.12-1.63] 
 Model2 1.29  
[1.09-1.53] 
1.26  
[0.93-1.70] 
1.24  
[0.94-1.64] 
1.34  
[1.05-1.71] 
1.31  
[1.07-1.59] 
1.30  
[1.07-1.57] 
Non-isolated Crude 1.55  
[1.19-2.02] 
1.35  
[0.63-2.86] 
1.57  
[1.09-2.27] 
1.58  
[1.04-2.41] 
1.52  
[1.05-2.20] 
1.58  
[1.19-2.09] 
 Model1 1.55  
[1.18-2.03] 
1.47  
[0.68-3.17] 
1.59  
[1.09-2.31] 
1.51  
[0.99-2.32] 
1.50  
[1.03-2.19] 
1.56  
[1.17-2.07] 
 Model2 1.41  
[1.07-1.87] 
1.42  
[0.65-3.11] 
1.42  
[0.96-2.08] 
1.40  
[0.91-2.17] 
1.41  
[0.96-2.07] 
1.41  
[1.05-1.90] 
Isolated Crude 1.28  
[1.05-1.55] 
1.24  
[0.90-1.70] 
1.20  
[0.83-1.73] 
1.35  
[1.02-1.78] 
1.30  
[1.05-1.61] 
1.29  
[1.03-1.62] 
 Model1 1.24  
[1.02-1.51] 
1.25  
[0.90-1.72] 
1.13  
[0.78-1.64] 
1.30  
[0.98-1.73] 
1.28  
[1.03-1.60] 
1.23  
[0.98-1.56] 
 Model2 1.23  
[1.01-1.50] 
1.23  
[0.89-1.71] 
1.09  
[0.75-1.59] 
1.31  
[0.99-1.74] 
1.28  
[1.02-1.60] 
1.23  
[0.97-1.55] 
OFCs: orofacial clefts; CL: cleft lip only; CP: cleft palate only; CLP: cleft lip with cleft palate; CL/P: cleft lip with/without cleft 
palate; CP/L: cleft palates with or without cleft lip  
a All diabetes refers to combination between pre-existing DM and GDM 
Model1: Covariates in multiple logistic regression models included maternal age, maternal education levels, and depression. 
Model2:  Covariates in multiple logistic regression models included maternal age, maternal education levels, depression, and all 
diabetes. 
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Table 3.5 Association between pre-existing diabetes and risk of orofacial clefts (1997-2011) 
Cleft Group  Odds Ratios and 95% Confidence Intervals by Cleft Subtypes 
OFCs CLO CPO CLP CL/P CP/L 
All Crude 2.25 
[1.22-4.15] 
1.10 
[0.26-4.63] 
2.50 
[1.03-6.06] 
2.76 
[1.26-6.07] 
2.12 
[1.03-4.37] 
1.68 
[1.24-2.29] 
 Model1 2.24 
[1.21-4.15] 
1.07 
[0.25-4.52] 
2.49 
[1.03-6.05] 
2.76 
[1.25-6.09] 
2.11 
[1.02-4.35] 
2.63 
[1.02-4.35] 
 Model2 2.19 
[1.18-4.09] 
1.02 
[0.24-4.34] 
2.54 
[1.04-6.22] 
2.64 
[1.19-5.88] 
2.03 
[0.97-4.21] 
2.59 
[1.35-4.97] 
Non-isolated Crude 3.89 
[1.77-8.56] 
N/A 2.89 
[0.87-9.55] 
6.48 
[2.47-16.97] 
4.91 
[1.88-12.81] 
4.42 
[2.00-9.73] 
 Model1 3.81 
[1.72-8.42] 
N/A 2.88 
[0.87-9.58] 
6.30 
[2.39-16.64] 
4.75 
[1.81-12.47] 
4.34 
[1.96-9.62] 
 Model2 3.83 
[1.71-8.58] 
N/A 2.99 
[0.89-10.10] 
6.23 
[2.31-16.81] 
4.64 
[1.74-12.40] 
4.41 
[1.96-9.90] 
Isolated Crude 1.58 
[0.72-3.47] 
1.27 
[0.30-5.37] 
2.21 
[0.67-7.30] 
1.41 
[0.43-4.65] 
1.35 
[0.52-3.51] 
1.72 
[0.71-4.16] 
 Model1 1.59 
[0.72-3.49] 
1.24 
[0.30-5.25] 
2.20 
[0.66-7.26] 
1.43 
[0.43-4.74] 
1.36 
[0.52-3.53] 
1.73 
[0.72-4.19] 
 Model2 1.54 
[0.70-3.41] 
1.19 
[0.28-5.06] 
2.21 
[0.65-7.40] 
1.35 
[0.41-4.50] 
1.30 
[0.50-3.38] 
1.68 
[0.69-4.09] 
OFCs: orofacial clefts; CL: cleft lip only; CP: cleft palate only; CLP: cleft lip with cleft palate; CL/P: cleft lip with/without cleft 
palate; CP/L: cleft palates with or without cleft lip.  
Model1: Covariates in multiple logistic regression models included maternal age, maternal education levels, and depression. 
Model2:  Covariates in multiple logistic regression models included maternal age, maternal education levels, depression, and body 
mass index. 
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Table 3.6 Association between gestational diabetes mellitus and risk of orofacial clefts (1997-2011) 
Cleft Group  Odds Ratios and 95% Confidence Intervals by Cleft Subtypes 
OFCs CLO CPO CLP CL/P CP/L 
All Crude 1.50 
[1.08-2.10] 
1.32 
[0.71-2.47] 
2.09 
[1.33-3.29] 
1.13 
[0.66-1.94] 
1.20 
[0.79-1.84] 
1.57 
[1.09-2.26] 
 Model1 1.45 
[1.04-2.04] 
1.35 
[0.72-2.53] 
1.92 
[1.20-3.05] 
1.11 
[0.64-1.91] 
1.20 
[0.78-1.85] 
1.48 
[1.02-2.15] 
 Model2 1.48 
[1.05-2.09] 
1.41 
[0.75-2.65] 
2.07 
[1.29-3.32] 
1.04 
[0.59-1.83] 
1.18 
[0.76-1.83] 
1.50 
[1.02-2.20] 
Non-isolated Crude 2.33 
[1.47-3.70] 
2.65 
[0.82-8.61] 
2.94 
[1.66-5.19] 
1.41 
[0.57-3.50] 
1.71 
[0.83-3.54] 
2.29 
[1.40-3.74] 
 Model1 2.15 
[1.33-3.45] 
2.64 
[0.80-8.69] 
2.67 
[1.47-4.82] 
1.31 
[0.53-3.27] 
1.62 
[0.78-3.37] 
2.08 
[1.25-3.45] 
 Model2 2.29 
[1.41-3.72] 
2.78 
[0.83-9.32] 
2.91 
[1.59-5.32] 
1.37 
[0.55-3.46] 
1.70 
[0.81-3.57] 
2.22 
[1.32-3.73] 
Isolated Crude 1.17 
[0.77-1.77] 
1.11 
[0.54-2.29] 
1.45 
[0.73-2.87] 
1.03 
[0.54-1.97] 
1.06 
[0.65-1.75] 
1.19 
[0.73-1.94] 
 Model1 1.16 
[0.76-1.77] 
1.14 
[0.55-2.36] 
1.36 
[0.68-2.72] 
1.03 
[0.53-1.98] 
1.08 
[0.65-1.78] 
1.17 
[0.71-1.90] 
 Model2 1.15 
[0.75-1.77] 
1.18 
[0.73-2.94] 
1.46 
[0.73-2.94] 
0.92 
[0.61-1.72] 
1.03 
[0.61-1.72] 
1.13 
[0.68-1.88] 
OFCs: orofacial clefts; CL: cleft lip only; CP: cleft palate only; CLP: cleft lip with cleft palate; CL/P: cleft lip with/without cleft 
palate; CP/L: cleft palates with or without cleft lip  
1 based on data during 1997-2011 
Model1: Covariates in multiple logistic regression models included maternal age, maternal education levels, and depression. 
Model2:  Covariates in multiple logistic regression models included maternal age, maternal education levels, depression, and body 
mass index. 
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Table 3.7 Association between all diabetes and risk of orofacial clefts (1997-2011)a 
Cleft Group  Odds Ratios and 95% Confidence Intervals by Cleft Subtypes 
OFCs CLO CPO CLP CL/P CP/L 
All Crude 1.55 
[1.17-2.06] 
1.16 
[0.65-2.05] 
2.09 
[1.41-3.09] 
1.36 
[0.89-2.08] 
1.28 
[0.90-1.83] 
1.68 
[1.24-2.29] 
 Model1 1.52 
[1.14-2.02] 
1.18 
[0.66-2.10] 
1.95 
[1.31-2.91] 
1.35 
[0.88-2.08] 
1.29 
[0.90-1.85] 
1.63 
[1.19-2.22] 
 Model2 1.52 
[1.14-2.04] 
1.19 
[0.67-2.13] 
2.05 
[1.36-3.08] 
1.30 
[0.83-2.02] 
1.26 
[0.87-1.82] 
1.63 
[1.19-2.24] 
Non-isolated Crude 2.40 
[1.62-3.56] 
1.99 
[0.62-6.45] 
2.77 
[1.67-4.57] 
2.03 
[1.06-3.91] 
2.02 
[1.14-3.61] 
2.45 
[1.63-3.70] 
 Model1 2.27 
[1.52-3.39] 
1.98 
[0.61-6.46] 
2.55 
[1.52-4.29] 
1.97 
[1.02-3.81] 
1.97 
[1.10-3.53] 
2.30 
[1.51-3.50] 
 Model2 2.38 
[1.58-3.59] 
1.97 
[0.59-6.54] 
2.71 
[1.59-4.62] 
2.08 
[1.06-4.07] 
2.05 
[1.13-3.72] 
2.43 
[1.58-3.74] 
Isolated Crude 1.20 
[0.85-1.72] 
1.03 
[0.54-1.96] 
1.56 
[0.88-2.77] 
1.11 
[0.65-1.90] 
1.08 
[0.70-1.65] 
1.28 
[0.86-1.92] 
 Model1 1.21 
[0.84-1.73] 
1.05 
[0.55-2.01] 
1.49 
[0.84-2.66] 
1.12 
[0.66-1.92] 
1.10 
[0.72-1.68] 
1.27 
[0.84-1.91] 
 Model2 1.18 
[0.82-1.71] 
1.06 
[0.55-2.05] 
1.56 
[0.87-2.80] 
1.03 
[0.59-1.80] 
1.04 
[0.67-1.62] 
1.23 
[0.81-1.87] 
OFCs: orofacial clefts; CL: cleft lip only; CP: cleft palate only; CLP: cleft lip with cleft palate; CL/P: cleft lip with/without cleft 
palate; CP/L: cleft palates with or without cleft lip  
a All diabetes refers to combination between pre-existing DM and GDM 
Model1: Covariates in multiple logistic regression models included maternal age, maternal education levels, and depression. 
Model2:  Covariates in multiple logistic regression models included maternal age, maternal education levels, depression, and body 
mass index. 
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Table 3.8 Total, direct, and indirect effects with 95% CI of the association between 
maternal obesity and risk of orofacial clefts mediated through maternal diabetes  
 Pre-existing 
diabetes 
GDM All diabetesa 
 OR [95% CIs] OR [95% CIs] OR [95% CIs] 
All OFCs    
   Direct effect 1.33 [1.12-1.58] 1.30 [1.09-1.54] 1.31 [1.11-1.55] 
   Indirect effect 1.02 [1.00-1.04] 1.00 [0.98-1.03] 1.00 [0.97-1.04] 
   Total effect 1.35 [1.14-1.61] 1.30 1.10-1.54] 1.32 [1.11-1.56] 
Non-isolated OFCs    
   Direct effect 1.44 [1.08-1.92] 1.42 [1.07-1.89] 1.45 [1.09-1.92] 
   Indirect effect 1.06 [1.01-1.12] 1.00 [0.95-1.06] 1.01 [0.95-1.08] 
   Total effect 1.53 [1.15-2.04] 1.43 [1.08-1.89] 1.46 [1.11-1.93] 
Isolated OFCs    
   Direct effect 1.28 [1.05-1.57] 1.25 [1.02-1.53] 1.25 [1.03-1.53] 
   Indirect effect 1.00 [0.98-1.02] 1.00 [0.98-1.03] 1.00 [0.97-1.03] 
   Total effect 1.28 [1.05-1.57] 1.25 [1.03-1.52] 1.25 [1.03-1.52] 
a All diabetes refers to combination between pre-existing DM and GDM 
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Figure 3.1 Prevalence of OFCs during 1995-2011 (per 1000 live birth) 
All: coefficient = -0.023; 95%confidence interval = -0.043, -0.004; p-value= 0.02 
Non-isolated: coefficient = -0.002; 95%confidence interval = -0.013, 0.009; p-value= 
0.73 
Isolated: coefficient = -0.02; 95%confidence interval = -0.04, -0.003; p-value= 0.03  
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Figure 3.2 The regression line of maternal obesity (BMI ≥ 30 kg/m2) prevalence by year 
divided by OFC cases and controls. 
OFC cases 
Controls 
OFC cases 
Controls 
p-value = 0.028 
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CHAPTER 4 
 
THE ASSOCIATION BETWEEN MATERNAL DIABETES AND BIOMARKERS 
  
OF METABOLIC SYNDROME AND OROFACIAL CLEFTS 
 
  
4.1 Abstract 
 
Background: The evidence of the association between mothers having a 
congenitally malformed offspring and risk of developing diabetes and metabolic 
syndrome later in life is limited. This approach however may provide clues to the 
presence of undetected metabolic abnormalities involved in teratogenesis early in 
pregnancy. 
Objective: to determine the association between the occurrence of maternal 
diabetes and maternal biomarkers of metabolic syndrome and isolated orofacial clefts 
(OFCs) using data from the Utah Cleft 2 study.  
Methods: Cases and controls were selected from the participants in the Utah Cleft 
1 study (1995-2005) and the National Birth Defects Prevention Study (NBDPS) in Utah 
(2005-2011). Participants were interviewed by telephone, and physical examination and 
blood collection was completed in clinical visits. Laboratory assays of metabolic 
syndrome-related biomarkers were performed by Laboratory Corporation of America 
(Labcorp), Utah and Quansys Bioscience, Logan, Utah. Independent t-test and chi-square 
tests were used to assess the association between OFCs and continuous and categorical 
variables. Two-way ANOVA was performed to assess the differences of adipokines and 
cytokines. Multivariable logistic regression was used to estimate risk for OFCs while 
adjusting for the potential confounding effects of maternal age and smoking. 
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Results: Mothers having GDM in any pregnancy had an increased risk of OFCs 
(OR: 3.05, 95% CI: 1.61-5.80) and this was consistent for each type of OFC. OFC case-
mothers tended to be more obese than controls (OR: 1.45, 95% CI 0.99-2.13).  Mothers 
of children with cleft palate, compared to controls, had higher mean levels of plasma 
glucose, insulin, triglycerides, waist circumference and systolic blood pressure, and lower 
HDL; these associations were not seen for mothers of children with cleft lip 
only.  Similarly, mean plasma IL-8 and leptin levels were associated with cleft palate but 
not with cleft lip; risk analysis by tertile revealed a weaker association for IL-8 and cleft 
palates with or without cleft lip (CP/L) (OR for highest vs lowest tertile: 1.36, 95% CI 
0.81-2.30; p-trend 0.24) and a stronger association for leptin and CP/L (OR for highest 
vs. lowest tertile: 2.21, 95% CI 1.28-3.81; p-trend 0.004)  Metabolic syndrome indices 
were associated with cleft palate (NCEP/ATP III score OR: 1.60, 95% CI 1.00-2.56; IDF 
score OR: 1.64, 95% CI 1.04-2.59); these scores were not associated with cleft lip alone.  
Conclusion: Gestational diabetes mellitus was associated with risk of OFCs and 
this association may reflect a progression of metabolic syndrome abnormalities that are 
teratogenic yet undetected in the periconceptional period.  Individual metabolic syndrome 
biomarkers and indices were associated with cleft palate, but were not associated with 
cleft lip alone, this may reflect specific vulnerabilities of palate development which occur 
later than lip development.  IL-8 and leptin levels were also associated with cleft palate 
and not cleft lip alone and suggest that further studies of novel metabolic syndrome-
related biomarkers in the periconceptional period may be useful in understanding the 
causes and prevention of OFCs.  
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4.2 Introduction 
OFCs occur in every 0.4 to 2 per 1000 births depending on geographic location, 
racial and ethnic groups, maternal age, environmental exposures, and socioeconomic 
status (1, 2). The U.S. National Birth Defects Prevention Network reported the 
prevalence of OFCs during 2002-2006 of CL/P was 1.33 per 1000 live births, and 0.73 
per 1000 live births for CP (3). The prevalence of OFCs in Utah is higher than the overall 
prevalence in the United States (2.25 per 1000 births) (4) 
Metabolic syndrome is the grouping of visceral obesity, insulin resistance, 
hyperglycemia, dyslipidemia (hypertriglyceridemia and hypo-HDL cholesterolemia), and 
hypertension (5). In addition, metabolic syndrome increases the risk of cardiovascular 
diseases (CVD), type 2 diabetes mellitus, and stroke. Both type 2 diabetes mellitus and 
gestational diabetes mellitus, risk factors of OFCs, have associations with metabolic 
syndrome. Many studies have reported that metabolic syndrome increases the risk of type 
2 diabetes mellitus (6-9). A meta-analysis study showed that the subsequent risk of 
metabolic syndrome increased in women with a history of GDM (10). On the other hand, 
metabolic syndrome in early pregnancy increases the incidence of GDM (11). 
Biochemical markers are hormones, enzymes, antibodies, or other substances in 
urine, blood, tissue, or other body fluids. These biomarkers have been used to detect 
abnormality or disease. Besides HDL and triglyceride, liver function tests (ALT: alanine 
aminotransferase and GGT: gamma-glutamyltransferase) (12-14), cytokines (CRP: C-
reactive protein, IL-6: interleukin-6, and TNF- α: tumor necrosis factor alpha) (15-18), 
and adipokines (leptin and adiponectin) (16-18) also have association with metabolic 
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syndrome. The biomarkers associated with metabolic syndrome have been correlated 
with the risk of developing diabetes mellitus (13, 19-21). 
A few studies have reported that mothers having a congenitally malformed child, 
including OFCs increased risk of developing diabetes many years later (22, 23). Thus, we 
hypothesize that Utah mothers giving birth to children with orofacial clefts have an 
enhanced risk of diabetes and abnormal biomarkers associated with metabolic syndrome. 
This study aims to analyze biomarkers related to metabolic syndrome in mothers after 
giving birth to an OFC child compared to control-mothers of unaffected children.  
4.3 Subjects and Methods 
4.3.1 Study Design 
The Utah Cleft 2 study is a case-control interview and clinical study of orofacial 
clefts in Utah.  The study protocol was reviewed and approved by the institutional review 
boards of Utah State University (USU), the University of Utah, and the Utah Department 
of Health (UDOH). 
4.3.2 Study Participants 
Cases and controls were selected from the participants in the Utah Cleft 1 case-
control study (24) and the National Birth Defects Prevention Study (NBDPS) in Utah 
(25). In the Utah Cleft 1 study, case‐mothers having a child with OFCs between January 
1995 and June 2005 were recruited from UDOH, and control mothers were randomly 
selected, frequency matched by birth month and year, and gender of case child at ratio 
1:1 by using Utah birth certificate files. The NBDPS in Utah, also a state-wide 
population-based case-control study, recruited case mothers having a child with OFCs 
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between 2005-2011 from the UDOH database, and randomly selected control mothers 
from birth certificates. The OFC cases were limited to isolated OFCs; cases with multiple 
birth defects were excluded. 
4.3.3 Data collection 
Data from the Utah Cleft 2 case-control study were collected by trained 
interviewers after participants were contacted by either mail or telephone during 2011-
2015. Verbal consent was obtained by telephone before interviewing mothers about 
medical history, nutritional supplements, and prescription medicines. In clinical visits, 
mothers gave written informed consent and height, weight, waist circumference, and 
blood pressure were measured and a blood sample was taken. 
4.3.4 Laboratory analyses of biomarkers 
Blood samples from non-fasting subjects were obtained using Purple top (EDTA) 
and Blue-top (EDTA) tubes from mothers. Blood samples were centrifuged for 10 min at 
3600 rpm and divided into aliquots of plasma, buffy coats, and red blood cells. Aliquots 
for metabolic biomarkers were analyzed at the Laboratory Corporation of America 
(Labcorp), Utah. Samples for analyzing cytokines and adipokines were kept at -80oC, and 
shipped on dry ice to Quansys Bioscience, Logan, Utah. (Table 4.1) 
a) Hematology, metabolic profiles, and lipid profiles b)  
Labcorp (26) methods for metabolic biomarkers included Kinetic for liver 
function tests, enzymatic for glucose, carbon dioxide, total cholesterol, triglyceride, 
high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density 
lipoprotein (VLDL), electrochemiluminescence immunoassay (ECLIA) for insulin, 
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and Roche Tina Quant for hemoglobin A1c. Liver function tests included alanine 
aminotransferase (ALT/SGPT), aspartate aminotransferase (AST/SGOT), and 
alkaline phosphatase.  
b) Cytokines and adipokines 
Blood samples were collected from non-fasting participants and specimens were 
placed on wet ice then centrifuged within 2 hours after collection and kept at -80oC 
until analysis. Plasma was shipped on dry ice to Quansys Biosciences (27) (Logan, 
Utah) in order to analyze CRP, cytokines (IL-1a, IL-6, IL-8, and TNFa), and 
adipokines (adiponectin, leptin, and resistin). The serum specimens were analyzed by 
the multiplex enzyme-linked, immuunosorbent assay (ELISAs) technology, 
microscaled and multiplexed to simultaneously measure multiple proteins. 
4.3.4  Statistical analyses 
Descriptive analyses were conducted to determine the distribution of maternal 
biomarkers by OFC status. Metabolic syndrome protocols of NCEP/ATP III (28) and IDF 
(29) were used to classify metabolic syndrome status. Independent-sample t-tests and chi-
square tests were used to assess the association between OFCs and continuous and 
categorical variables respectively. Multivariable linear regression was used to adjust for 
the potential confounding effects of maternal age and smoking status in the comparison 
of continuous biomarkers of cases and controls. Multivariable logistic regression analysis 
was used to estimate odds ratios (ORs) with 95% confident intervals (95% CI) for 
evaluation of OFC risk. The linear trend test was analyzed to determine the trend of risk 
across levels of each biomarker. All multivariate analyses were adjusted for maternal age 
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and smoking. Due to wide range of undetected samples of cytokines and adipokines (0-
39.7%), two-way ANOVA was performed to estimate the difference of mean between 
OFC groups and the control group with models including covariates for detected-
undetected status and the measured values for detected samples. All statistical analyses 
were performed using the Statistical Package for Social Sciences (IBM SPSS) statistics 
version 22 for Windows. 
Table 4.1 Laboratory tests used in the Utah Cleft 2 case-control study  
Items Method Laboratory 
Lipid profiles (total cholesterol, 
triglyceride, lipoproteins) 
Enzymatic  Labcorp1 
Liver function test (alkaline 
phosphatase, alanine aminotransferase,  
and aspartate aminotransferase ) 
Kinetic Labcorp1 
Glucose Enzymatic Labcorp1 
Insulin  ECLIA2  
Hemoglobin A1c Roche Tina Quant Labcorp1 
C-reactive protein (CRP) Multiplex ELISAs3 Quansys Bioscience 
Cytokines and adipokines (interleukin-1 
alpha, interleukin-6, interleukin-8, 
leptin, resistin, tumor necrosis factor 
alpha, and adiponectin) 
Multiplex ELISAs3 Quansys Bioscience 
1 Labcorp: Laboratory Corporation of America  
2ECLIA: Electrochemiluminescence immunoassay 
3 ELISAs: Enzyme-Linked, Immuunosorbent Assay 
 
4.4 Results 
Efforts were made to recruit 1431 participants from the Utah Cleft 1 case-control 
study and 456 participants from the NBDPS. A total of 794 participants (435 (30.4%) 
from the Utah Cleft 1 case-control study and 359 (78.7%) from the NBDPS) were 
enrolled in this study; 612 participants (77.1%) completed telephone interviews, clinic 
visits and blood collection, and 157 (19.8%) completed the telephone interview only. 
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Refusals included 167 participants (116 (12.8%) controls and 51 (6.0%) cases) and 541 
participants (189 (20.9%) controls and 352 (41.1%) cases) were unable to be contacted or 
scheduled (table 4.2).  
The mean maternal age at birth and age at clinical visit was not different between 
cases and controls and the data collection for both groups was an average of 10 years 
after the index birth. Among 360 isolated OFC cases, cleft palate only (CPO) accounted 
for 25% (n=90), cleft lip only (CLO) accounted for 31.1% (n=112), and cleft lip with 
cleft palate (CLP) accounted for 42.5% (n=153). The mean body mass index (BMI) of 
cases and controls was not different. The rate of maternal smoking in three months before 
interview was greater in all OFC groups compared to controls (Table 4.3). Alcohol 
consumption in three months before interview was greater in OFC cases compared to 
controls (Table 4.3). Type 2 diabetes was less common than GDM and was not associated 
with OFC risk (Tables 4.3 and 4.4). Gestational diabetes (GDM) was associated with an 
increased risk of OFCs (OR: 3.05, 95% CI: 1.61-5.80) and this was consistent for each 
type of OFCs. OFC mothers tended to be more obese than controls (OR: 1.45, 95% CI: 
0.99-2.13) (Tables 4.3 and 4.4).  
When adjusted for maternal age and smoking, means of waist circumference, 
insulin, glucose and triglyceride in the CP/L (cleft palate with or without cleft lip) group 
were significant higher and mean HDL was lower than control mothers (Table 4.5); the 
mean values for the CLO group were not significantly different from controls. The odds 
ratios analyzed by tertiles generally showed similar finding, though the 95% CIs for most 
comparisons included 1.0.  
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OFC risk by level of the metabolic syndrome scores computed on the basis of 
NCEP/ATPIII and IDF criteria, and risk by the individual component scores appear in 
Table 4.8. Metabolic syndrome defined by NCEP/ATPIII criteria (≥ 3) was associated 
with an increased risk of CP/L (OR: 1.60, 95% CI: 1.00-2.56) but no higher risk of CLO 
(OR: 1.06, 95% CI: 0.54-2.05). Similarly, metabolic syndrome defined by IDF criteria 
was associated with a greater risk of all CP (OR: 1.64, 95% CI: 1.04-2.59) but no greater 
risk of CLO (OR: 1.16, 95% CI: 0.62-2.17). Elevated blood pressure, defined as systolic 
blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg was associated with 
CP/L (OR: 1.77, 95% CI: 1.02-3.09) but not CL only (OR: 1.03, 95% CI: 0.46-2.32). The 
other individual metabolic syndrome component scores did not appear to be associated 
with OFCs, underscoring the importance of combined metabolic syndrome indices rather 
than individual components in association with OFC risk. 
Mothers having CLO and cleft lip with/without cleft palate (CL/P) offspring had 
AST levels higher than mothers in the control group when adjusted for maternal age and 
smoking (adjusted p-value 0.05 and 0.05, respectively) (Table 4.7).  
The mean and median cytokine IL-8 (p-value=0.003) and the adipokine leptin (p-
value = 0.006) levels were higher in CP/L cases compared to controls (Table 4.6). The 
risk analysis by tertile revealed a weaker associated for IL-8 (OR for highest vs lowest: 
1.36, 95% CI: 0.81-2.30, p-trend 0.24) and a stronger association for leptin (OR for 
highest vs lowest: 2.21, 95% CI: 1.28-3.81, p-trend 0.004). IL-8 and leptin levels were 
not associated with CLO. When analyses were stratified by BMI level (normal weight, 
BMI 18.5 to 24.9 kg/m2; overweight, BMI 25 to 29.9 kg/m2; obese: BMI more than 30 
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kg/m2), IL-8 and leptin levels generally increased with increasing BMI levels, and 
significant differences emerged between CP/L vs controls. Based on BMI classification, 
obese mothers having CPO offspring had higher leptin levels than obese mothers in the 
control group when adjusted for maternal age and smoking (Figures 4.1).  
4.5 Discussion 
Mothers having GDM in any pregnancy had an increased risk of all types of 
OFCs. Mothers having CLO and CL/P offspring were associated with obesity later in life. 
Mothers having CP/L offspring had an increased risk of developing metabolic syndrome 
based on both NCEP/ATP III and IDF definitions. Mothers having CP/L offspring had 
higher IL-8 and leptin levels than control mothers. 
The association between gestational diabetes mellitus and risk of non-isolated 
OFCs is consistent with limited previous studies (30, 31). Correa et al. using the data 
from the National Birth Defect Prevention Study (NBDPS) during 1997-2003 showed an 
association between both pre-existing diabetes (type 1 or 2) and GDM and risk isolated 
OFCs, while only pre-existing diabetes was associated with syndromic OFCs (31). 
Correa et al. also reported higher estimates of odds ratios and wider confidence intervals 
than our study (non-isolated CPO, OR: 10.73, 95% CI: 3.99-28.86 and non-isolated 
CL/P, OR: 8.07, 95% CI: 3.05-21.39). Data from a large international consortium of 
case-control studies from the U.S., Denmark, and Norway (30) found an association 
between GDM and syndromic OFCs and CPO. A prospective study by Moore et al (32) 
reported suggestive associations between pre-existing (type 1 or 2) and GDM and risk of 
OFCs but also with very wide confidence intervals that included 1.0 (prevalence ratios 
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(PR): 8.9, 95% CI: 0.85-46.5; and PR: 2.6, 95% CI: 0.82-8.5, respectively). The 
mechanisms explaining the relationship between maternal diabetes and orofacial clefts 
are unknown. Elevated blood glucose and insulin stimulates the production of many 
adverse metabolic factors including ketone bodies, branched chain amino acids, 
inflammatory markers, advanced glycation end products, altered expression levels of 
specific genes, and increase the variation of gene expression levels (33-36). These factors 
may disrupt normal embryonic development. 
This study reported associations between CLO and CL/P and obesity, which is 
consistent with the findings of the Utah birth certificate study of pre-pregnancy weight 
reported in chapter 3. A large international consortium of U.S. and European population-
based studies by Kutbi et al (37) found that pre-pregnancy maternal obesity had an 
increased risk of CPO, CLP, and CP/L but not CLO; this study suggested that obesity has 
a specific effect on palate formation but not lip formation. A recent meta-analysis by 
Blanco et al also presented that maternal obesity increased risk of CPO and CL/P (38). 
Metabolic syndrome is a major public health issue because it increases the risk of 
cardiovascular diseases (CVD), type 2 diabetes mellitus, stroke, etc. We found that 
mothers of children with CP/L had an increased risk of developing metabolic syndrome 
later in life. A case-control study in Mexico (23) found that the prevalence of diabetes in 
mothers delivering a malformed child was higher than control group (controls: 4% and 
cases: 16.7, 40.4 5, and 53.1% when follow-up 0, 12, and 25 years after the index 
pregnancy, respectively). Another case-control study in the United Kingdom (22) 
307 
 
 
reported mothers having CPO or CL/P offspring had a higher prevalence of increased 
antagonism to insulin than control mothers (CPO: 75%, CL/P: 68.1%, and controls: 28%) 
This study found that using the IDF definition identified a higher prevalence of 
metabolic syndrome than using the NCEP/ATP III definition. Previous studies also 
reported that using IDF criteria for screening metabolic syndrome provided a higher 
prevalence than NCEP/ATP III criteria (39-42). The National Health and Nutrition 
Examination Survey (NHANES) 1999-2002 (39) found that prevalence of metabolic 
syndrome was 39.0±1.1 % based on IDF criteria, while 34.5±0.9 % based on NCEP/ATP 
III. Both metabolic syndrome criteria had similar associations with OFCs in the present 
study. 
Previous studies found the association between NCEP/ATP III definition and risk 
of carotid atherosclerosis (43, 44). However, recent studies suggested that metabolic 
syndrome definition proposed by IDF was a better predictor for cardiovascular risk than 
the definition by NCEP/ATP III. A cross sectional study in China presented that IDF 
definition was more strongly associated with CHD than NCEP/ATP III definition (45). A 
case-control study in Greece found that IDF definition for metabolic syndrome provided 
a higher odd ratio for acute coronary syndrome than NCEP/ATP III (OR: 3.26, 95% CI: 
2.12-5.00 vs OR: 2.32, 95% CI: 1.53-3.52) (46). A 13-year follow up study in Finns (42) 
found that metabolic syndrome defined by IDF was associated with risk of coronary heart 
disease (CHD) mortality (hazard ratio (HR): 1.42, 95% CI: 1.01-1.99), while the 
association between metabolic syndrome defined by NCEP/ATP III definition and CHD 
mortality was not significant (HR: 1.30, 95% CI: 0.94-1.81). However, this study also 
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reported a 1.35 fold (95% CI: 1.05-1.74) risk of CVD mortality was associated with 
metabolic syndrome according to NCEP/ATP III criteria, which was a bit higher than 
metabolic syndrome diagnosed by IDF (HR: 1.33, 95% CI: 1.03-1.77). A cross sectional 
analysis in a Greek population reported that NCEP/ATP III definition was more 
predictive of cardiovascular disease (CVD) risk than IDF definition (47). A prospective 
study in Austria (48) found metabolic syndrome defined by NCEP/ATP III definition was 
strongly predictive of vascular events than the IDF definition (HR: 1.58, 95% CI: 1.10-
2.26 vs HR: 1.06, 95% CI: 0.76-1.50). 
Both definitions use the same five components, but there are a few differences.  
The IDF definition requires the presence of central obesity plus two of the rest 
components while NCEP/ATP III definition makes central obesity one of the five equally 
weighted criteria. Moreover, the thresholds for waist circumference and fasting blood 
glucose by the IDF definition are lower than those of the NCEP definition. The 
thresholds of triglycerides and HDL cholesterol levels, and systolic and diastolic blood 
pressure are the same. IDF definition emphasizes waist circumference, an index of 
abdominal obesity which has an effect on metabolic processes by the intra-abdominal 
visceral fat which has higher lipolysis rate than any other depots. Abdominal adipose 
tissue elevates free fatty acids (FFA), cytokines (tumor necrosis factor alpha (TNF-𝛼) and 
interleukin-6 (IL-6)), adipokines, and angiotensin II. Excess FFA circulation induces 
insulin resistance, which results from reduced hepatic insulin clearance, decreased 
skeletal muscle insulin sensitivity, increased hepatic cholesterol production with elevated 
triglycerides and very low density lipoprotein (VLDL), and altered endothelial function. 
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Elevated levels of cytokines also impair insulin sensitivity (5, 49). In addition, enlarged 
fat cells causing fat overflow to muscles, the liver, and the pancreas lead to insulin 
resistance (50), which plays an important role in the development of metabolic syndrome 
(51). The IDF consensus group has mentioned other parameters that require further 
research into metabolic syndrome including tomographic assessment of fat distribution 
and liver fat, adipose tissue biomarkers (leptin and adiponectin), apolipoprotein B, small 
LDL particles, insulin resistance parameters (fasting insulin, proinsulin levels, 
homeostatic model assessment-insulin resistance (HOMA-IR), free fatty acid), oral 
glucose tolerance test, measurement of endothelial dysfunction, microalbuminuria, 
inflammatory markers (CRP, TNF-α, IL-6), thrombotic markers (plasminogen activator 
type 1, fibrinogen), and pituitary-adrenal axis (29).    
This study found that mothers having offspring with CP/L had higher insulin 
levels than control mothers. Insulin resistance is defined as a condition in which normal 
insulin levels are not adequate at maintaining a normal insulin response in peripheral 
target tissues (adipose, muscle, and liver), which causes pancreatic beta cells to secrete 
more insulin (hyperinsulinemia) to overcome the hyperglycemia condition (5). Elevated 
levels of inflammatory markers also impair insulin sensitivity (5, 49). An in vitro study 
by Hotanisligil et al found that TNF-α inhibits insulin receptor substrate 1 (IRS-1) 
signaling pathway, which leads to insulin resistance (52). A human study by Bastard et al 
reported that IL-6 level was associated with insulin resistance (53). This study 
hypothesized that IL-6 overproduction from adipose tissue activates extracellular signal 
regulated kinase (ERK) pathway and induces IRS-1, which inhibits insulin signaling. In 
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addition, insulin resistance is a risk factor for developing GDM. Prospective studies 
found that pregnant women having high fasting plasma insulin levels (FPI) in the first 
trimester of gestation had an increased risk of GDM (54-56). The association between 
insulin and OFCs requires further study. 
We found that mothers of children having CPO and CP/L had higher IL-8 and 
leptin levels than control mothers. IL-8 is a proinflammatory cytokine, which is produced 
by macrophages and monocytes (57). A case-control study by Bruun et al (58) found that 
plasma IL-8 levels were 38% higher in obese participants than in lean participants. In 
addition, in the obesity group, IL-8 levels had a positive correlation with fasting insulin 
levels and homeostasis model assessment for insulin resistance (HOMA-IR). A case-
control study by Zozulinska et al (59) reported that serum IL-8 levels in participants with 
type 1 and type 2 diabetes mellitus were higher than healthy participants (160.29 ± 34.81 
and 138.7 ± 32.8 pg/ml VS 39.93 ± 4.96 pg/ml).  
Serum leptin levels reflect the proportion of adipose tissue in the body, which is 
highly correlated with fat mass. During pregnancy, leptin is also produced by placenta, 
which has a pro-angiogenic effect in placental tissue (60) and an anti-apoptotic effect on 
trophoblast cells (61). A study by Pérez-Pérez et al reported increased leptin and leptin 
receptor gene expression in placentas from GDM pregnancies compared with normal 
pregnancies (62). Many studies reported that leptin levels were significantly higher in 
pregnancies with GDM compared with normal pregnancies (63-65). Studies focusing on 
the association between either hyperleptinemia or leptin expression and birth defects are 
limited. A study by Jones et al. (66) found that placental leptin RNA expression was 
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significantly increased in hypoplastic left heart syndrome (HLHS) cases compared to 
controls. However, a meta-analysis study reported that SGA (small for gestational age) 
infants had lower cord blood leptin levels than AGA (appropriate for gestational age) 
infants (67). An impact of increased leptin levels on placental nutrient transfer was 
proposed by a cell study by Araujo et al (68).  The study showed that there is no 
significant change of the steady-state intracellular accumulation of folic acid, while 
diabetic trophoblasts (DTB) cells from gestational diabetic pregnancies had higher rates 
of inward and outward transport of intracellular folic acid. The higher turnover of 
intracellular folic acid in DTB cells is required to maintain normal folic acid homeostasis. 
Moreover, hyperleptinemic condition leads to decreased folic acid uptake. These findings 
showed that leptin may act as a regulator of placental nutrient transport especially folic 
acid, and a regulator of fetal growth. However, the study of that effect of leptin on folic 
acid placental transport is limited.  
The leptin gene is transcriptionally activated in response to hypoxia (69). A 
mouse study by Webster et al. (70) showed that pregnant mice receiving phenytoin 
during the period of early facial development had cleft lip offspring because phenytoin 
causes bradycardia leading to a prolonged period of embryonic hypoxia. This study 
proposed additional exposures increase the risk of cleft lip in humans including maternal 
cigarette smoking, residence at high altitudes, and exposure to corticosteroids.  High 
leptin circulation decreases folic acid transportation (68), which may relate to not only 
GDM pregnancies, but also pregnancies exposed to prolonged hypoxia. The association 
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between increased leptin resulting from hypoxia and risk of birth defect requires further 
study.   
Our results suggest that gestational diabetes, maternal obesity, and metabolic 
syndrome are associated with an increased risk of OFCs. When compared with control 
mothers, mothers having cleft palate offspring had higher insulin, IL-8, and leptin levels. 
Therefore, insulin, IL-8, and leptin levels may be links between GDM, metabolic 
syndrome, and OFCs. Insulin, IL-8 and leptin might be performed as biomarkers for 
predicting OFC occurrence. Mechanistic studies are needed to understand the causal 
effects of maternal obesity, metabolic abnormalities, and gestational diabetes mellitus on 
OFCs risk. The potential of using insulin, leptin, IL-8 and related biomarkers as 
predictors of birth defect risk requires further study. 
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Table 4.2 Tracking status of orofacial cleft (OFC) cases and controls in the Utah Cleft 2 
Study. 
Status Controls 
n (%) 
OFC cases 
n (%) 
Completed interview, clinical visit, and 
blood collection 
344 (38.0) 268 (31.3) 
Completed interview, clinical visit, and no 
blood collection  
4 (0.4) 2 (0.2) 
Completed only interview, no clinical 
visit, and no blood collection 
74 (8.2) 83 (9.7) 
Completed clinical visit and blood 
collection, and no interview 
5 (0.6) 3 (0.4) 
Completed only blood collection 8 (0.9) 3 (0.4) 
Refuse 116 (12.8) 51 (6.0) 
Move out of state 135 (14.9) 70 (8.2) 
Out of clinic area 25 (2.8) 15 (1.8) 
Unable to contact or schedule 189 (20.9) 352 (41.1) 
Non-isolated OFCs 0 (0) 1 (0.1) 
Spanish speaking 5 (0.6) 8 (0.9) 
Deceased 0 (0) 1 (0.1) 
OFC: Orofacial cleft 
 
 
 
 
 
 
 
 
 
3
1
4
 
Table 4.3 Demographic characteristics of isolated orofacial cleft case and controls: The Utah Cleft 2 Study 
Characteristic Controls Orofacial cleft cases 
 All OFCs CLO CL/P CLP CPO CP/L 
 
Maternal age at birth 
of index child (SD) 
  p-value1 
n= 436 
27.8(5.3) 
n=358 
27.5(5.3) 
 
0.44 
n=112 
27.4(5.0) 
 
0.40 
n=268 
27.5(5.2) 
 
0.46 
n=156 
27.6(5.2) 
 
0.24 
n=90 
27.54(5.70) 
 
0.27 
n=246 
27.6(5.4) 
 
0.56 
 
Maternal age at blood 
collection (SD) 
  p-value1 
n=360 
37.7(7.0) 
n=274 
37.4(6.5) 
 
0.62 
n=90 
36.9(6.3) 
 
0.33 
n=211 
37.4(6.6) 
 
0.56 
n=121 
37.7(6.9) 
 
0.98 
n=63 
37.7(6.2) 
 
0.97 
n=184 
37.7(6.6) 
 
0.97 
 
Number of past 
pregnancies (%) 
  p-value1 
n=423 
4.5(2.21) 
n=349 
4.2(1.98) 
 
0.04 
n=109 
4.2 (1.9) 
 
0.27 
n=261 
4.3(2.0) 
 
0.18 
n=152 
4.3(2.1) 
 
0.34 
n=88 
3.9(1.9) 
 
0.01 
n=240 
4.2(2.0) 
 
0.05 
 
Number of live birth 
(%) 
  p-value1 
n=423 
4.1(6.7) 
n=349 
4.0(7.4) 
 
0.77 
n=109 
3.5(1.5) 
 
0.36 
n=261 
3.8(6.1) 
 
0.59 
n=152 
4.1(7.9) 
 
0.94 
n=88 
4.4(10.4) 
 
0.79 
n=240 
4.2(8.9) 
 
0.93 
 
Current weight (lb) 
  p-value1 
n=351 
163.8(40.5) 
n=269 
168.3(43.9) 
0.18 
n=89 
170.4(44.6) 
0.17 
n=208 
168.4(44.2) 
0.20 
n=119 
166.9(44.1) 
0.47 
n=61 
167.9(43.4) 
0.47 
n=180 
167.2(43.7) 
0.36 
 
Current height (cm) 
  p-value1 
n=351 
164.6(8.5) 
n=268 
164.4(7.6) 
0.75 
n=89 
164.6(8.0) 
0.98 
n=207 
164.6(8.0) 
0.96 
n=118 
164.6(8.0) 
0.96 
n=61 
163.9(6.4) 
0.49 
n=179 
164.3(7.50) 
0.69 
 
Current BMI (kg/m2) 
  p-value1 
n=351 
27.67.5 
 
n = 267 
28.37.5 
0.26 
n = 89 
28.57.0 
0.29 
n = 207 
28.37.3 
0.30 
n = 118 
28.17.6 
0.55 
n = 60 
28.36.9 
0.52 
n = 178 
28.17.4 
0.43 
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Table 4.3 Demographic characteristics of isolated orofacial cleft case and controls: The Utah Cleft 2 Study (Cont.) 
Characteristic Control Orofacial cleft cases 
 All OFCs CLO CL/P CLP CPO CP/L 
Type 1 diabetes 
mellitus 
  p-value2 
n=422 
3 (0.7) 
n=349 
2 (0.6) 
1.00 
n=109 
0 (0) 
1.00 
n=261 
0 (0) 
0.29 
n=152 
0 (0) 
0.57 
n=88 
2 (2.3) 
0.21 
n=240 
2 (0.8) 
1.00 
 
Type 2 diabetes 
mellitus 
  p-value2 
n=422 
5 (1.2) 
n=348 
7 (2.0) 
 
0.39 
n=109 
1 (0.9) 
 
1.00 
n=260 
6 (2.3) 
 
0.35 
n=151 
5 (3.3) 
 
0.14 
n=88 
1 (1.1) 
 
1.00 
n=239 
6 (2.5) 
 
0.22 
 
Gestational diabetes 
mellitus 
  p-value2 
n=422 
14 (3.3) 
n=348 
33 (9.5) 
 
<0.001 
n=109 
10 (9.2) 
 
0.02 
n=260 
24 (9.2) 
 
0.002 
n=151 
14 (9.3) 
 
0.007 
n=88 
9 (10.2) 
 
0.009 
n=239 
23 (9.6) 
 
0.001 
 
Maternal smoking in 
past 3 months (%) 
  p-value2 
n=423 
19 (4.5) 
n=349 
39 (11.2) 
 
0.001 
n=109 
10 (9.2) 
 
0.06 
n=261 
26 (10) 
 
0.007 
n=152 
16 (10.5) 
 
0.02 
n=88 
13 (14.9) 
 
0.001 
n=240 
29 (12.1) 
 
<0.001 
 
Second hand smoking 
(%) 
  p-value2 
n=420 
17 (4.0) 
n=347 
29 (8.4) 
 
0.01 
n=108 
7 (6.5) 
 
0.30 
n=259 
22 (8.5) 
 
0.02 
n=151 
15 (9.9) 
 
0.01 
n=88 
7 (8.0) 
 
0.16 
n=239 
22 (9.2) 
 
0.009 
 
Maternal alcohol 
consumption in past 3 
months (%) 
  p-value2 
n=422 
86 (20.4) 
 
 
 
n=349 
93 (26.7) 
 
 
0.04 
n=109 
28 (27.5) 
 
 
0.24 
n=261 
66 (25.3) 
 
 
0.13 
n=152 
38 (25.0) 
 
 
0.25 
n=88 
27 (31.0)  
 
 
0.05 
n=240 
65 (27.2) 
 
 
0.05 
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Table 4.3 Demographic characteristics of isolated orofacial cleft case and controls: The Utah Cleft 2 Study (Cont.) 
Characteristic Control Orofacial cleft cases 
 All OFCs CLO CL/P CLP CPO CP/L 
Frequency of alcohol 
consumption in past 3 
months (%) 
  Never 
   < 1 time/month  
  1-3 times/month 
  1-2 times/week 
  3-4 times/week 
  p-trend 
 
 
 
337 (79.7) 
30 (7.1) 
27 (6.4) 
21 (5.0) 
8 (1.9) 
 
 
 
256 (73.6) 
31 (8.9) 
36 (10.3) 
18 (5.2) 
7 (2.0) 
0.12 
 
 
 
61 (70.1) 
11 (12.6) 
7 (8.0) 
5 (5.7) 
3 (3.4) 
0.13 
 
 
 
195 (74.7) 
20 (7.7) 
29 (11.1) 
13 (5.0) 
4 (1.5) 
0.25 
 
 
 
114 (75.0) 
10 (6.6) 
20 (13.2) 
6 (3.9) 
2 (1.3) 
0.39 
 
 
 
81 (74.3) 
10 (9.2) 
9 (8.3) 
7 (6.4) 
2 (1.8) 
0.33 
 
 
 
175 (73.2) 
21 (8.8) 
27 (11.3) 
11 (4.6) 
5 (2.1) 
0.15 
OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CLP: cleft lip with cleft palate; CL/P: cleft lip with or without cleft 
palate; CP/L: cleft palate with or without cleft lip. 
1 p-value for independent t-test for OFC group compared to controls. 
2 p-value for chi-square for OFC group compared to controls.   
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Table 4.4 Odds ratio analysis of maternal diabetes history and risk of orofacial clefts 
Diabetes history Odds ratios (95 percent confidence intervals) 
All OFCs CLO CL/P CLP CPO CP/L 
Type 2 diabetes 
mellitus 
  No 
  Yes 
 
 
1 [reference] 
1.71 [0.54-5.44] 
 
 
1 [reference] 
0.77 [0.09-6.68] 
 
 
1 [reference] 
1.97 [0.60-6.52] 
 
 
1 [reference] 
2.86[0.82-10.01] 
 
 
1 [reference] 
0.96 [0.11-8.31] 
 
 
1 [reference] 
2.15 [0.65-7.11] 
Gestational 
diabetes mellitus 
  No 
  Yes 
 
 
1 [reference] 
3.05 [1.61-5.80] 
 
 
1 [reference] 
2.94 [1.27-6.82] 
 
 
1 [reference] 
2.96 [1.50-5.84] 
 
 
1 [reference] 
2.98 [1.39-6.40] 
 
 
1 [reference] 
3.32 [1.39-7.94] 
 
 
1 [reference] 
3.10 [1.57-6.15] 
OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CLP: cleft lip with cleft palate; CL/P: cleft lip with or without cleft 
palate; CP/L: cleft palate with or without cleft lip. 
History of GDM at any pregnancy 
History of type 2 diabetes at any time. 
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Table 4.5 Mean metabolic syndrome-related biomarkers by orofacial cleft case groups and controls: The Utah Cleft 2 Study 
Biomarker Control Orofacial cleft cases 
 All OFCs CLO CL/P CLP CPO CP/L 
 
Systolic BP (mmHg) 
  Unadjusted p-value 
  Adjusted p-value 
n = 353 
109.412.2 
 
n = 268 
110.512.0 
0.30 
0.71 
n = 89 
110.411. 7 
0.53 
0.58 
n = 208 
109.811.8 
0.74 
0.88 
n = 119 
109.411.9 
0.96 
0.48 
n = 60 
112.812.5 
0.05 
0.23 
n = 179 
110.512.2 
0.34 
0.96 
 
Diastolic BP (mmHg)    
  Unadjusted p-value 
  Adjusted p-value 
n = 353 
71.89.1 
 
n = 268 
72.510.4 
0.43 
0.88 
n = 89 
72.49.8 
0.59 
0.85 
n = 208 
72.110.5 
0.79 
0.64 
n = 119 
71.811.1 
0.98 
0.57 
n = 60 
73.89.8 
0.12 
0.16 
n = 179 
72.510.7 
0.49 
0.81 
 
Waist  (cm) 
  Unadjusted p-value 
  Adjusted p-value 
n = 352 
92.317.2 
 
n = 268 
94.418.0 
0.14 
0.06 
n = 89 
94.317.3 
0.32 
0.75 
n = 208 
93.917.9 
0.27 
0.16 
n = 119 
93.718.4 
0.44 
0.09 
n = 60 
95.818.6 
0.14 
0.07 
n = 179 
94.418.4 
0.19 
0.03 
 
Glucose (mg/dL) 
  Unadjusted p-value 
  Adjusted p-value 
329 
91.020.4 
 
n = 248 
93.425.7 
0.22 
0.07 
n = 82 
93.030.6 
0.49 
0.99 
n = 189 
93.026.0 
0.34 
0.13 
n = 107 
93.022.0 
0.39 
0.04 
n = 59 
94.624.6 
0.23 
0.21 
n = 166 
93.622.9 
0.21 
0.02 
 
Insulin (μlU/mL) 
  Unadjusted p-value 
  Adjusted p-value 
n = 316 
19.726.8 
 
n = 233 
21.624.4 
0.40 
0..01 
n = 78 
15.715.2 
0.21 
0.14 
n = 182 
20.421.6 
0.76 
0.68 
n = 104 
24.025.0 
0.16 
0.10 
n = 51 
25.832.3 
0.21 
0.14 
n = 155 
24.627.5 
0.07 
0.04 
 
HbA1c (%) 
  Unadjusted p-value 
  Adjusted p-value 
n = 324 
5.420.30 
 
n = 246 
5.440.53 
0.66 
0.58 
n = 83 
5.450.54 
0.49 
0.52 
n = 187 
5.430.45 
0.85 
0.54 
n = 104 
5.410.36 
0.74 
0.69 
n = 59 
5.470.73 
0.41 
0.88 
n = 163 
5.430.52 
0.81 
0.71 
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Table 4.5 Mean metabolic syndrome-related biomarkers by orofacial cleft case groups and controls: The Utah Cleft 2 Study (Cont.) 
Biomarker Control Orofacial cleft cases 
 All OFCs CLO CL/P CLP CPO CP/L 
 
Cholesterol (mg/dL) 
  Unadjusted p-value 
  Adjusted p-value 
n = 328 
177.533.6 
 
n = 247 
176.336.6 
0.70 
0.48 
n = 82 
173.232.2 
0.30 
0.66 
n = 188 
173.834.6 
0.23 
0.27 
n = 106 
174.236.6 
0.40 
0.22 
n = 59 
184.441.4 
0.16 
0.56 
n = 165 
177.838.6 
0.91 
0.51 
 
Triglyceride (mg/dL) 
  Unadjusted p-value 
  Adjusted p-value 
n = 329 
110.369.5 
 
n = 247 
118.281.3 
0.21 
0.03 
n = 82 
107.854.6 
0.76 
0.57 
n = 188 
113.472.5 
0.63 
0.19 
n = 106 
117.783.7 
0.37 
0.19 
n = 59 
133.4103.8 
0.10 
0.01 
n = 165 
123.391.4 
0.11 
0.02 
 
HDL (mg/dL) 
  Unadjusted p-value 
  Adjusted p-value 
329 
55.514.4 
 
n = 247 
54.214.3 
0.28 
0.02 
n = 82 
54.113.7 
0.40 
0.40 
n = 188 
54.113.9 
0.27 
0.06 
n = 106 
54.114.0 
0.38 
0.05 
n = 59 
54.615.9 
0.66 
0.08 
n = 165 
54.314.7 
0.37 
0.02 
 
LDL (mg/dL) 
  Unadjusted p-value 
  Adjusted p-value 
n = 328 
99.928.0 
 
n = 244 
98.631.3 
0.59 
0.64 
n = 82 
97.627.9 
0.50 
0.99 
n = 187 
97.030.6 
0.27 
0.45 
n = 105 
96.632.7 
0.31 
0.28 
n = 57 
103.833.10 
0.35 
0.63 
n = 162 
99.132.9 
0.78 
0.53 
 
VLDL (mg/dL) 
  Unadjusted p-value 
  Adjusted p-value 
n = 328 
21.813.2 
 
n = 244 
22.713.6 
0.44 
0.99 
n = 82 
21.611.0 
0.88 
0.61 
n = 187 
22.313.3 
0.70 
0.93 
n = 105 
22.815.0 
0.50 
0.79 
n = 57 
24.014.4 
0.26 
0.91 
n = 162 
23.214.7 
0.28 
0.79 
 
LDL/HDL ratio 
  Unadjusted p-value 
  Adjusted p-value 
n = 328 
1.920.75 
 
n = 244 
1.950.86 
0.60 
0.88 
n = 82 
1.920.72 
0.99 
0.81 
n = 187 
1.930.84 
0.91 
0.84 
n = 105 
1.930.93 
0.88 
0.91 
n = 57 
2.050.91 
0.26 
0.40 
n = 162 
1.970.92 
0.52 
0.78 
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Table 4.5 Mean metabolic syndrome-related biomarkers by orofacial cleft case groups and controls: The Utah Cleft 2 Study (Cont.). 
Biomarker Control Orofacial cleft cases 
 All OFCs CLO CL/P CLP CPO CP/L 
 
Alkaline 
phosphatase (IU/L) 
 Unadjusted p-value 
 Adjusted p-value 
n = 328 
64.318.7 
 
n = 247 
65.820.1 
 
0.36 
0.60 
n = 81 
64.418.9 
 
0.95 
0.72 
n = 188 
65.920.2 
 
0.35 
0.50 
n = 107 
67.121.1 
 
0.19 
0.21 
n = 59 
65.219.7 
 
0.73 
0.86 
n = 166 
66.420.6 
 
0.25 
0.37 
 
ALT (SGPT) (IU/L) 
 Unadjusted p-value 
 Adjusted p-value 
n = 328 
18.18.9 
 
n = 247 
19.210.4 
0.15 
0.18 
n = 81 
19.510.4 
0.20 
0.30 
n = 188 
19.611.2 
0.09 
0.11 
n = 107 
19.611.8 
0.15 
0.14 
n = 59 
18.17.1 
1.00 
0.96 
n = 166 
19.110.4 
0.26 
0.25 
 
AST (SGOT)(IU/L) 
Unadjusted p-value 
Adjusted p-value 
n = 328 
18.15.1 
 
n = 247 
19.413.2 
0.14 
0.08 
n = 81 
20.316.6 
0.25 
0.05 
n = 188 
19.914.8 
0.11 
0.05 
n = 107 
19.613.4 
0.26 
0.08 
n = 59 
17.95.8 
0.74 
0.94 
n = 166 
19.011.3 
0.34 
0.15 
OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CLP: cleft lip with cleft palate; CL/P: cleft lip with or without cleft 
palate; CP/L: cleft palate with or without cleft lip. 
BP: blood pressure, WC: waist circumference, HbA1c: Hemoglobin A1c, HDL: high-density lipoprotein cholesterol, LDL: Low-
density lipoprotein, VLDL: Very low-density lipoprotein ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase. 
NCEP/ATP III: National Cholesterol Education Program, Adult Treatment Panel III  
IDF: International Diabetes Federation 
Unadjusted p-value for independent sample t-test 
Adjusted p-value form analysis of covariance model including maternal age and smoking (Model) 
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Table 4.6 Cytokine and adipokine levels of orofacial cleft cases and controls: The Utah Cleft 2 Study  
 Control 
(n = 241) 
Orofacial cleft cases 
All OFCs  
(n = 182) 
CLO 
(n = 60) 
CL/P 
(n = 138) 
CLP 
(n = 78) 
CPO  
(n = 44) 
CP/L 
(n = 122) 
Adiponectin 
(ng/ml)  
  %Undetected 
  Median1IQR 
  Mean2SD 
  p-valuea 
  p-valueb 
 
 
0 
89217379 
10937560 
 
 
0 
76898220 
10413644 
0.54 
0.70 
 
 
0 
736010204 
107921185 
0.91 
0.82 
 
 
0 
78938412 
10489749 
0.63 
0.79 
 
 
0 
85228223 
10256971 
0.54 
0.61 
 
 
0 
72308120 
101731327 
0.60 
0.81 
 
 
0 
82738083 
10226767 
0.45 
0.57 
CRP (ng/ml) 
  %Undetected 
  Median1IQR 
   
  Mean2SD 
   
  p-valuea 
  p-valueb 
 
1.2 
23324 
123764 
159345 
384310 
 
 
0 
33834 
115461 
152771 
427596 
0.59 
0.67 
 
0 
26365 
58834 
79971.1 
155579.0 
0.47 
0.41 
 
0 
30200 
73054 
147468 
469983 
0.88 
0.84 
 
0 
35225 
121045 
199388 
606773 
0.70 
0.72 
 
0 
50447 
241589 
169406 
255936 
0.11 
0.15 
 
0 
38130 
146133 
188575 
507720 
0.25 
0.29 
IL-1a (pg/ml) 
  %Undetected 
  Median1IQR 
  Mean2SD 
  p-valuea 
  p-valueb 
 
21.2 
3.514.50 
3.692.80 
 
 
17.6 
3.704.34 
3.852.63 
0.99 
0.94 
 
15.0 
4.194.14 
4.252.79 
0.32 
0.52 
 
17.4 
3.724.40 
3.932.70 
0.71 
0.88 
 
19.2 
3.464.50 
3.692.63 
0.74 
0.73 
 
18.2 
3.283.25 
3.582.38 
0.47 
0.54 
 
18.9 
3.354.27 
3.652.53 
0.52 
0.58 
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Table 4.6 Cytokine and adipokine levels of orofacial cleft cases and controls: The Utah Cleft 2 Study (Cont.) 
 
 Control 
(n = 241) 
Orofacial cleft cases 
All OFCs  
(n = 182) 
CLO 
(n = 60) 
CL/P 
(n = 138) 
CLP 
(n = 78) 
CPO  
(n = 44) 
CP/L 
(n = 122) 
IL-6 (pg/ml) 
  %Undetected 
  Median1IQR 
  Mean2SD 
  p-valuea 
  p-valueb 
 
11.6 
3.823.15 
3.873.22 
 
 
12.6 
4.023.55 
3.892.55 
0.93 
0.91 
 
11.7 
4.384.00 
4.272.94 
0.53 
0.54 
 
13.0 
4.363.56 
4.042.61 
0.35 
0.34 
 
14.1 
4.253.20 
3.862.32 
0.40 
0.38 
 
11.4 
3.103.49 
3.422.32 
0.10 
0.11 
 
13.1 
3.583.38 
3.702.32 
0.76 
0.83 
IL-8 (pg/ml) 
  %Undetected 
  Median1IQR 
  Mean2SD 
  p-valuea 
  p-valueb 
 
34.9 
2.851.59 
3.181.21 
 
 
33.5 
3.051.78 
3.451.88 
0.03 
0.02 
 
35.0 
2.691.53 
3.191.33 
0.88 
0.47 
 
37.7 
2.711.61 
3.221.35 
0.40 
0.60 
 
39.7 
2.831.72 
3.241.38 
0.16 
0.16 
 
20.5 
3.322.21 
4.162.89 
<0.001 
0.001 
 
32.8 
3.121.93 
3.572.09 
0.003 
0.003 
Leptin (ng/ml) 
  %Undetected 
  Median1IQR 
  Mean2SD 
  p-valuea 
  p-valueb 
 
0.8 
8.7915.36 
18.4023.16 
 
 
0 
10.1433.50 
26.8739.83 
0.04 
0.06 
 
0 
8.9923.68 
20.1426.67 
0.83 
0.71 
 
0 
9.6331.21 
26.4742.91 
0.13 
0.26 
 
0 
10.7834.68 
31.3451.73 
0.03 
0.05 
 
0 
11.0637.48 
28.1328.44 
0.01 
0.01 
 
0 
10.8735.14 
30.1844.64 
0.004 
0.006 
Resistin (ng/ml) 
  %Undetected 
  Median1IQR 
  Mean2SD 
  p-valuea 
  p-valueb 
 
1.7 
29243284 
22351602 
 
 
1.1 
26863283 
21931740 
0.74 
0.92 
 
3.3 
26863298 
23691947 
0.46 
0.45 
 
1.4 
26713239 
21321771 
0.54 
0.61 
 
0 
25163150 
19491611 
0.12 
0.16 
 
0 
28173368 
23861643 
0.66 
0.47 
 
0 
26893274 
21071630 
0.35 
0.50 
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Table 4.6 Cytokine and adipokine levels of orofacial cleft cases and controls: The Utah Cleft 2 Study (Cont.) 
 Control 
(n = 241) 
Orofacial cleft cases 
All OFCs  
(n = 182) 
CLO 
(n = 60) 
CL/P 
(n = 138) 
CLP 
(n = 78) 
CPO  
(n = 44) 
CP/L 
(n = 122) 
TNF-α (pg/ml) 
  %Undetected 
  Median1IQR 
  Mean2SD 
  p-valuea 
  p-valueb 
 
7.1 
12.077.61 
12.7611.09 
 
 
7.1 
12.528.36 
13.097.43 
0.50 
0.46 
 
5.0 
13.086.06 
14.128.05 
0.27 
0.31 
 
5.8 
12.687.99 
13.417.55 
0.43 
0.41 
 
6.4 
12.326.36 
12.877.14 
0.83 
0.75 
 
11.4 
12.079.38 
12.077.04 
0.98 
0.96 
 
8.2 
12.327.81 
12.587.09 
0.86 
0.74 
OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CLP: cleft lip with cleft palate; CL/P: cleft lip with or without cleft 
palate; CP/L: cleft palate with or without cleft lip. 
CRP: C-reactive protein, IL-1a: Interleukin-1 alpha, IL-6: Interleukin-6, IL-8: Interleukin-8, TNF-α: Tumor necrosis factor alpha 
1 median and interquartile range (IQR) from all samples 
2 mean and standard deviation (SD)  
aUnadjusted p-value for test difference to control among detected group (two-way ANOVA) 
bAdjusted p-value for test difference to control among detected group with analysis of covariance model including maternal age and 
smoking (two-way ANOVA).  
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Table 4.7 Odds ratio analysis of body mass index and biomarkers related to metabolic syndrome and risk of orofacial clefts: The Utah 
Cleft 2 Study 
 Odds ratios (95 percent confidence intervals) 
 All OFCs CLO CL/P CLP CPO CP/L 
BMI (kg/m2) 
  Underweight 
  Normal 
  Overweight 
  Obese 
 
0.77 [0.22-2.61] 
Reference 
1.09 [0.72-1.63] 
1.45 [0.99-2.13] 
p-trend 0.06 
 
0.63 [0.08-5.18] 
Reference 
0.86 [0.45-1.66] 
2.01 [1.17-3.45] 
p-trend 0.012 
 
1.03 [0.30-3.52] 
Reference 
1.13 [0.73-1.75] 
1.53 [1.01-2.31] 
p-trend 0.048 
 
1.31 [0.33-5.15] 
Reference 
1.31 [0.78-2.20] 
1.19 [0.71-2.00] 
p-trend 0.47 
 
N/A 
Reference 
0.97 [0.49-1.93] 
1.24 [0.65-2.35] 
p-trend 0.54 
 
0.83 [0.21-3.22] 
Reference 
1.19 [0.76-1.86] 
1.21 [0.78-1.87] 
p-trend 0.39 
Glucose (mg/dl) 
  ≤ 84 
  85-93 
  ≥ 94 
 
1 (reference) 
1.13 (0.76-1.69) 
1.16 (0.78-1.75) 
p-trend 0.46 
 
1 (reference) 
0.92 (0.52-1.64) 
0.85 (0.47-1.54) 
p-trend 0.59 
 
1 (reference) 
1.18 (0.77-1.82) 
1.20 (0.77-1.86) 
p-trend 0.42 
 
1 (reference) 
1.47 (0.85-2.54) 
1.58 (0.92-2.74) 
p-trend 0.10 
 
1 (reference) 
0.99 (0.50-1.94) 
1.07 (0.54-2.09) 
p-trend 0.86 
 
1 (reference) 
1.27 (0.80-2.00) 
1.37 (0.86-2.17) 
p-trend 0.19 
HbA1c (%) 
  ≤ 5.30 
  > 5.30 - 5.50 
  > 5.50 
 
1 (reference) 
0.73 (0.49-1.08) 
0.87 (0.58-1.32) 
p-trend 0.41 
 
1 (reference) 
0.86 (0.49-1.52) 
0.96 (0.53-1.76) 
p-trend 0.85 
 
1 (reference) 
0.73 (0.47-1.12) 
1.04 (0.67-1.61) 
p-trend 0.98 
 
1 (reference) 
0.63 (0.36-1.08) 
1.09 (0.64-1.85) 
p-trend 0.90 
 
1 (reference) 
0.73 (0.39-1.35) 
0.45 (0.20-0.99) 
p-trend 0.04 
 
1 (reference) 
0.67 (0.43-1.04) 
0.83 (0.52-1.33) 
p-trend 0.33 
Insulin 
(μlU/mL) 
  ≤ 7.80 
  >7.80 -18.10 
  > 18.10 
 
 
1 (reference) 
1.07 (0.70-1.61) 
1.25 (0.83-1.90) 
p-trend 0.29 
 
 
1 (reference) 
0.91 (0.50-1.64) 
0.87 (0.47-1.61) 
p-trend 0.66 
 
 
1 (reference) 
1.06 (0.68-1.67) 
1.26 (0.80-1.97) 
p-trend 0.32 
 
 
1 (reference) 
1.23 (0.70-2.16) 
1.65 (0.95-2.86) 
p-trend 0.07 
 
 
1 (reference) 
1.07 (0.52-2.23) 
1.24 (0.60-2.56) 
p-trend 0.56 
 
 
1 (reference) 
1.17 (0.72-1.90) 
1.50 (0.93-2.41) 
p-trend 0.09 
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Table 4.7 Table 4.7 Odds ratio analysis of body mass index and biomarkers related to metabolic syndrome and risk of orofacial clefts: 
The Utah Cleft 2 Study (Cont.) 
 
 Odds ratios (95 percent confidence intervals) 
 All OFCs CLO CL/P CLP CPO CP/L 
Cholesterol 
(mg/dL) 
  ≤ 161 
  162-188 
  ≥189 
 
 
1 (reference) 
1.04 (0.70-1.56) 
1.09 (0.73-1.63) 
p-trend 0.67 
 
 
1 (reference) 
1.06 (0.59-1.88) 
0.88 (0.48-1.61) 
p-trend 0.69 
 
 
1 (reference) 
0.99 (0.64-1.53) 
0.92 (0.59-1.43) 
p-trend 0.72 
 
 
1 (reference) 
0.94 (0.56-1.61) 
0.95 (0.56-1.62) 
p-trend 0.86 
 
 
1 (reference) 
1.27 (0.61-2.64) 
1.85 (0.93-3.68) 
p-trend 0.07 
 
 
1 (reference) 
1.04 (0.65-1.65) 
1.21 (0.77-1.90) 
p-trend 0.42 
Triglyceride 
(mg/dL) 
  ≤ 70 
  71-120 
  ≥ 121 
 
1 (reference) 
1.07 (0.71-1.60) 
1.20 (0.80-1.79) 
p-trend 0.38 
 
1 (reference) 
1.13 (0.63-2.05) 
1.11 (0.62-2.02) 
p-trend 0.72 
 
1 (reference) 
0.95 (0.61-1.47) 
1.05 (0.68-1.62) 
p-trend 0.84 
 
1 (reference) 
0.82 (0.48-1.41) 
1.00 (0.60-1.69) 
p-trend 0.99 
 
1 (reference) 
1.64 (0.79-3.39) 
1.91 (0.94-3.89) 
p-trend 0.08 
 
1 (reference) 
1.03 (0.65-1.64) 
1.24 (0.79-1.95) 
p-trend 0.36 
HDL (mg/dL) 
  ≤ 48 
  49-61 
  ≥ 62 
 
1 (reference) 
0.79 (0.53-1.18) 
0.72 (0.48-1.08) 
p-trend 0.11 
 
1 (reference) 
0.71 (0.36-1.41) 
0.80 (0.41-1.55) 
p-trend 0.49 
 
1 (reference) 
0.82 (0.53-1.26) 
0.70 (0.45-1.09) 
p-trend 0.11 
 
1 (reference) 
0.72 (0.42-1.22) 
0.70 (0.41-1.18) 
p-trend 0.17 
 
1 (reference) 
0.96 (0.54-1.71) 
0.71 (0.38-1.30) 
p-trend 0.27 
 
1 (reference) 
0.72 (0.45-1.13) 
0.73 (0.46-1.15) 
p-trend 0.16 
LDL (mg/dL) 
  ≤ 86 
  87-109 
  ≥ 110 
 
1 (reference) 
0.88 (0.59-1.32) 
0.84 (0.56-1.27) 
p-trend 0.41 
 
1 (reference) 
1.05 (0.59-1.86) 
0.79 (0.43-1.46) 
p-trend 0.46 
 
1 (reference) 
0.84 (0.55-1.29) 
0.72 (0.46-1.12) 
p-trend 0.15 
 
1 (reference) 
0.70 (0.42-1.20) 
0.67 (0.39-1.15) 
p-trend 0.14 
 
1 (reference) 
1.07 (0.52-2.20) 
1.39 (0.69-2.77) 
p-trend 0.34 
 
1 (reference) 
0.80 (0.51-1.27) 
0.87 (0.55-1.37) 
p-trend 0.53 
  
326 
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Table 4.7 Odds ratio analysis of body mass index and biomarkers related to metabolic syndrome and risk of orofacial clefts: The Utah 
Cleft 2 Study (Cont.) 
 Odds ratios (95 percent confidence intervals) 
 All OFCs CLO CL/P CLP CPO CP/L 
VLDL (mg/dL) 
  ≤ 14 
  15-24 
  ≥ 25 
 
1 (reference) 
1.10 (0.74-1.65) 
1.19 (0.79-1.78) 
p-trend 0.41 
 
1 (reference) 
1.22 (0.67-2.19) 
1.23 (0.68-2.23) 
p-trend 0.49 
 
1 (reference) 
0.94 (0.61-1.45) 
1.07 (0.70-1.65) 
p-trend 0.77 
 
1 (reference) 
0.76 (0.44-1.31) 
0.97 (0.58-1.64) 
p-trend 0.87 
 
1 (reference) 
1.92 (0.94-3.93) 
1.76 (0.85-3.65) 
p-trend 0.14 
 
1 (reference) 
1.05 (0.66-1.66) 
1.17 (0.74-1.84) 
p-trend 0.52 
LDL/HDL ratio 
  ≤ 1.50 
  > 1.50-2.13 
  > 2.13 
 
1 (reference) 
0.78 (0.52-1.18) 
0.99 (0.66-1.48) 
p-trend 0.97 
 
1 (reference) 
0.97 (0.53-1.77) 
1.19 (0.66-2.16) 
p-trend 0.56 
 
1 (reference) 
0.75 (0.48-1.17) 
0.95 (0.61-1.46) 
p-trend 0.80 
 
1 (reference) 
0.62 (0.36-1.07) 
0.80 (0.47-1.36) 
p-trend 0.39 
 
1 (reference) 
0.90 (0.44-1.82) 
1.16 (0.58-2.29) 
p-trend 0.67 
 
1 (reference) 
0.70 (0.44-1.12) 
0.91 (0.58-1.43) 
p-trend 0.67 
OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CLP: cleft lip with cleft palate; CL/P: cleft lip with or without cleft 
palate; CP/L: cleft palate with or without cleft lip. 
BMI: body mass index, HbA1c: Hemoglobin A1c, HDL: high-density lipoprotein cholesterol, LDL: Low-density lipoprotein, VLDL: 
Very low-density lipoprotein, ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase.  
BMI: underweight, ≤ 18.5 kg/m2; normal, 18.5-24.9 kg/m2; overweight, 25.-29.9 kg/m2; obese, ≥ 30 kg/m2.  
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Table 4.8 Risk of orofacial clefts associated with NCEP/ATP III and IDF metabolic syndrome criteria and components. 
 Odds ratios (95 percent confidence intervals) 
 All OFCs CLO CL/P CLP CPO CP/L 
MET score 
(NCEP/ATP 
III) 
  < 3 
  ≥ 3 
 
 
 
1 [reference] 
1.42 [0.92-2.17] 
 
 
 
1 [reference] 
1.06 [0.54-2.05] 
 
 
 
1 [reference] 
1.31 [0.82-2.09] 
 
 
 
1 [reference] 
1.51[0.88-2.60] 
 
 
 
1 [reference] 
1.78 [0.91-3.49] 
 
 
 
1 [reference] 
1.60 [1.00-2.56] 
MET score (IDF) 
  WC < 80 cm 
  WC > 80 cm + 2 
more 
 
1 [reference] 
1.48 [0.98-2.24] 
 
1 [reference] 
1.16 [0.62-2.17] 
 
1 [reference] 
1.38 [0.89-2.18] 
 
1 [reference] 
1.58 [0.93-2.67] 
 
1 [reference] 
1.78 [0.92-3.42] 
 
1 [reference] 
1.64 [1.04-2.59] 
Systolic BP ≥ 130 or 
diastolic BP ≥ 85 
mmHg 
1.51 [0.91-2.53] 1.03 [0.46-2.32] 1.30 [0.73-2.29] 1.50 [0.78-2.89] 2.34 [1.10-4.96] 1.77 [1.02-3.09] 
WC > 88 cma 1.09 [0.79-1.50] 1.18 [0.74-1.89] 1.11 [0.79-1.57] 1.06 [0.70-1.61] 1.04 [0.58-1.75] 1.04 [0.73-1.50] 
WC > 80 cmb 1.13 [0.78-1.64] 1.03 [0.60-1.77] 1.16 [0.77-1.74] 1.27 [0.77-2.10] 1.04 [0.55-1.95] 1.18 [0.77-1.81] 
TG ≥ 150 mg/dL 1.05 [0.70-1.58] 0.77 [0.40-1.47] 1.00 [0.64-1.55] 1.18 [0.70-1.97] 1.24 [0.65-2.39] 1.20 [0.77-1.87] 
HDL < 50 mg/dL 1.22 [0.87-1.69] 1.16 [0.71-1.90] 1.21 [0.84-1.73] 1.25 [0.81-1.93] 1.23 [0.71-2.15] 1.24 [0.86-1.80] 
FPG > 110 mg/dLa 1.41 [0.70-2.84] 1.01 [0.33-3.10] 1.30 [0.60-2.81] 1.52 [0.63-3.67] 1.75 [0.62-4.98] 1.61 [0.75-3.42] 
FPG > 100 mg/dLb 1.20 [0.65-2.23] 0.87 [0.32-2.35] 1.13 [0.57-2.21] 1.32 [0.61-2.87] 1.46 [0.57-3.74] 1.37 [0.70-2.67] 
OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CLP: cleft lip with cleft palate; CL/P: cleft lip with or without cleft 
palate; CP/L: cleft palate with or without cleft lip. 
BP: blood pressure, WC: waist circumference, TG: triglyceride, HDL: high-density lipoprotein cholesterol, FPG: fasting plasma 
glucose 
a National Cholesterol Education Program, Adult Treatment Panel III  
bInternational Diabetes Federation 
MET: metabolic syndrome 
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NCEP/ATP III: National Cholesterol Education Program, Adult Treatment Panel III [raised waist circumference (≥ 102 cm in males, 
≥ 88 cm in females), raised blood pressure (systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg), raised 
triglyceride (≥ 150 mg/dL), reduced HDL cholesterol (<40 mg/dL in males, <50 mg/dL in females), raised fasting plasma glucose 
(fasting plasma glucose ≥ 110 mg/dL or previous diagnosed type 2 diabetes)] 
IDF: International Diabetes Federation [raised waist circumference (≥ 94 cm in males, ≥ 80 cm in females), raised blood pressure 
(systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg), raised triglyceride (≥ 150 mg/dL), reduced HDL 
cholesterol (<40 mg/dL in males, <50 mg/dL in females), raised fasting plasma glucose (fasting plasma glucose ≥ 100 mg/dL or 
previous diagnosed type 2 diabetes)] 
WC: Waist circumference  
N/A: Not applicable 
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Table 4.9 Risk of orofacial clefts associated with cytokine and adipokine levels. 
Tertile Odds ratios (95 percent confidence intervals) 
 All OFCs CLO CL/P CLP CPO CP/L 
Adiponectin (mg/L) 
  ≤ 6199.51 
  > 6199.52-
10907.73 
  ≥ 10907.73 
 
1 (reference) 
0.73 (0.45-1.17) 
 
0.80 (0.50-1.27) 
p-trend 0.34 
 
1 (reference) 
0.79 (0.40-1.56) 
 
0.74 (0.37-1.48) 
p-trend 0.39 
 
1 (reference) 
0.73 (0.44-1.22) 
 
0.83 (0.50-1.38) 
p-trend 0.48 
 
1 (reference) 
0.68 (0.36-1.30) 
 
0.90 (0.49-1.66) 
p-trend 0.76 
 
1 (reference) 
0.72 (0.33-1.55) 
 
0.69 (0.31-1.52) 
p-trend 0.35 
 
1 (reference) 
0.70 (0.41-1.19) 
 
0.82 (0.49-1.39) 
p-trend 0.47 
CRP (mg/L) 
  ≤ 14061.55 
  > 14061.55-
71263.16 
  > 71263.16 
 
1 (reference) 
1.28 (0.80-2.05) 
 
1.17 (0.73-1.88) 
p-trend 0.51 
 
1 (reference) 
1.31 (0.68-2.54) 
 
0.72 (0.34-1.51) 
p-trend 0.43 
 
1 (reference) 
1.28 (0.77-2.11) 
 
0.98 (0.58-1.65) 
p-trend 0.96 
 
1 (reference) 
1.24 (0.66-2.33) 
 
1.21 (0.65-2.27) 
p-trend 0.55 
 
1 (reference) 
1.31 (0.55-3.08) 
 
1.96 (0.88-4.34) 
p-trend 0.09 
 
1 (reference) 
1.26 (0.73-2.18) 
 
1.45 (0.85-2.47) 
p-trend 0.18 
IL-1a (pg/ml) 
  ≤ 2.08 
  > 2.08-4.96 
  > 4.96 
 
1 (reference) 
1.12 (0.70-1.79) 
1.17 (0.73-1.87) 
p-trend 0.52 
 
1 (reference) 
1.26 (0.61-2.63) 
1.68 (0.84-3.39) 
p-trend 0.14 
 
1 (reference) 
1.02 (0.60-1.71) 
1.27 (0.77-2.11) 
p-trend 0.35 
 
1 (reference) 
0.87 (0.47-1.64) 
1.04 (0.56-1.92) 
p-trend 0.91 
 
1 (reference) 
1.44 (0.68-3.07) 
0.85 (0.36-1.98) 
P-trend 0.75 
 
1 (reference) 
1.06 (0.63-1.80) 
0.97 (0.57-1.67) 
p-trend 0.93 
IL-6 (pg/ml) 
  ≤ 2.78 
  > 2.78-5.01 
  > 5.01 
 
1 (reference) 
0.72 (0.45-1.16) 
1.00 (0.63-1.60) 
p-trend 1.00 
 
1 (reference) 
0.77 (0.38-1.56) 
1.10 (0.56-2.18) 
p-trend 0.77 
 
1 (reference) 
0.74 (0.44-1.25) 
1.13 (0.68-1.88) 
p-trend 0.62 
 
1 (reference) 
0.72 (0.38-1.38) 
1.15 (0.62-2.13) 
p-trend 0.63 
 
1 (reference) 
0.66 (0.31-1.42) 
0.67 (0.30-1.48) 
p-trend 0.30 
 
1 (reference) 
0.70 (0.41-1.20) 
0.96 (0.56-1.62) 
p-trend 0.86 
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Table 4.9 Risk of orofacial clefts associated with cytokine and adipokine levels (Cont.). 
Tertile Odds ratios (95 percent confidence intervals) 
 All OFCs CLO CL/P CLP CPO CP/L 
IL-8 (pg/ml) 
  ≤ 2.20 
  > 2.20-3.53 
  > 3.53 
 
1 (reference) 
0.93 (0.58-1.49) 
1.21 (0.76-1.93) 
p-trend 0.43 
 
1 (reference) 
1.06 (0.54-2.07) 
0.92 (0.45-1.87) 
p-trend 0.83 
 
1 (reference) 
0.82 (0.49-1.36) 
0.96 (0.58-1.60) 
p-trend 0.85 
 
1 (reference) 
0.65 (0.35-1.24) 
0.99 (0.54-1.81) 
p-trend 0.93 
 
1 (reference) 
1.57 (0.65-3.84) 
2.65 (1.14-6.14) 
p-trend 0.018 
 
1 (reference) 
0.86 (0.50-1.49) 
1.36 (0.81-2.30) 
p-trend 0.24 
Leptin (ng/ml) 
  ≤ 5.95 
  > 5.95-15.44 
  > 15.44 
 
1 (reference) 
1.07 (0.67-1.73) 
1.73 (1.07-2.77) 
p-trend 0.02 
 
1 (reference) 
0.81 (0.41-1.61) 
1.07 (0.54-2.12) 
p-trend 0.89 
 
1 (reference) 
0.97 (0.57-1.62) 
1.56 (0.94-2.60) 
p-trend 0.09 
 
1 (reference) 
1.13 (0.59-2.20) 
2.10 (1.12-3.93) 
p-trend 0.02 
 
1 (reference) 
1.55 (0.66-3.65) 
2.46 (1.07-5.63) 
p-trend 0.03 
 
1 (reference) 
1.27 (0.73-2.22) 
2.21 (1.28-3.81) 
p-trend 0.004 
Resistin (ng/ml) 
  ≤ 481.22 
  >481.22- 3328.74 
  > 3328.74 
 
1 (reference) 
1.20 (0.75-1.92) 
1.00 (0.62-1.60) 
p-trend 1.00 
 
1 (reference) 
1.43 (0.71-2.90) 
1.24 (0.61-2.51) 
p-trend 0.58 
 
1 (reference) 
1.06 (0.64-1.77) 
0.92 (0.55-1.53) 
p-trend 0.74 
 
1 (reference) 
0.86 (0.46-1.59) 
0.74 (0.40-1.38) 
p-trend 0.34 
 
1 (reference) 
1.81 (0.80-4.08) 
1.36 (0.59-3.14) 
p-trend 0.50 
 
1 (reference) 
1.11 (0.65-1.88) 
0.91 (0.53-1.54) 
p-trend 0.72 
TNF-α (pg/ml) 
  ≤ 9.54 
  > 9.54-14.48 
  > 14.48 
 
1 (reference) 
0.82 (0.51-1.31) 
1.09 (0.68-1.74) 
p-trend 0.72 
 
1 (reference) 
0.92 (0.45-1.89) 
1.39 (0.70-2.76) 
p-trend 0.34 
 
1 (reference) 
0.92 (0.55-1.54) 
1.11 (0.66-1.85) 
p-trend 0.69 
 
1 (reference) 
0.92 (0.50-1.70) 
0.92 (0.49-1.74) 
p-trend 0.80 
 
1 (reference) 
0.54 (0.23-1.25) 
1.04 (0.50-2.18) 
p-trend 0.93 
 
1 (reference) 
0.77 (0.45-1.32) 
0.97 (0.57-1.64) 
p-trend 0.89 
OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CLP: cleft lip with cleft palate; CL/P: cleft lip with or without cleft 
palate; CP/L: cleft palate with or without cleft lip.  
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Figure 4.2 Medians of leptin levels divided by maternal body mass index 
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OFCs: orofacial clefts; CPO: cleft palate only; CLO: cleft lip only; CP/L: cleft palate with or without cleft lip. 
p-value for test difference to control among detected group with analysis of covariance model including maternal age and 
smoking (two-way ANOVA) 
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CHAPTER 5 
 
THE ASSOCIATION BETWEEN GENES RELATED TO GESTATIONAL 
 
 DIABETES MELLITUS AND THE RISK OF OROFACIAL CLEFTS  
 
 
5.1 Abstract 
 
Background: Gestational diabetes mellitus (GDM) has been associated with an 
increased risk of orofacial clefts (OFCs) and there is some evidence that GDM may be 
specifically related to palate development rather than lip. Genetic studies have identified 
many genes associated with non-syndromic OFCs, but none are clearly associated with 
GDM. 
Objective: to determine the association between genes related to GDM and the 
risk of OFCs. 
Methods: Genetic data from the GENEVA study of OFCs consisted of 892 cleft 
lip with or without cleft palate (CL/P) and 910 cleft palate with or without cleft lip 
(CP/L) trios of Asian ancestry and 665 CL/P and 644 CP/L trios of European ancestry. 
Twenty GDM-related genes were selected for analysis of association with OFCs. 
Genotypic transmission disequilibrium tests (gTDT) were used to analyze genetic effects 
and gene-environment (GxE) interactions with periconceptional maternal multivitamin 
use (PCMV), smoking, and environmental tobacco smoke (ETS). 
Results: SLC30A8 was associated with CL/P and HNF1B was associated with 
CP/L in Asian trios. In Europeans, ADRB3 and TNF-α were associated with both CL/P 
and CP/L; ABCC8 was associated with CL/P only and ADIPOQ and HNF1 were 
associated with CP/L only. Considering interactions with PCMV, associations were 
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found for ABCC8 and CDKAL1 in Europeans. Considering interactions with maternal 
smoking, associations were found for CDKN2A/2B in Asian and for LEP in Europeans. 
In Asians, FTO, HHEX, and PPARG had associations with OFCs when considering 
interaction with ETS.  
Conclusion: Several genes related to GDM were associated with risk of isolated 
CL/P and CP/L through genotypic effects alone and gene-environment interactions with 
PCMV, maternal smoking, and ETS. These associations do not point to a single major 
GDM gene associated with OFCs, but support the hypothesis that GDM may be causally 
related to OFCs via multiple GDM susceptibility genes and interactions with 
environmental factors.  
5.2 Introduction 
Orofacial clefts (OFCs) are among the most common congenital birth defects. 
Globally, approximately 1.43 in 1000 newborns suffer from OFCs (1). The prevalence of 
OFCs is different among varying ethnic and racial groups (2). National Birth Defects 
Prevention Network reported the prevalence of OFCs during 2002-2006 of CL/P was 
1.33 per 1000 live births, and 0.73 per 1000 live births for CP (3). The prevalence of 
OFCs in Utah is higher than the overall prevalence of the United States (2.25 per 1000 
births) (4).  
The etiology of orofacial clefts is not fully understood. The updated evidence 
suggests that there are the multiple factors for this defect including both genetic and 
environmental factors (5). Maternal diabetes mellitus, obesity, and underweight have 
been found as risk factors for OFCs (6-13). Pre-diabetes mellitus and GDM increased risk 
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of OFCs (6-8). Many case-control studies and a meta-analysis found that maternal 
obesity increased risk of OFCs. The previous study by Kutbi (11) reported the association 
between maternal obesity and risk of CL/P and CP/L. In addition, we found that GDM 
increased risk of cleft palate only (CPO) and CP/L in the previous chapter. 
OFCs are classified as either syndromic or non-syndromic. Syndromic OFCs are 
those occurring with other birth defects, while non-syndromic clefts have no other 
structural or functional anomalies. The prevalence of syndromic OFCs is around 25 
percent of all OFCs; around seventy-five percent of syndromic OFCs can be described by 
known genetic conditions including Van der Woude syndrome, Bamforth–Lazarus 
syndrome, Kabuki syndrome, Pierre Robin syndrome, and Treacher Collins syndrome 
(14). Genetic studies have identified genes related to syndromic OFCs and have provided 
clear associations between cleft phenotypes and the mutations of genes (15). Genetic 
studies have also found associations between non-syndromic orofacial clefts and genes 
related to growth factors, transcription factors, xenobiotic metabolism, immune response, 
and one-carbon metabolism (16). Genome-wide association studies (GWAS) have 
identified additional genes associated with non-syndromic orofacial clefts, but none to 
date are clearly associated with GDM (17-20).  
Several environmental factors, including PCMV, smoking, and ETS have been 
associated with OFCs. These same exposures have been associated with diabetes, 
therefore it is of interest to explore possible interaction between GDM-related genes and 
these environmental factors. 
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There has been no genetic association study focusing on GDM-related genes and 
OFC risk. Therefore, this study aims to determine the association between genes known 
to be related to GDM and risk of OFCs through genetic effects and gene-environment 
interactions.  
5.3 Subjects and Methods 
5.3.1 Study Design 
The study design is based on trios of children with an isolated orofacial cleft and 
their mothers and fathers using genome wide association (GWA) data available from the 
International Genetic Epidemiology study of Oral Clefts, a part of the Gene-Environment 
Association Studies Initiative (GENEVA) of the National Institutes of Health (NIH) (20). 
This study is a multi-center, international study of trios from Europe, the U.S., including 
Utah, China, Taiwan, Singapore, Korea, and the Philippines, which aims to investigate 
genes associated with oral clefts. Families were recruited from treatment centers or 
population-based registries. Research protocols for human study were reviewed and 
approved by institutional review boards of each participating institutions and parents 
provided informed consent. 
Principal Components Analysis (PCA) was used to document ancestral population 
affiliation. OFC cases were examined by either a clinical geneticist or an experienced 
clinician to minimize misclassification of the OFCs. All cases with cleft palate with or 
without cleft lip (CP/L) were analyzed together based on evidence that maternal obesity 
and diabetes have a specific effect on palate development (11). Trios having CL/P and 
CP/L were analyzed in this study separately.   
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5.3.2 Maternal exposure assessment 
Parents were asked about family history of oral clefts and other birth defects and 
maternal exposures during the periconceptional period (three months before conception 
through the first trimester) including smoking, alcohol consumption, environmental 
tobacco smoke exposure (ETS), and multivitamin use (PCMV).  
5.3.3 Gene selection and genotyping 
Gene selection was based on publications focusing on genes associated with 
GDM through March 2015. Eighty-three genes were found to have significant 
associations with GDM. In order to narrow the gene list, GDM candidate genes (Table 
5.1) were limited to those with statistically significant associations with GDM and either 
type 2 diabetes or obesity in at least three candidate gene studies or at least two GWA 
studies or at least one meta-analysis study. Genomic coordinates of selected genes were 
obtained from the major human genome assembly released by the Genome Reference 
Consortium, NCBI36/hg18, via the website of the National Center for Biotechnology 
Information (NCBI) (21).  Case and parent samples were collected as whole blood in 
EDTA tube for analyzing DNA. DNA samples were previously genotyped using the 
Illumina Human610 Quad v.1 B BeadChip at the Center for Inherited Disease Research 
(CIDR) and 99.1% passed quality control standards (20). Genotypes were not called if 
the quality score was more than 1 HapMap replicate error, more than 1 percent difference 
in call rate between genders, or more than 4% difference in heterozygote frequency.  
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5.3.4 Statistical analysis 
Statistical analyses were performed in the R program 3.1.2 TRIO package (22). 
Isolated CL/P and CP/L were analyzed separately. Individuals with more than 10 percent 
missing genotypes were excluded from the study. Four quality control (QC) criteria were 
used to flag and remove SNPs: 1) high rates of missing genotype calls (>10%), 2) low 
minor allele frequency (MAF <0.01), 3) high rates of Mendelian errors (> 5%) and 4) 
significant deviation from Hardy-Weinberg equilibrium (p >10-5). MAFs were calculated 
using parents only. SNPs within 100kb upstream and downstream of the selected genes 
were selected and used in this analysis in order include the promoter region (23, 24). 
Because this study included hypotheses for targeted GDM genes, based on strong 
evidence from previous studies, a gene-level approach to analysis was employed with 
Bonferroni adjustment of p-values based on the number of SNPs used in each individual 
gene region as employed in previous studies (25-28).  
The associations between genes related to GDM and risk of OFCs was examined 
by the genotypic transmission disequilibrium (gTDT) test developed by Schwender et al 
(29). Europeans and Asians were analyzed separately because of different allelic 
frequencies. All each SNP, one of the four possible pairs of parental alleles is known to 
be inherited by the case-child, and the other three untransmitted genotypes are used as 
pseudo-controls. The gTDT approach can be formulated as a conditional logistic 
regression model which can be written as: 
 
ln {P(ith case) / [(1-P(ith case))]}{ =  β0i + βGXi,  
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where Xi represents the corresponding risk genotypes under an additive, 
dominant, or recessive model. P(ith case) is the probability of being the observed case in 
the case and pseudo-controls set in the ith trio. The association between SNPs and OFCs 
was estimated with odds ratios as OR (OFCs) = exp (βG) with 95 percent confidence 
intervals (CIs) calculated from estimated standard errors of βG.  
The effects of gene-environment (GxE) interactions were examined using the 
conditional logistic regression model assuming an additive model of inheritance by the 
following model: 
 
 ln {P(ith case) / [(1-P(ith case))]} =  β0i + βGXi, + βEEi + βEG (XiEi)  
 
where Ei is environmental factor (exposed or unexposed). βEG represents the 
coefficient of GxE interaction. Both the gene and GxE interaction terms included in 
conditional logistic regression model provided an estimate of odds ratio (OR) under the 
additive model. The estimated OR of being a case with one copy of the risk allele in the 
unexposed mother was given by OR(OFCs|G no E) = exp (βG) and among the exposed 
mothers was OR(OFCs|G and E) = exp (βG+ βEG) for the odds ratio of being a case with 
one copy of the risk allele in the presence of maternal exposure. A one-degree of freedom 
(df) likelihood ratio test (LRT) was performed for studying the effect of GxE interaction 
alone (30) and 2 df LRT examined the inherited effect of genotype while accounting for 
effects of GxE interaction within the same model (31). 
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5.4 Results 
For Asians, 892 CL/P and 910 CP trios, and for Europeans, 665 CL/P and 644 
CP/L trios were analyzed (Table 5.2). European mothers had a higher rate of PCMV use 
than Asians (Tables 5.3 and 5.4) (CL/P: 54.0% vs 14.7%; CP/L: 54.5% vs 16.5). 
European trios with CL/P and CP/L had high missing rates of ETS (31.4 and 31.7%, 
respectively). Therefore, GxE interaction with ETS was analyzed only in Asian trios. 
Test of association considering genotypic effect alone in Asians and Europeans 
In Asian trios, SLC30A8 (rs924388) was associated with CL/P under the 
dominant model (OR: 1.42, 95% CIs: 1.16-1.74) (Table 5.5). The estimated OR of having 
a CP/L child carrying the minor allele at rs2158254 in HNF1B gene under the recessive 
model in Asians was 0.53 (95%CI: 0.37-0.75).   
In Europeans, ADRB3 (rs7812866) and TNF-α (rs28470596) were both 
associated with CL/P and CP/L (Table 5.6). Moreover, both rs2237991 and rs2074315 in 
ABCC8 showed significant association with CL/P under the dominant model (OR: 0.64, 
95%CI: 0.52-0.79; OR: 0.64, 95%CI: 0.52-0.79; respectively). The estimated odds ratios 
for Europeans for CP/L carrying the minor allele at rs17373877 in ADIPOQ and 
rs6607292 in HNF1B were 0.55 (95%CI: 0.39-0.78; additive model) and 0.50 (95%CI: 
0.35-0.73; recessive model), respectively. There were no significant associations between 
genes related to GDM and risk of CL/P and CP/L in analyses that combined Asians and 
Europeans. 
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Tests of association jointly considering genotypic effects and GxE interactions in 
Asians and Europeans: periconceptional maternal multivitamin (PCMV) as exposure. 
ABCC8 (rs4148622) and CDKAL1 (rs12201217) showed evidence of GxPCMV 
interaction in the 1 df LRT in European CL/P and CP/L, respectively (ABCC8: OR 
(CL/P│G no PCMV): 0.58, 95% CI: 0.42-0.81 and OR (CL/P│G and PCMV): 1.26, 95% 
CI: 1.01-1.58; CDKAL1: OR (CP/L│G no PCMV): 2.10, 95%CI: 1.45-3.03 and OR 
(CP/L│G and PCMV): 1.30, 95%CI: 1.04-1.61). After considering GxE interaction 
effects in the 2 df LRT, genotypic effects for FTO (rs836994) in Asian CL/P, ADIPOQ 
(rs7645316) in European CP/L, and  TNF-α (rs28470596) in European CL/P and CP/L 
became significant (OR (CL/P│G and PCMV): 1.23, 95%CI: 0.88-1.70;  (OR (CP/L│G 
and PCMV): 0.71, 95%CI: 0.57-0.89; OR (CL/P│G and PCMV): 0.49, 95% CI: 0.29-
0.82; OR (CP/L│G and PCMV): 0.28, 95%CI: 0.15-0.52; respectively). There was no 
gene that showed evidence of GxPCMV in Asian CP trios (Table 5.7). 
Test of association jointly considering genotypic effect and GxE interaction in Asians 
and Europeans: periconceptional maternal smoking (smoke) as exposure. 
CDKN2A/2B (rs1063192) and LEP (rs12538332) showed evidence of  gene-
environment interactions with maternal smoking in the 1 df LRT in Asian CL/P and 
European CL/P, respectively (CDKN2A/2B:  OR (CL/P│G no smoking): 1.16, 95%CI: 
0.98-1.37 and OR (CL/P│G and smoking): 0.15, 95%CI: 0.03-0.68; LEP: OR (CL/P│G 
no smoking): 0.83, 95%CI: 0.68-1.02 and OR (CL/P│G and smoking): 1.52, 95% CI: 
1.11-2.13). After considering GxE interaction effects in the 2 df LRT, genotypic effects 
for ABCC8 in European CL/P (rs2237991) and CP/L (rs4148617), and  TNF-α 
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(rs28470596) in European CL/P and CP/L became significant (OR (CL/P│G and 
Smoke): 0.56, 95%CI: 0.40-0.79, OR (CP/L│G and Smoke): 0.52, 95%CI: 0.38-0.73, 
OR (CL/P│G and smoke): 0.25, 95%CI: 0.12-0.52, and OR (CP/L│G and smoke): 0.29, 
95%CI: 0.15-0.60, respectively). There was no gene that showed evidence of GxPCMV 
in Asian CP/L trios (Table 5.8). 
Test of association jointly considering genotypic effect and GxE interaction in 
Asians: periconceptional maternal environmental tobacco smoke (ETS) as exposure. 
Four SNPs in FTO (rs3751812, rs8050136, rs9930333, and rs9941349) had 
protective minor allele associations with CL/P, but only in mothers not exposed to ETS 
(OR range: 0.59-0.60; Table 5.9). Similar protective associations were found for CP/L for 
FTO (rs3751812 and rs8050136). Increased risk for CL/P was found for ETS exposed 
only for five SNPs of HHEX (OR range 1.45-6.00) and found these were also associated 
with CP/L (OR range 8.50-16.0) though the 95% CI, while not including 1.0, were large. 
Three SNPs of PPARG were associated with increased risk of CL/P among ETS-exposed 
mothers (OR range 1.25-1.45).  
5.5 Discussion 
This study found several novel associations between GDM-related genes and 
OFCs and interaction with maternal environmental factors previously associated with 
OFCs. The study reported that HNF1B was associated with CP/L in both Asians and 
Europeans. SLC30A8 had an association with CL/P in Asian trios only. In Europeans, 
ADRB3 and TNF-α had associations with both CL/P and CP/L. Moreover, ABCC8 and 
ADIPOQ were associated with CL/P and CP/L, respectively, in Europeans. Five genes 
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were associated with OFCs when interaction with PCMV was considered -- FTO in 
Asians and ABCC8, ADIPOQ, CDKAL1, and TNF-α in Europeans. Interactions between 
genotype and maternal smoking were found for CDKN2A/2B in Asian CL/P, and in 
Europeans, ABCC8, LEP, and TNF-α were associated with CL/P. In Asian mothers 
exposed to environmental smoking, FTO and HHEX were associated with an increased 
risk of CL/P and CP/L, and PPARG was associated with an increased risk of CL/P.  
Linkage and association studies have reported over two dozen genes significantly 
associated with OFCs, but these differ across populations (32). While these studies have 
revealed the novel genes, it has been difficult to identify the etiologic mechanisms. A 
family-based study by Meeks et al.(33) focused on genes associated with one-carbon 
metabolism (OCM), and found that FUT6 (fucosyltransferase 6) and TCN2 
(transcobalamin 2) had an association with OFCs in Asian population.  
GxE interaction in OFCs have been conducted by many studies but not to date 
have focused on GDM-related genes. A case-parent trio study by Beaty et al (34) 
reported genes associated with cleft palate only (CPO) when maternal environmental 
exposures were considered including BAALC (brain and acute leukemia gene 
cytoplasmic) with maternal multivitamin use, ZNF236 (Zinc Finger Protein 236) and 
TBK1(tank-binding kinase 1) with maternal smoking, and MLLT3 (brain and acute 
leukemia gene cytoplasmic) and SMC2 (structural maintenance of chromosomes 2) with 
maternal alcohol exposure. Another study by Beaty et al. (25) reported GRID2 (glutamate 
Ionotropic Receptor Delta Type Subunit 2) and ELAVL2 (ELAV like RNA binding 
protein 2) had an association with CL/P when interaction with maternal smoking was 
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considered. A family-based study focusing on a Chinese population by Wu et al (35) 
showed interactions between IRF6 and both maternal multivitamin use and 
environmental tobacco smoke in CL/P risk. Another study by Wu et al (36) reported that 
SLC2A9 (solute carrier family 2 member 9) and WDR1 (WD repeat domain 1) gene 
increased risk of CP/L if mothers were exposed to environmental tobacco smoke. A 
family-based study by Wang et al (37) reported a novel gene (FGFR2: fibroblast growth 
factor receptor 2) was associated with CL/P when maternal multivitamin use and 
smoking were considered.  A study by Meeks (33) found that six genes related to one-
carbon metabolism had an association with OFCs if mothers used PCMV (DHFR 
(dihydrofolate reductase), MMAA (methylmalonic aciduria (cobalamin deficiency) cblA 
type), MTR (5-methyltetrahydrofolate-homocysteine methyltransferase), and TCN2 in 
European populations and CBS (cystathionine-beta-synthase) and MTHFD2L 
(methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like) gene in Asian 
populations).  
The association between maternal environmental exposures and risk of orofacial 
is inconsistent. Maternal use of multivitamin supplements in early pregnancy has been 
linked to decreased risk of OFCs; in a meta-analysis on overall 25% reduction in birth 
prevalence of OFCs with multivitamin use was reported (38). However, later data from 
the National Birth Defects Prevention Study (NBDPS) found no association between 
maternal use of supplement containing folic acid and risk of CL/P and CPO (39). 
Maternal smoking has been reported to increase the risk of both CL/P and cleft palate. An 
international population-based study, including Norway and the United States, reported 
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that mothers with active smoking increased risk of all types of isolated clefts (OR: 1.27, 
95% confidence interval (95% CI): 1.11-1.46 for all OFCs; OR: 1.28, 95% CI: 1.09-1.51 
for CL/P, OR: 1.25, 95% CI: 1.01-1.55 for CPO) (40). A study from Brazil by Leite et al. 
(41), however, presented no association between maternal smoking during the first 
trimester of gestation and OFCs. In addition, the effect of environmental tobacco smoke 
from passive exposure on the risk of OFCs still appears to be inconsistent. Case-control 
studies in China reported that passive smoke exposure of mothers increased the risk of 
OFCs (42, 43). However, a cohort study in the United States reported that environmental 
tobacco smoke exposure was not associated with CL/P and CPO (44). Inconsistent 
association between ETS and risk of OFCs might result from GxE interaction, which 
requires further study. The statistically significant gene-environment interactions may or 
may not correspond to biological interaction. Therefore, biological interaction requires 
further study to confirm the mechanisms involved. 
This study found that the presence of the minor allele at rs924388 in SLC30A80 
increased risk of CL/P in Asians by 42% under the dominant model. SLC30A8, a 
member of zinc transporter (ZNT) family, encodes the zinc transporter ZnT8. ZnT 
proteins transport zinc out of cells when zinc is excess, and sequester cytoplasmic zinc 
into cell when zinc is replete. Zinc facilitates the formation of dense core granules for 
insulin crystallization in pancreatic β-cell and has a positive influence on insulin gene 
transcription (45). Reduced zinc concentration in the secretory granules leads to increased 
proinsulin to insulin ratio in blood circulation and decreased glucose-induced insulin 
secretion (45). A cross-sectional study in the Chinese Han population found a strong 
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interaction between SLC30A8 (rs13266634) variant and plasma zinc concentrations in 
association with type 2 diabetes (46). Moreover, a cross sectional meta-analysis study 
also reported the interaction effect between SLC30A8 (rs11558471) variant and total zinc 
intake on fasting plasma glucose concentration (47). The association between plasma zinc 
concentration and risk of non-syndromic OFCs was reported in a Philippine population 
with poor zinc status, but the association was not found in Utah, U.S. population with 
adequate zinc status (48, 49). However, due to limited data in this study, the interaction 
between SLC30A8 and plasma zinc levels in association with OFCs cannot be 
determined. The mechanism explaining the association between SLC30A8 variant and 
risk of OFCs requires further studies in zinc-poor and zinc-replete populations.  
In European trios, the presence of the minor allele of ADRB3 at rs7812866 
increased the risk of CL/P and CP/L (44% and 53%, respectively) under the dominant 
model. ADRB3 is a member of beta-adrenergic receptor family, which regulates energy 
balance through lipolysis in adipocytes, free fatty acid mobilization from adipose cells 
and thermogenesis in skeletal muscle (50, 51). The mutation of ADRB3 is associated 
with decreased resting metabolic rate, obesity, obesity-related diseases (diabetes and 
hypertension), calorigenic dysfunction, early onset of diabetes mellitus, and increased 
body weight with aging (51, 52). Therefore, gene related to obesity (Table 5.11) might be 
associated with CP/L. This hypothesis is supported by a study by Kutbi et al reporting the 
association between maternal obesity and risk of CP/L and suggesting that obesity has a 
specific effect on palate formation but not lip formation (11). However, the association 
between obese genes and risk of CP/L requires further study to confirm the hypothesis. 
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While ADRB3 has been strongly linked to obesity and diabetes, the mechanisms 
explaining the association between ADRB3 gene and risk of OFCs require further study.  
 HNF1B (rs2158254) had an association with CP/L in both European and Asian trios. 
HNF1B (HNF1 homeobox B), a member of the homeodomain-containing superfamily of 
transcription factors, is expressed in liver, pancreas, bile ducts, thymus, genital tract, 
lung, and gut (53). Functions of HNF1B include epithelial differentiation during human 
organogenesis (54), renal tubulogenesis regulation (55), hepatic insulin sensitivity control 
(56), and pancreatic endocrine cell generation (57). Moreover, HNF1B gene is also 
associated with pancreatic β cell dysfunction and insulin resistance (56). Polymorphisms 
in HNF1B have been strongly associated with diabetes, but the mechanisms explaining 
the association between HNF1B and risk of OFCs require further study.  
ADIPOQ (rs17373877) was associated CP/L in Europeans, and ADIPOQ 
(rs7645316) was associated with CP in European trios when GxE interaction (PCMV) 
was considered. ADIPOQ has an influence on adiponectin concentration, which is 
involved in increased glucose uptake via glucose transporter-4, and increased fatty acid 
uptake and oxidation (58). Yamauchi reported that adiponectin stimulated 
phosphorylation of acetyl coenzyme A carboxylase, glucose uptake, lactate production, 
and fatty acid oxidation through activated 5-prime-AMP-activated protein kinase (59). 
While ADIPOQ has been strongly linked to obesity and diabetes, the mechanism of 
ADIPOQ or adiponectin level and risk of OFCs requires further study.  
TNF-α (rs28470596) was associated with both CL/P and CP/L in European trios 
in the gTDT and in the 2 df that controlling for gene-environment interactions with 
359 
 
PCMV and smoking. Rs28470596 is located approximately 85 kb upstream of TNF-α, a 
region with several genes related to immune function in MICB, MHC (major 
histocompatibility complex) Class I Polypeptide-Related Sequence B, which is expressed 
in monocytes and normal tissues (60). Polymorphisms of MICB cause autoreactive T-cell 
stimulation, which relates to relevant differences in immune response against infections, 
autoimmune diseases, and tumor transformation (61). TNF-α encodes a cell signaling 
protein produced at inflammatory sites. TNF-α interferes with insulin signaling in 
adipose, muscle, and liver cells. TNF-α inhibit glucose-induced insulin secretion (62). A 
cell study by Tsiotra et al. (63) found that TNF-α suppressed both basal and glucose-
induced insulin secretion and proinsulin mRNA transcription. TNF-α reduces GLUT4 
mRNA levels in adipocytes and myocytes and inhibits insulin-stimulated glucose 
transport, which induces insulin resistance (64).  It is uncertain whether polymorphisms 
in the TNF-α region are related to the regulation of TNF-α or to effects on other genes in 
the MHC regions. For example, a study by Rahimov et al of the IRF6-OFC association 
(65) found that rs642961 (10 kb downstream of IRF6, an IRF6 enhancer), disrupted the 
binding site of transcription factor AP-2α, which appeared to be the causal variant 
associated with cleft lip. The mechanism of rs28470596 on TNF-α and OFCs requires 
further study 
ABCC8 (rs2237991 and rs2074315) showed significant association with CL/P in 
the dominant model in Europeans. When GxE interactions were considered, ABCC8 was 
associated with CL/P (rs4148622 for PCMV and rs2237991 for maternal smoking). 
ABCC8 influences the K-ATP channel function, which causes increased insulin secretion 
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by pancreatic β-cells. Elbein et al. reported ABCC8 polymorphism that decreased 
pancreatic β-cell compensation leading to reduce insulin sensitivity (66).  
Interactions with ETS reveal that FTO (rs9930333, rs9941349, rs3751812 and 
rs8050136), HHEX (rs7078243, rs2497351, rs12784232, rs11187173 and rs1418388) and 
PPARG (rs7618046, rs3856806 and rs12629751) were associated with CL/P and CP in 
Asians.  FTO shares sequence with iron- and 2-oxoglutarate-dependent oxygenases, and 
FTO mRNA levels found in the hypothalamus are regulated by feeding and fasting (67). 
A mouse study by Gao et al (68) found that mice with FTO mutations had postnatal 
growth retardation (lower body weight, shorter body length, and lower bone mineral 
density) and decreased insulin-like growth factor 1 (IGF-1) levels. A case-control study 
in Romanian by Duicu et al found that rs9939609 in FTO was associated with 
adiponectin and leptin levels. HHEX encodes a transcription factor related to Wnt 
signaling for cell growth and development. A mouse study found that HHEX knockout 
mice had impaired forebrain, cardiovascular, thyroid, and liver development (69, 70). 
PPARG is associated with insulin action, adipocyte differentiation, lipid storage, and fat-
specific gene expression (71). PPARG (72) also activates glucose transporter 2 and 
glucokinase in liver and pancreatic β-cells, which improves glucose homeostasis.  
 LEP was associated with European CL/P when interaction with maternal smoking 
was considered. LEP encodes leptin hormone which regulates body weight through leptin 
receptors. Leptin is involved in food intake inhibition, energy expenditure regulatory, 
energy and glucose homeostasis, bone formation, immune and inflammatory response, 
angiogenesis, hematopoiesis, and would healing (73). Elevated leptin level during 
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pregnancy result from the production in placenta rather than adipose tissue. Maternal 
leptin increases the mobilization of maternal fat stores, and regulates placental growth, 
angiogenesis, and nutrient transfer. (74). A vitro study by Araujo et al (75) reported that 
increased leptin levels in GDM mothers inhibit placental folic acid transport. The 
previous chapter (chapter 4) analyzing the association between biomarkers and risk of 
OFCs reported that mothers having CL/P, CPO, and CP/L offspring had higher leptin 
levels than control mothers. Many studies have found that leptin concentrations were 
lower in smokers than in nonsmokers (76-80). The study by Nagayasu et al. (80) also 
presented that nicotine suppressed leptin gene expression. The study by Larsson and 
Ahren (81) and Donahue et al. (82) reported that leptin levels were not different between 
smoker and nonsmoker. However, the study Pertkins and Fonte (83) reported that 
smoking cessation increased leptin concentrations, and suggested that nicotine in tobacco 
caused leptinemia by inducing corticosteroid release from adrenal glands. The 
inconsistent associations between smoking and leptin levels may result from the study 
designs disregarding the different ethnicities, age, health status, and genetic variation 
(84). Thus there are many possible mechanism where by leptin may influence OFC risk. 
The interaction effect between leptin and smoking on risk of OFCs and effect of smoking 
on LEP gene expression require further study to explore.  
Major genes having associations with CL/P and CP/L when considering genotypic 
effect alone are related to beta-cell dysfunction and insulin resistance (Table 5.11). Five 
of seven genes showing gene-environment interaction with maternal smoking and ETS 
are related to beta-cell dysfunction (Table 5.12). A study by Beaty et al (20) reported 
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MAFB was associated with CL/P based on GWAS data, and had a role in palate 
formation based on expression study in mice. A mouse study by Banerjee et al (85) found 
that decreased MAFB expression in maternal beta-cell caused GDM. The hypothesis 
about the association between genes related to beta-cell dysfunction and insulin 
resistance and OFCs through genetic effects alone and gene-environment interactions 
requires further study to confirm. Moreover, the mechanism of gene-environment 
interaction with maternal smoking and ETS in OFCs, which focuses on genes related to 
beta-cell function, requires further study. 
This study is a multi-center, international family-based study. Family-based 
designs can control confounding bias from the population stratification which is a critical 
issue in international multi-center designs. For rare diseases, family-based designs 
provide better statistical power than case-control designs. Moreover, GxE interaction 
analysis provided additional genes associated when considering GxE interaction (Table 
5.13). However, this study cannot identify the etiological mechanism of significant genes 
on OFC risk. Biological interaction studies are needed to identify the mechanisms of 
interaction effects between genes and maternal exposures on lip and palate development.                                                                           
 This study reported the association between novel genes related to GDM and risk 
of CL/P and CP/L in term of genetic effects or GxE interactions with PCMV, maternal 
smoking, and ETS. Strong association between GDM and risk of OFCs has been reported 
in previous studies.  Therefore, this study supports the hypothesis that genes related to 
GDM are associated with OFCs through genotypic effects alone and gene-environment 
interactions with PCMV, maternal smoking, and ETS. The study does not point to a 
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single major GDM gene associated with OFCs, but supports the hypothesis that GDM 
may be causally related to OFCs via multiple GDM susceptibility genes and interactions 
with environmental factors. Further studies are needed to understand the mechanism 
through which genes related to diabetes and obesity influence the risk of OFCs.  
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Table 5.1 Summary of genes associated with gestational diabetes (GDM), diabetes mellitus, and obesity selected for analysis. 
  
Gene ID Gene name 
Mechanism1 
SNP2 
References 
BC IR IN OB AT T2DM3 GDM4 Obesity 
ABCC8 
(11p15.1) 
ATP-binding cassette, sub-
family C (CFTR/MRP), 
member 8 
X     rs4148643 (86) (86) - 
rs1799854 (86-88) (86) - 
rs1799859 (86, 87) - - 
ADIPOQ 
(3q27) 
 
Adiponectin, C1Q and 
collagen domain 
containing 
 X X  X rs266729 - (89, 90) (91) 
rs822396 - - (92) 
rs1063537 (93, 94) - - 
rs1501299 (95, 96) - (91, 92) 
rs2241766 (95, 96) (97-99) - 
rs2241767 - - (92) 
rs12637534 (100) - - 
rs16861194 (93, 94) - - 
rs16861209 (100) - - 
rs17366568 (100) - - 
rs17846866 (101) - - 
ADRB3 
(8p12) 
Adrenoceptor beta 3    X  rs4994 (95, 102) (103) (104, 105) 
rs72655364  (106) - - 
rs72655365 (106) - - 
CDKAL1 
(6p22.3) 
CDK5 regulatory subunit  
associated protein 1-like 1 
X     rs2206734 (107) - - 
rs2237892 (108) - - 
rs4712524 (109) - - 
rs7754840 (110-115) (116, 117) - 
rs7756992 (110-114) (116, 118) - 
rs9295475 (109) - - 
 3
6
5
 
Table 5.1 Summary of genes associated with gestational diabetes (GDM), diabetes mellitus, and obesity selected for analysis (Cont.). 
Gene ID Gene name 
Mechanism1 
SNP2 
References 
BC IR IN OB AT T2DM3 GDM4 Obesity 
CDKAL1 
(Cont.) 
      rs9460546 (109) - - 
rs10946398 (119-122) - - 
CDKN2A/2B 
(9p21) 
 
Cyclin-dependent kinase 
inhibitor 2A/B 
X     rs564398 (120-122) - - 
rs1412829 (123) - - 
rs2383208 - (124) - 
rs10811661 (113-115, 
120-122, 
125-128) 
(116) - 
FTO 
(16q12.2) 
Fat mass and obesity  
associated 
   X  rs965670 - - (129) 
rs1121980 - - (129) 
rs1421085 (130) - (130, 131) 
rs3751812 (132) - - 
rs6499640 (132) - - 
rs6602024 - - (129) 
rs7193144 - - (129) 
rs7907949 - - (129) 
rs8050136 (121, 122, 
133) 
- (129) 
rs965670 - - (129) 
rs9926289 - - (129) 
rs9930506 - - (129) 
rs9939609 (134, 135) (136) (129, 130, 
137-139) 
rs17817449 (133) - - 
 3
6
6
 
Table 5.1 Summary of genes associated with gestational diabetes (GDM), diabetes mellitus, and obesity selected for analysis (Cont.). 
Gene ID Gene name 
Mechanism1 
SNP2 
References 
BC IR IN OB AT T2DM3 GDM4 Obesity 
GCK 
(7p15.3-
p15.1) 
Glucokinase X     rs1799884 - (140-142) - 
rs2244164 (143) - - 
rs2268573 (143) - - 
rs2284779 (144) - - 
rs12534623 (143) - - 
rs4604517 (145)   
HHEX 
(10q23.33) 
Haematopoietically 
expressed  
homeobox 
X     rs7923837 (110, 113, 
115, 119, 
122, 128, 
146) 
(116) - 
rs5015480 (113, 119, 
121) 
(116) - 
rs1111875 (110, 113-
115, 119, 
122, 127, 
128, 146) 
(116) - 
HNF1A 
(12q24.2) 
HNF1 homeobox A X     rs1169288 (147, 148) (140) - 
rs2701175 (149) - - 
rs7305618 (150) - - 
rs7957197 (151) - - 
rs21573907 (150) - - 
HNF1B 
(17q12) 
Hepatocyte nuclear factor 
1-beta 
X X    rs10962 (144) - - 
rs2688 (88) - - 
rs1008284 (143) - - 
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Table 5.1 Summary of genes associated with gestational diabetes (GDM), diabetes mellitus, and obesity selected for analysis (Cont.) 
Gene ID Gene name 
Mechanism1 
SNP2 
References 
BC IR IN OB AT T2DM3 GDM4 Obesity 
HNF1B 
(Cont.) 
      rs1016991 (88) - - 
rs2285741 (144) - - 
rs3110641 (144) - - 
rs4430796 (151) (152) - 
rs6422978 (144) - - 
rs11263755 (144) - - 
rs12450628 (143) - - 
rs1470579 (110, 113-
115, 128, 153) 
(117) - 
IGF2BP2 
(3q27.2) 
Insulin-like growth factor 
2mRNA binding protein 2 
X     rs4376068 (109) - - 
rs4402960 (108, 110, 
113-115, 128, 
153) 
(124, 154) - 
rs6769511 (109) - - 
rs7651090 (125) - - 
IRS1 
(2q36) 
Insulin receptor substrate-
1 
 X    rs1801278 (155, 156) (157-160) (161) 
rs2943641 (162) - - 
KCNJ11 
(11p15.1) 
 
Potassium channel, 
inwardly  
rectifying subfamily J, 
member 11 
X 
 
 
 
 
 
 
 
 
 
rs5215 (119, 122) - - 
rs5219 (115, 125, 
128, 153) 
(163) - 
KCNQ1 
(11p15.5-
p15.4) 
Potassium channel, 
voltage gated KQT-like 
subfamily Q, member 1 
X     rs2074196 (164) (165) - 
rs2237892 (150, 164) (165-167) - 
rs2237895 - (166, 168) - 
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Table 5.1 Summary of genes associated with gestational diabetes (GDM), diabetes mellitus, and obesity selected for analysis (Cont.) 
 
 
Gene ID Gene name 
Mechanism1 
SNP2 
References 
BC IR IN OB AT T2DM3 GDM4 Obesity 
KCNQ1 
(Cont.) 
      rs2237896 - (168) - 
rs231362 (151)   
 LEP 
(7q31.3) 
Leptin X   X  rs2167270 - (90) (169, 170) 
rs6966536 - - (171) 
rs7799039 - (172) - 
rs10954173 (173) - - 
rs10954174 - - (171) 
rs11761556 (173) - - 
MTNR1B 
(11q21-q22) 
Melatonin receptor 1B X     rs1387153 - (157, 174) - 
rs10830962 - (117) - 
rs10830963 (175-177) 
(157, 174, 
178) 
- 
PPARG 
(3p25) 
 
Peroxisome proliferator-
activated receptor gamma 
 X    rs1801282 (115, 121, 
122, 125, 153, 
179) 
(180) (181) 
rs3856806 - (180) - 
SLC30A8 
(8q24.11) 
Solute carrier family 30 
(zinc transporter), member 
8 
X     rs3802177 (110, 119, 
123, 133) 
- - 
rs11558471 (119) - - 
rs13266634 (110, 115, 
119, 121, 123, 
125, 133, 146, 
153) 
(116) - 
 3
6
9
 
Table 5.1 Summary of genes associated with gestational diabetes (GDM), diabetes mellitus, and obesity selected for analysis (Cont.)  
1Mechanism related to diabetes and metabolic syndrome, BC: beta-cell dysfunction; IR: insulin resistance; IN: inflammation markers 
(cytokines and adipokines); OB: Obesity; AT: Atherosclerotic processes 
2 SNP, single-nucleotide polymorphism 
3T2DM, type 2 diabetes mellitus 
4GDM, gestational diabetes mellitus 
  
Gene ID Gene name 
Mechanism1 
SNP2 
References 
BC IR IN OB AT T2DM3 GDM4 Obesity 
TCF7L2 
(10q25.3) 
Transcription factor 7-like 
2 
X     rs4506565 - (136) - 
rs6585205 (119) - - 
rs7901695 (108) (182) - 
rs7903146 (113, 115, 
119, 121-123, 
126, 146, 153, 
183, 184) 
(116, 118, 
182, 185) 
- 
rs10885409 (127) - - 
rs114748339 (186) - - 
rs12255372 - (187) - 
TNF-α 
(6p21.3) 
Tumor necrosis factor 
alpha 
 X X   rs361525 (188) - - 
rs1800610 (149) - - 
rs1800629 (189, 190) (191, 192) (193, 194) 
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Table 5.2 Number of complete trios by recruitment site; GENEVA Orofacial Cleft Consortium 
Recruitment Site Asian Trios European 
CL/P CP/L CL/P CP/L 
Denmark - - 21 (3.2%) 20 (3.1%) 
Norway 3 (0.3%) 3 (0.3%) 275 (41.4%) 270 (41.9%) 
Iowa, US - - 44 (6.6%) 52 (8.1%) 
Maryland, US 1 (0.1%) 2 (0.2%) 83 (12.5%) 88 (13.7%) 
Pittsburgh, Pennsylvania, US - - 87 (13.1%) 73 (11.3%) 
Utah, US - 1 (0.1%) 152 (22.9%) 135 (21.0%) 
Philippines 94 (10.5%) 94 (10.3%) - - 
Singapore 56 (6.3%) 84 (9.2%) 3 (0.4%) 6 (0.9%) 
Taiwan 218 (24.4%) 250 (27.5%) - - 
Weifang, People Republic of China 183 (20.5%) 159 (17.5%) - - 
Wuhan, People Republic of China 176 (19.7%) 178 (19.6%) - - 
Chengdu, People Republic of China 106 (11.9%) 101 (11.1%) - - 
Korea 55 (6.2%) 38 (4.2%) - - 
Total 892 910 665 644 
CL/P: cleft lip with or without cleft palate; CP/L: cleft palate with or without cleft lip  
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Table 5.3: Environmental maternal exposures in Asian trios by site. 
Environmental 
risk factor 
exposure by 
Site 
Cleft lip with or without cleft palate (N=892) Cleft palate with or without cleft lip (N=910) 
Smoking PCMV Drinking ETS Smoking PCMV Drinking ETS 
Norway 
  No 
  Yes 
  Missing 
 
3 (100%) 
- 
- 
 
1 (33.3%) 
1 (33.3%) 
1 (33.3%) 
 
2 (66.7%) 
1 (33.3%) 
- 
 
2 (66.7%) 
1 (33.3%) 
- 
 
3 (100%) 
- 
- 
 
1 (33.3%) 
1 (33.3%) 
1 (33.3%) 
 
2 (66.7%) 
1 (33.3%) 
- 
 
2 (66.7%) 
1 (33.3%) 
- 
Maryland, US 
  No 
  Yes 
  Missing 
 
1 (100%) 
- 
- 
 
- 
1 (100%) 
- 
 
1 (100%) 
- 
- 
 
- 
- 
1 (100%) 
 
2 (100%) 
- 
- 
 
- 
2 (100%) 
- 
 
2 (100%) 
- 
- 
 
1 (50.0%) 
- 
1 (50.0%) 
Utah, US 
  No 
  Yes 
  Missing 
 
- 
- 
- 
 
- 
- 
- 
 
- 
- 
- 
 
- 
- 
- 
 
1 (100%) 
- 
- 
 
- 
1 (100%) 
- 
 
1 (100%) 
- 
- 
 
1 (100%) 
- 
- 
Philippines 
  No 
  Yes 
  Missing 
 
90 (95.7%) 
4 (4.3%) 
- 
 
65 (69.1%) 
29 (30.9%) 
- 
 
89 (94.7%) 
5 (5.3%) 
- 
 
- 
- 
94 (100%) 
 
90 (95.7%) 
4 (4.3%) 
- 
 
65 (69.1%) 
29 (30.9%) 
- 
 
89 (94.7%) 
5 (5.3%) 
- 
 
- 
- 
94 (100%) 
Singapore 
  No 
  Yes 
  Missing 
 
51 (91.1%) 
5 (8.9%) 
- 
 
29 (51.8%) 
27 (48.2%) 
- 
 
54 (96.4%) 
2 (3.6%) 
- 
 
42 (75.0%) 
14 (25.0%) 
- 
 
78 (92.9%) 
6 (7.1%) 
- 
 
44 (52.4%) 
40 (47.6%) 
- 
 
78 (92.9%) 
6 (7.1%) 
- 
 
67 (79.8%) 
17 (20.2%) 
- 
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Table 5.3: Environmental maternal exposures in Asian trios by site (Cont.).  
Environmental 
risk factor 
exposure by 
Site 
Cleft lip with or without cleft palate (N=892) Cleft palate with or without cleft lip (N=910) 
Smoking PCMV Drinking ETS Smoking PCMV Drinking ETS 
Taiwan 
  No 
  Yes 
  Missing 
 
203(93.1%) 
15 (6.9%) 
- 
 
173(79.4%) 
44 (20.2%) 
1 (0.5%) 
 
210(96.3%) 
8 (3.7%) 
- 
 
103(47.2%) 
113(51.8%) 
2 (0.9%) 
 
233(93.2%) 
17 (6.8%) 
- 
 
199(79.6%) 
51 (20.4%) 
- 
 
239(95.6%) 
11 (4.4%) 
- 
 
120(48.0%) 
128(51.2%) 
2 (0.8%) 
Weifang, PRC 
  No 
  Yes 
  Missing 
 
182(99.5%) 
1 (0.5%) 
- 
 
162(88.5%) 
11 (6.0%) 
10 (5.5%) 
 
182(99.5%) 
- 
1 (0.5%) 
 
116(63.4%) 
65 (35.5%) 
2 (1.1%) 
 
158(99.4%) 
1 (0.6%) 
- 
 
143(89.9%) 
7 (4.4%) 
9 (5.7%) 
 
157(98.7%) 
2 (1.3%) 
- 
 
99 (62.3%) 
59 (37.1%) 
1 (0.6%) 
Wuhan, PRC 
  No 
  Yes 
  Missing 
 
176 (100%) 
- 
- 
 
37 (21.0%) 
14 (8.0%) 
125(71.0%) 
 
173(98.3%) 
- 
3 (1.7%) 
 
171(97.2%) 
3 (1.7%) 
2 (1.1%) 
 
178(100%) 
- 
- 
 
38 (21.3%) 
16 (9.0%) 
124(69.7%) 
 
175(98.3%) 
- 
3 (1.7%) 
 
172(96.6%) 
2 (1.1%) 
4 (2.2%) 
Chengdu, PRC 
  No 
  Yes 
  Missing 
 
105(99.1%) 
1 (0.9%) 
- 
 
101(95.3%) 
2 (1.9%) 
3 (2.8%) 
 
103(97.2%) 
3 (2.8%) 
- 
 
12 (11.3%) 
92 (86.8%) 
2 (1.1%) 
 
100(99.0%) 
1 (1.0%) 
- 
 
97 (96.0%) 
2 (2.0%) 
2 (2.0%) 
 
98 (97.0%) 
3 (3.0%) 
- 
 
14 (13.9%) 
86 (85.1%) 
1 (1.0%) 
Korea 
  No 
  Yes 
  Missing 
 
55 (100%) 
- 
- 
 
53 (96.4%) 
2 (3.6%) 
- 
 
48 (87.3%) 
- 
7 (12.7%) 
 
37 (67.3%) 
12 (21.8%) 
6 (10.9%) 
 
38 (100%) 
- 
- 
 
37 (97.4%) 
1 (2.6%) 
- 
 
33 (86.8%) 
- 
5 (13.2%) 
 
27 (71.1%) 
7 (18.4%) 
4 (10.5%) 
Smoking: mother smokes in the periconceptional period (3 months prior through 3rd month of pregnancy) 
PCMV: mother takes multivitamins or prenatal vitamins in the periconceptional period (3 months prior through 3rd month of 
pregnancy) 
Drinking: mother has alcohol consumption in the perinatal period (3 months prior through 3rd month of pregnancy) 
ETS: mother exposed to environmental tobacco smoke during pregnancy or three months before pregnancy 
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Table 5.4 Environmental maternal exposures in European trios by site. 
Site Cleft lip with or without cleft palate (N=665) Cleft palate with or without cleft lip (N=644) 
Smoking PCMV Drinking ETS Smoking PCMV Drinking ETS 
Denmark 
  No 
  Yes 
  Missing 
 
14 (66.7%) 
7 (33.3%) 
- 
 
9 (42.9%) 
12 (57.1%) 
- 
 
15 (71.4%) 
6 (28.6%) 
- 
 
- 
- 
21 (100%) 
 
14 (70%) 
6 (30%) 
- 
 
8 (40.0%) 
12 (60.0%) 
- 
 
14 (70%) 
6 (30%) 
- 
 
- 
- 
20 (100%) 
Norway 
  No 
  Yes 
  Missing 
 
150(54.5%) 
125(45.5%) 
- 
 
104(37.8%) 
87 (31.6%) 
84 (30.5%) 
 
130(47.3%) 
145(52.7%) 
- 
 
232(84.4%) 
43 (15.6%) 
- 
 
158(58.5%) 
112(41.5%) 
- 
 
108(40.0%) 
88 (32.6%) 
74 (27.4%) 
 
123(45.6%) 
147(54.4%) 
- 
 
229(84.8%) 
41 (15.2%) 
- 
Iowa, US 
  No 
  Yes 
  Missing 
 
31 (70.5%) 
13 (29.5%) 
- 
 
11 (25.0%) 
32 (72.7%) 
1 (2.3%) 
 
13 (29.5%) 
31 (70.5%) 
- 
 
- 
- 
44 (100%) 
 
37 (71.2%) 
15 (28.8%) 
- 
 
12 (23.1%) 
39 (75.0%) 
1 (1.9%) 
 
17 (32.7%) 
35 (67.3%) 
- 
 
- 
- 
52 (100%) 
Maryland, US 
  No 
  Yes 
  Missing 
 
58 (69.9%) 
23 (27.7%) 
2 (2.4%) 
 
12 (14.5%) 
66 (79.5%) 
5 (6.0%) 
 
56 (67.5%) 
25 (30.1%) 
2 (2.4%) 
 
21 (25.3%) 
6 (7.2%) 
56 (67.5%) 
 
59 (67.0%) 
27 (30.7%) 
2 (2.3%) 
 
11 (12.5%) 
73 (83.0%) 
4 (4.5%) 
 
60 (68.2%) 
25 (28.4%) 
3 (3.4%) 
 
23 (26.1%) 
7 (8.0%) 
58 (65.9%) 
Pittsburgh, 
Pennsylvania, US 
  No 
  Yes 
  Missing 
 
 
66 (75.9%) 
21 (24.1%) 
- 
 
 
16 (18.4%) 
70 (80.5%) 
1 (1.1%) 
 
 
49 (56.3%) 
37 (42.5%) 
1 (1.1%) 
 
 
- 
- 
87 (100%) 
 
 
53 (72.6%) 
20 (27.4%) 
- 
 
 
14 (19.2%) 
58 (79.5%) 
1 (1.4%) 
 
 
41 (56.2%) 
31 (42.5%) 
1 (1.4%) 
 
 
- 
- 
73 (100%) 
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Table 5.4 Environmental maternal exposures in European trios by site (Cont.) 
Site Cleft lip with or without cleft palate (N=665) Cleft palate with or without cleft lip (N=644) 
Smoking PCMV Drinking ETS Smoking PCMV Drinking ETS 
Utah, US 
  No 
  Yes 
  Missing 
 
140(92.1%) 
12 (7.9%) 
- 
 
63 (41.4%) 
89 (58.6%) 
- 
 
132(86.8%) 
20 (13.2%) 
- 
 
137(90.1%) 
14 (9.2%) 
1 (0.7%) 
 
120(88.9%) 
15 (11.1%) 
- 
 
57 (42.2%) 
78 (57.8%) 
- 
 
119(88.1%) 
16 (11.9%) 
- 
 
119(88.1%) 
15 (11.1%) 
1 (0.7%) 
Singapore 
  No 
  Yes 
  Missing 
 
2 (66.7%) 
1 (33.3%) 
- 
 
- 
3 (100%) 
- 
 
2 (66.7%) 
1 (33.3%) 
- 
 
2 (66.7%) 
1 (33.3%) 
- 
 
5 (83.3%) 
1 (16.7%) 
- 
 
3 (50.0%) 
3 (50.0%) 
- 
 
5 (83.3%) 
1 (16.7%) 
- 
 
4 (66.7%) 
2 (33.3%) 
- 
Smoking: mother smokes in the periconceptional period (3 months prior through 3rd month of pregnancy) 
PCMV: mother takes multivitamins or prenatal vitamins in the periconceptional period (3 months prior through 3rd month of 
pregnancy) 
Drinking: mother has alcohol consumption in the perinatal period (3 months prior through 3rd month of pregnancy) 
ETS: mother exposed to environmental tobacco smoke during pregnancy or three months before pregnancy
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Table 5.5 Conditional logistic regression results from genotypic Transmission Disequilibrium Test (gTDT): risk of orofacial clefts 
among Asian trios from GENEVA Orofacial Cleft Consortium.  
phenotype Gene ID Significant 
SNPs 
Allele MAF 
(%) 
Model fitted Odds ratios 
(95%CIs) 
Raw  
p-value1 
Threshold 
 P-value2 
CL/P SLC30A8 rs924388 A/G 17.3 Additive 1.31 [1.10-1.57] 2.7x10-3 7.7x10-4 
     Dominant* 1.42 [1.74-1.16] 7.2x10-4 
     Recessive 1.21 [0.77-1.90] 0.41 
CP/L HNF1B rs2158254 A/G 27.4 Additive 0.88 [0.76-1.02] 8.9x10-2 8.3x10-4 
     Dominant 0.92 [0.77-1.10] 0.38 
     Recessive* 0.53 [0.37-0.75] 4.5x10-4 
CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip 
Allele: minor allele/major allele; MAF: minor allele frequency 
Threshold p-value was adjusted for the number of SNPs in each gene as reported in Table 5.10 
* Model achieves significance after Bonferroni correction 
1 p-value significance of the gTDT without multiple testing correction. 
2 p-value significance of the gTDT after gene-level Bonferroni correction, calculated as 0.05 divided by the number of SNPs in each 
gene. 
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Table 5.6 Conditional logistic regression results from genotypic Transmission Disequilibrium Test (gTDT): risk of orofacial clefts 
among European trios from GENEVA Orofacial Cleft Consortium. 
phenotype Gene ID Significant 
SNPs 
Allele MAF 
(%) 
Model fitted Odds ratios 
(95%CIs) 
Raw           
p-value1 
Threshold 
 P-value2 
CL/P ABCC8 rs2237991 C/T 27.9 Additive* 0.72 [0.60-0.86] 2.5x10-4 3.1x10-4 
     Dominant* 0.64 [0.52-0.79] 3.6x10-5  
     Recessive 0.90 [0.62-1.30] 0.58  
  rs2074315 G/T 27.2 Additive 0.73 [0.61-0.87] 4.1x10-4  
     Dominant* 0.64 [0.52-0.79] 4.3x10-5  
     Recessive 0.93 [0.65-1.35] 0.71  
CL/P ADRB3 rs7812866 C/A 47.3 Additive 1.07 [0.92-1.24] 0.41 5.6x10-3 
     Dominant* 1.44 [1.13-1.83] 3.5x10-3  
     Recessive 0.81 [0.64-1.03] 8.4 x10-2  
CL/P TNF-α rs28470596 T/C 5.0 Additive* 0.36 [0.24-0.55] 9.6x10-7 2.4x10-4 
     Dominant* 0.36 [0.24-0.55] 1.3x10-6  
     Recessive N/A N/A  
CP/L ADIPOQ rs17373877 A/G 6.1 Additive* 0.55 [0.39-0.78] 6.7x10-4 8.5x10-4 
     Dominant 0.56 [0.40-0.80] 1.4x10-3  
     Recessive N/A N/A  
CP/L ADRB3 rs7812866 C/A 46.8 Additive 1.11 [0.94-1.30] 0.21 5.6x10-3 
     Dominant* 1.53 [1.19-1.97] 9.2x10-4  
     Recessive 0.83 [0.65-1.06] 0.14  
CP/L HNF1B rs6607292 A/G 35.5 Additive 0.82 [0.69-0.98] 2.6x10-2 7.1x10-4 
     Dominant 0.96 [0.76-1.20] 0.71  
     Recessive* 0.50 [0.35-0.73] 3.6x10-4  
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Table 5.6 Conditional logistic regression results from genotypic Transmission Disequilibrium Test (gTDT): risk of orofacial clefts 
among European trios from GENEVA Orofacial Cleft Consortium (Cont.). 
phenotype Gene ID Significant 
SNPs 
Allele MAF 
(%) 
Model fitted Odds ratios 
(95%CIs) 
Raw           
p-value1 
Threshold 
 P-value2 
CP/L TNF-α rs28470596 T/C 4.7 Additive* 0.27 [0.17-0.42] 8.75x10-9 2.4x10-4 
     Dominant* 0.27 [0.17-0.42] 1.1x10-8  
     Recessive N/A N/A  
 
CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip 
Allele: minor allele/major allele; MAF: minor allele frequency 
Threshold p-value was adjusted for the number of SNPs in each gene as reported in Table 5.10 
* Model achieves significance after Bonferroni correction 
1 p-value significance of the gTDT without multiple testing correction. 
2 p-value significance of the gTDT after gene-level Bonferroni correction, calculated as 0.05 divided by the number of SNPs in each 
gene.  
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Table 5.7 Estimated odds ratio (OR) (caseG no E) and OR (caseG and E) from conditional logistic regression using cases and 3 
pseudo-controls in both Asian and European trios from GENEVA Orofacial Cleft Consortium for 21 genes related to gestational 
diabetes mellitus considering G-E interaction between each SNP and mother taking multivitamins or prenatal vitamins in the perinatal 
period (PCMV) 
 
Ancestry phenotype Gene ID Significant 
SNPs 
Allele MAF 
(%) 
OR (caseG no 
PCMV) 
OR (caseG and 
PCMV) 
LRT 1 
df P-
value 
LRT 2 
df P-
value 
Asian CL/P FTO** rs836994 A/G 50.1 1.36 [1.16-1.60] 1.23 [0.88-1.70] 0.58 3.0x10-4 
European CL/P ABCC8* rs4148622 T/C 26.8 0.58 [0.42-0.81] 1.26 [1.01-1.58] 1.0x10-4 5.0x10-4 
 CL/P TNF-α ** rs28470596 T/C 5.0 0.22 [0.10-0.50] 0.49 [0.29-0.82] 0.09 3.6x10-6 
 CP/L ADIPOQ** rs7645316 C/T 33.5 0.70 [0.52-0.93] 0.71 [0.57-0.89] 0.90 6.8x10-4 
 CP/L CDKAL1* rs12201217 T/C 37.8 2.10 [1.45-3.03] 1.30 [1.04-1.61] 6.5x10-5 3.5x10-4 
 CP/L TNF-α** rs28470596 T/C 4.7 0.25 [0.12-0.54] 0.28 [0.15-0.52] 0.81 2.53x10-8 
CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip 
Allele: minor allele/major allele; MAF: minor allele frequency 
1 Raw p-value for 1 degree of freedom likelihood ratio test examining the exclusive effect of gene-environment interaction. 
2 Raw p-value for 2 degree of freedom likelihood ratio test examining the effect of genotype after considering effect of gene-
environment interaction. 
* only 1 degree of freedom likelihood ratio test achieved significance after Bonferroni correction (Table 5.10) 
** only 2 degree of freedom likelihood ratio test achieved significance after Bonferroni correction (Table 5.10) 
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Table 5.8 Estimated odds ratio (OR) (caseG no E) and OR (caseG and E) from conditional logistic regression using cases and 3 
pseudo-controls in both Asian and European trios from GENEVA Oralfacial Cleft Consortium for 21 genes related to gestational 
diabetes mellitus considering G-E interaction between each SNP and maternal smoking in the perinatal period. 
 
Ancestry phenotype Gene ID Significant 
SNPs 
Allele MAF 
(%) 
OR (caseG no 
smoke) 
OR (caseG 
and smoke) 
LRT 1 
df P-
value1  
LRT 2 
df P-
value2 
Asian CL/P CDKN2A/2B* rs1063192 C/T 19.5 1.16 [0.98-1.37] 0.15 [0.03-0.68] 1.2x10-3 2.4x10-3 
European CL/P ABCC8** rs2237991 C/T 27.9 0.79 [0.64-0.98] 0.56 [0.40-0.79] 0.09 2.7x10-4 
 CL/P LEP* rs12538332 C/A 29.7 0.83 [0.68-1.02] 1.52 [1.11-2.13] 1.3x10-4 5.6x10-3 
 CL/P TNF-α ** rs28470596 T/C 5.0 0.45 [0.28-0.74] 0.25 [0.12-0.52] 0.18 7.5x10-7 
 CP/L ABCC8** rs4148617 T/C 24.5 0.89 [0.71-1.12] 0.52 [0.38-0.73] 9.2x10-3 2.6x10-4 
 CP/L TNF-α ** rs28470596 T/C 4.7 0.25 [0.14-0.46] 0.29 [0.15-0.60] 0.76 2.2x10-9 
CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip 
Allele: minor allele/major allele; MAF: minor allele frequency 
1 Raw p-value for 1 degree of freedom likelihood ratio test examining the exclusive effect of gene-environment interaction. 
2 Raw p-value for 2 degree of freedom likelihood ratio test examining the effect of genotype after considering effect of gene-
environment interaction. 
* only 1 degree of freedom likelihood ratio test achieved significance after Bonferroni correction (Table 5.10) 
** only 2 degree of freedom likelihood ratio test achieved significance after Bonferroni correction (Table 5.10) 
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Table 5.9 Estimated odds ratio (OR) (caseG no E) and OR (caseG and E) from conditional logistic regression using cases and 3 
pseudo-controls in both Asian and European trios from GENEVA Oral Cleft Consortium for 21 genes related to gestational diabetes 
mellitus considering G-E interaction between each SNP and maternal exposure to environmental tobacco smoke in the perinatal period 
(ETS). 
 
Ancestry phenotype Gene ID Significant 
SNPs 
Alelle MAF 
(%) 
OR (caseG no 
ETS) 
OR (caseG and 
ETS) 
LRT 1 
df P-
value1 
LRT 2 
df P-
value2 
Asian CL/P FTO rs9930333*** G/T 4.4 0.62 [0.49-0.78] 1.17 [0.86-1.59] 1.2x10-3 2.5x10-4 
   rs9941349*** T/C 16.9 0.62 [0.49-0.79] 1.16 [0.85-1.59] 1.6x10-3 2.8x10-4 
   rs3751812*** T/G 12.4 0.59 [0.45-0.78] 1.35 [0.94-1.93] 3.5x10-3 3.0x10-4 
   rs8050136*** A/C 12.4 0.60 [0.45-0.79] 1.37 [0.95-1.96] 3.0x10-3 3.3x10-4 
 CL/P HHEX rs7078243* A/C 17.5 0.72 [0.56-0.92] 1.45 [1.08-1.94] 3.1x10-4 1.3x10-3 
   rs2497351* A/G 3.1 0.78 [0.44-1.38] 6.00 [1.77-20.37] 7.1x10-4 1.1x10-2 
   rs12784232* A/G 2.9 0.81 [0.46-1.43] 6.00 [1.77-20.37] 9.3x10-4 1.3x10-2 
   rs11187173* A/G 2.9 0.81 [0.46-1.43] 6.00 [1.77-20.37] 9.3x10-4 1.3x10-2 
   rs1418388* A/G 2.9 0.81 [0.46-1.43] 6.00 [1.77-20.37] 9.3x10-4 1.3x10-2 
 CL/P PPARG rs7618046* C/T 45.8 0.87 [0.73-1.04] 1.50 [1.18-1.90] 3.5x10-4 1.2x10-3 
   rs3856806* T/C 22.6 0.86 [0.69-1.07] 1.60 [1.21-2.12] 5.6x10-4 1.5x10-3 
   rs12629751* T/C 28.8 0.82 [0.67-1.00] 1.45 [1.12-1.88] 6.0x10-4 2.7x10-3 
 CP/L FTO rs3751812*** T/G 12.3 0.58 [0.44-0.76] 1.25 [0.87-1.81] 9.2x10-4 1.9x10-4 
   rs8050136*** A/C 12.3 0.59 [0.45-0.78] 1.27 [0.88-1.84] 9.4x10-4 3.0x10-4 
 CP/L HHEX rs12784232*** A/G 2.5 1.21 [0.66-2.22] 16.0 [2.12-120.65] 1.5x10-3 2.8x10-4 
   rs11187173*** A/G 2.5 1.15 [0.63-2.09] 16.0 [2.12-120.65] 1.1x10-3 3.1x10-4 
   rs1418388*** A/G 2.8 1.15 [0.63-2.09] 16.0 [2.12-120.65] 1.1x10-3 3.1x10-4 
   rs2497351** A/G 2.7 1.21 [0.66-2.22] 8.50 [1.96-36.79] 4.9x10-3 7.4x10-4 
CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip 
Allele: minor allele/major allele; MAF: minor allele frequency 
1 Raw p-value for 1 degree of freedom likelihood ratio test examining the exclusive effect of gene-environment interaction. 
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2 Raw p-value for 2 degree of freedom likelihood ratio test examining the effect of genotype after considering effect of gene-
environment interaction. 
* only 1 degree of freedom likelihood ratio test achieved significance after Bonferroni correction (Table 5.10) 
** only 2 degree of freedom likelihood ratio test achieved significance after Bonferroni correction (Table 5.10) 
*** both 1 and 2 degree of freedom likelihood ratio test achieved significance after Bonferroni correction (Table 5.10) 
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Table 5.10 Threshold p-value was adjusted for the number of SNPs in each gene as 
reported. 
Gene 
Asian trios European trios 
No. 
SNP 
Threshold P-value 
No. 
SNP 
Threshold P-value 
ABCC8 152 3.3x10-4 159 3.1x10-4 
ADIPOQ 56 8.9x10-4 59 8.5x10-4 
ADRB3 10 5.0x10-3 9 5.6x10-3 
CDKAL1 252 2.0x10-4 280 1.8x10-4 
CDKN2A/2B 43 1.2x10-3 44 1.1x10-3 
GCK 45 1.1x10-3 45 1.1x10-3 
FTO 124 4.0x10-4 128 3.9x10-4 
HHEX 34 1.5x10-3 38 1.3x10-3 
HNF1A 38 1.3x10-3 43 1.2x10-3 
HNF1B 60 8.3x10-4 70 7.1x10-4 
IGF2BP2 43 1.2x10-3 47 1.1x10-3 
IRS1 38 1.3x10-3 44 1.1x10-3 
KCNJ11 105 4.8x10-4 108 4.6x10-4 
KCNQ1 179 2.8x10-4 184 2.7x10-4 
LEP 33 1.5x10-3 38 1.3x10-3 
MTNR1B 44 1.1x10-3 47 1.1x10-3 
PPARG 52 9.6x10-4 59 8.5x10-4 
SLC30A8 65 7.7x10-4 66 7.6x10-4 
TCF7L2 59 8.5x10-4 70 7.1x10-4 
TNF-α 188 2.7x10-4 210 2.4x10-4 
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Table 5.11 Summary genes showing significant association with orofacial clefts with the genotypic Transmission Disequilibrium 
(gTDT) test. 
Gene Mechanism1 SNP Asian 
MAF 
European 
MAF 
Asians Europeans 
BC IR IN OB AT CL/P CP/L CL/P CP/L 
ABCC8 X     rs2237991 26.1 27.9   Additive 
 Dominant 
 
rs2074315 25.3 27.2   Dominant  
ADIPOQ  X X  X rs17373877 9.9 6.1    Additive 
ADRB3    X  rs7812866 29.1 46.8   Dominant Dominant 
HNF1B X X    rs2158254 27.4 45.4  Recessive   
rs6607292 46.7 35.5    Recessive 
SLC30A8 X     rs924388 17.3 9.6 Additive    
TNF-α  X X   rs28470596 12.9 4.7   Additive 
 Dominant 
Additive 
 Dominant 
CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip 
1Mechanism based on gene function; BC: Beta-cells dysfunction; IR: Insulin resistance; IN: Inflammatory markers (cytokines and 
adipokines); OB: Obesity; AT: Atherosclerotic process 
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Table 5.12 Summary genes showing significant gene-environment interaction (GxE) at 1df LRT 
Gene Mechanism1 Asians Europeans 
PCMV Smoke ETS PCMV Smoke 
BC IR IN OB AT CL/P CP/L CL/P CP/L CL/P CP/L CL/P CP/L CL/P CP/L 
ABCC8* X           X    
CDKAL1 X            X   
CDKN2A/2B X       X        
FTO    X  X    X X     
HHEX X         X X     
LEP X   X          X  
PPARG  X        X      
CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip 
 1Mechanism related to diabetes and metabolic syndrome, BC: Beta-cells dysfunction; IR: Insulin resistance; IN: Inflammatory 
markers (cytokines and adipokines); OB: Obesity; AT: Atherosclerotic process 
* significant genetic association (genotypic transmission disequilibrium; gTDT) among European trios 
GxE, PCMV: Periconceptional multivitamin, Smoke: maternal smoking, ETS: Environment Tobacco Smoke. 
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Table 5.13 Summary genes showing significant when considering gene-environment interaction (GxE) at 2 df LRT. 
Gene Mechanism1 Asians Europeans 
PCMV Smoke ETS PCMV Smoke 
BC IR IN OB AT CL/P CP/L CL/P CP/L CL/P CP/L CL/P CP/L CL/P CP/L 
ABCC8* X             X X 
ADIPOQ* X            X   
FTO    X  X    X X     
HHEX X         X X     
PPARG  X        X      
TNF-α *  X X         X X X X 
CL/P: cleft lip with/without cleft palate; CP/L: cleft palate with or without cleft lip 
 1Mechanism related to diabetes and metabolic syndrome, BC: Beta-cells dysfunction; IR: Insulin resistance; IN: Inflammatory 
markers (cytokines and adipokines); OB: Obesity; AT: Atherosclerotic process 
* significant genetic association (genotypic transmission disequilibrium; gTDT) among European trios 
GxE, PCMV: Periconceptional multivitamin, Smoke: maternal smoking, ETS: Environment Tobacco Smoke.  
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 CHAPTER 6  
 
CONCLUSION 
 
 
6.1 Summary 
Epidemiological research on orofacial clefts (OFCs) has determined the etiology 
of OFCs to be multifactorial including genetic factors, environmental factors, and 
combination of these factors. Environmental factors including maternal smoking, 
maternal alcohol consumption, maternal nutritional status, certain medicines and 
supplement intakes, eating behavior during pregnancy and prior to pregnancy, and 
maternal medical conditions (diabetes and obesity) have been reported to be associated 
with the incidence of OFCs (1-5). Insulin resistance and obesity are considered as risk 
factors of metabolic diseases. Several biomarkers including HDL, triglyceride, liver 
function tests (ALT: alanine aminotransferase and GGT: gamma-glutamyltransferase) (6-
8), cytokine (CRP: C-reactive protein, IL-6: interleukin-6, TNF- α: tumor necrosis factor 
alpha, and leptin) (9-12), and adipokines (adiponectin) (10-12) are associated with 
metabolic syndrome. Genetic studies have identified several genes associated with OFCs 
most of which have unknown etiologic mechanism. Genome-wide association studies 
have reported the significant genetic effects alone and with gene-environment interaction 
effect on the risk of OFCs but these effects differ across populations (13).  
The results from this dissertation support the association between maternal 
obesity and diabetes and risk cleft palate. Moreover, underweight mothers had a 
decreased risk of cleft lip only (CLO) and an increased risk of cleft palate only (CPO). 
The protective effect of underweight mothers on CLO risk is inconsistent with previous 
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studies (14). Maternal body mass index (BMI) and maternal diabetes might have effects 
on facial formation in a variety of pathways. It is difficult to identify the independent 
effects of maternal obesity and diabetes on OFCs because the relationship between 
obesity and diabetes is complex. Obesity increases the risk of inadequate folate status 
(15-18); BMI may have an adverse effect on cellular uptake and tissue distribution of 
folate. Obesity leads to insulin resistance because of the impairment of insulin sensitivity 
in sites of glucose disposal, which can develop to type 2 diabetes mellitus and GDM (19). 
Elevated blood glucose and insulin stimulates the production of ketone bodies, branched 
chain amino acid, inflammatory markers, and advanced glycation end products. These 
products alter expression levels of specific genes and increase the variation of gene 
expression levels (20-23). Inadequate folate status and adverse metabolic production may 
disrupt normal embryonic development.  
The results suggest that gestational diabetes, maternal obesity, and metabolic 
syndrome are associated with increased risk of cleft palate. Mothers having cleft palate 
with or without cleft lip (CP/L) offspring had an increased risk of developing metabolic 
syndrome based on both NCEP/ATP III and IDF definitions. When compared with 
control mothers, mothers having cleft palate offspring had a higher insulin, IL-8, and 
leptin levels. Insulin resistance associated with insulin and IL-8 levels is a risk factors of 
developing GDM (24). Leptin levels are significant higher in pregnancies with GDM 
compared with normal pregnancies (25-27). Therefore, insulin, IL-8, and leptin levels 
may be links among GDM, metabolic syndrome, and OFCs. Having OFCs offspring 
might be a risk factor of developing metabolic syndrome among mothers later in life. 
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Insulin, IL-8 and leptin might be performed as biomarkers for predicting OFC 
occurrence. 
The strong association between maternal diabetes and risk of OFCs leads to the 
genetic association study related to these metabolic conditions. The study of genetic 
effects alone found that two genes (SLC30A8 and HNF1B) were associated with Asian 
OFCs and five genes (ABCC8, ADIPOQ, ADRB3, HNF1 and TNF-α) were associated 
with European OFCs. Two genes were associated with OFCs when interaction with 
perinatal period (PCMV) was considered-- ABCC8 and CDKAL1 in Europeans. 
Interactions between genotype and maternal smoking were found for CDKN2A/2B in 
Asians, and for LEP in Europeans.  When considering gene-environment interaction with 
environmental tobacco smoke (ETS), FTO, HHEX, and PPARG increased risk of OFCs 
in Asians. Our result suggests that genes related to GDM have an effect on risk of non-
syndromic OFCs through either genetic effect alone or gene-environment interaction 
effects with maternal periconceptional multivitamin use, smoking, and environment 
tobacco smoke. Therefore, the etiology of non-syndromic OFCs is multifactorial between 
genes and environment.  
6.2 Future Direction 
This dissertation examines role of maternal diabetes mellitus in orofacial clefts 
through studies of medical histories, biomarkers, and genes. Further study is required to 
confirm the result and transcend the limitations of this project.  
The completeness of the data from registries is a limitation in this dissertation. We 
found under-reporting of maternal medical conditions and a large amount of missing data 
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of potential confounders (smoking and alcohol consumption). Training programs might 
help registry recorders give priority to complete data.  Moreover, the small number of 
participants with diabetes results in wide confidence intervals and small mediation effects 
of maternal diabetes on the association between maternal overweight and obesity and risk 
of OFCs. Therefore, further studies require larger sample sizes in order to confirm the 
association and mediation effect. 
This dissertation found associations between maternal biomarkers of metabolic 
syndrome and orofacial clefts. We found that insulin, IL-8, and leptin levels were higher 
in mother having cleft palate offspring than control mother. Therefore, a prospective 
study that regularly monitors insulin, IL-8 and leptin levels before the conception period 
until the next pregnancy may be in order to determine predictability for OFC occurrence. 
Moreover, the association between cytokines and adipokines and risk of OFCs requires 
further study with larger sample sizes and different ethnic groups in order to confirm and 
compare the associations.  
Genetic association have found that many SNPs in same gene were associated 
with OFCs; therefore, haplotype analysis and gene-gene interactions may find more 
regions or genes which have small effects individually but show strong statistical 
evidence of linkage and association when combined. This dissertation analyzed gene-
environment interaction associations between genes related to diabetes and obesity and 
maternal environmental factors (maternal multivitamin use, smoking, and environmental 
tobacco smoke). Additional environmental data for gene-environment interaction analysis 
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is required in further studies such as maternal BMI and biomarkers related to metabolic 
syndrome and diabetes mellitus. 
Observational studies provide evidence of association between exposures and 
diseases, but often cannot identify the etiological mechanisms of disease from exposure. 
Therefore, strong associations between maternal diabetes and obesity on risk of OFCs 
found through maternal medical conditions, maternal biomarkers and genetic associations 
require further research to explore the etiological mechanisms. Further studies will be 
required to understand how maternal diabetes and obesity has an effect on OFCs 
occurrence. Moreover, biological interaction studies needs to identify the mechanisms of 
interaction effects between genes and maternal exposures on fetal development. 
6.3 Public Health Significance 
The association between maternal diabetes and obesity and risk of OFCs may lead 
to increased awareness among people and health care providers. Effective interventions 
are needed for promoting healthy body weight and metabolic status in reproductive age 
women in order to reduce the risk of OFCs.  Moreover, early screening for GDM risk is 
needed for the periconceptional period and in the first month of gestation in order to 
allow early interventions for controlling hyperglycemia, hyperinsulinemia and other 
associated metabolic abnormalities to prevent OFCs and other congenital malformations. 
Mothers having an OFC child developed metabolic syndrome and had abnormal 
biomarkers later in life may and it may be proposed that having OFC child is a risk 
indicator for subsequent maternal metabolic syndrome. These mothers may receive 
regularly metabolic syndrome monitoring and intervention to prevent developing 
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metabolic syndrome and related diseases. On the contrary, metabolic syndrome score, 
insulin, IL-8, and leptin levels may be focus as indicator for OFC prediction. Moreover, 
the association of biomarkers before or during periconceptional period and risk of OFCs 
requires further study.  
The association between genetic effects alone and gene-environment interaction 
effects and risk of OFCs might be difficult to apply in public health because the 
biological function of detected variants is still difficult to interpret and people may carry 
the effects of one or more variants in several genes. Strategies for dealing with multiple 
causal genes and applying the strategy effectively are required in genetic studies of 
OFCs.  These associations do not point to a single major GDM gene associated with 
OFCs, but support the hypothesis that GDM may be causally related to OFCs via 
multiple GDM susceptibility genes and interactions with environmental factors. 
However, the finding in this dissertation confirms that etiology of OFCs is multifactorial 
including genetics and environment. 
Individuals with OFCs face both physical and mental health problems, which 
require multi-specialty team care. OFC prevention and prediction are important to public 
health. This dissertation reported that maternal diabetes mellitus, maternal pre-pregnancy 
weight and genes related to GDM had associations with the risk of OFCs. Mothers 
having an OFC child had an increased risk of developing metabolic abnormalities later in 
life. Potential risk factors were reported in this dissertation that can be applied for OFC 
prevention. This dissertation also reported potential biomarkers for predicting OFCs. 
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Moreover, mothers having an OFC child require regular monitoring for metabolic 
abnormalities later in life. 
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